Effects of particle surface modifications on dry powder formulation performances by Schueller, Laurent Bruno
EFFECT OF PARTICLE SURFACE 
MODIFICATIONS ON DRY POWDER 
FORMULATION PERFORMANCES
A thesis submitted for the degree of Doctor of Philosophy 
Laurent Bruno Schueller
»
Department of Pharmaceutics 
The School of Pharmacy 
University of London 
29-39 Brunswick Square 
London WC1N 1AX, UK
ProQuest Number: 10104859
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest.
ProQuest 10104859
Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States Code.
Microform Edition © ProQuest LLC.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Abstract
Described in this dissertation are systematic studies designed to correlate the 
physico-chemical properties of dry powder inhalation formulations to the in vitro 
deposition patterns. Two model asthmatic drugs were selected for investigation: 
the hydrophilic (32 adrenoreceptor agonist, salbutamol sulphate (SS) and the 
hydrophobic synthetic steroid, beclomethasone dipropionate (BDP).
To examine deposition differences between carrier particles from different 
sources, three different marketed grades of lactose were evaluated. In vitro 
assessment of the deposition using the Clickhaler®, as a device displayed 
significant differences depending on the carrier chosen. In particular BDP 
seemed to be positively influenced by the presence of fine lactose, whereas SS 
seemed to be more linked to the surface energetics of the coarse lactose.
The influence played by the fines was further evaluated by using crystalline 
lactose/polyethylene glycol 4000 (PEG 4000 g moM) particles that were 
prepared by spray drying. Different parameters such as the chemical nature and 
the proportion of fines, the mixing sequence, and the drug to carrier ratio all 
influenced the deposition patterns of the drugs. Significant standardisation in 
the performances of BDP was achieved by modifying the surface of the coarse 
lactose.
Improvements in SS deposition were also achieved using a new type of carrier 
surface modification. Partially amorphous lactose/PEG 4000 fines were allowed 
to crystallise onto air-jet sieved lactose surfaces. Parameters such as particle 
morphology and surface energetics appeared to play a key role in the drug 
deposition. PEG 4000 [45-90] pm was also studied as a probe carrier using the 
Aerolizer® This study also represented an opportunity to consider the device 
implication on the Twin Stage Impinger (TSI) deposition.
Finally, the possibility of modifying the surface properties of the drug substance 
was investigated by a spray drying process. It was found by inverse gas 
chromatography (IGC) that PEG modified the surface energy parameters of the 
drug. Different solutions and suspensions were studied in order to generate 
crystalline particles with suitable properties for pulmonary administration.
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1.1. Summary of chapter 1
For several decades, aerosol therapy has been accepted as a valuable tool in 
local treatment of pulmonary diseases. The emergence of new bioengineered 
proteins and peptides for new molecular targets led the pharmaceutical industry 
to consider the lungs as an alternative to more invasive routes such parenteral 
delivery. This chapter gives an introduction to the general principles of 
inhalation therapy and the major characteristics that should be considered for 
either local or systemic delivery of actives. Pulmonary delivery technology may 
be correlated to the devices employed to administer the aerosol, which is 
defined as biphasic system containing solid particles or liquid droplets 
suspended in air or another gaseous medium. After a brief description of the 
different inhalation delivery devices that are clinically available, emphasis is 
directed to dry powder inhalers (DPIs). Particle interactions affecting dry powder 
inhalation efficiency (i.e. capillary forces, electrostatic forces, solid bridge 
formation and van der Waals forces) are described in detail, with emphasis on 
the factors that influence these interactions.
1.2. Pulmonary delivery: advantages and applications
The administration of a medicine by inhalation has been clinically used for the 
treatment of many conditions in the lung, such as asthma, chronic obstructive 
bronchopneumopathy and cystic fibrosis (Clark, 1972; Neville et a/., 1977). To 
administer a medicine into the lungs the therapeutic agent must be aerosolised. 
An aerosol is typically defined as a two-phase system of solid particles or liquid 
droplets dispersed in air or another gaseous phase, having a sufficiently small 
size to display considerable stability as a suspension. The pulmonary route has 
several distinct advantages over other routes of administration. The direct 
delivery of medication to the tracheobronchial tree allows a rapid and 
predictable onset of action, which is particularly important for reliever therapy 
such as bronchodilators, and also avoids the first-pass effect (Zheng et al., 
1999). Furthermore, degradation within the gastrointestinal tract is avoided and 
lower dosages (Clarke and Newman, 1984) can be administered with similar 
efficacy. This means that fewer side effects will be induced which is particularly 
important for therapy with antibiotics and steroids.
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In the past 20 years, DNA technologies have been refined, allowing “designer” 
biomaterials to be considered as candidates for new molecular targets. These 
promising developments do not come without new challenges: the use of 
traditional dosage routes such as oral or transdermal for these new entities 
(Agu et al., 2001) is limited by the combination of their large molecular weight, 
hydrophilicity and lability both chemical and enzymatic. The only presently 
available route of administration is the injection route with its inherent 
compliance and cost issues. At present, the delivery of proteins and peptides 
such as insulin, calcitonin, a-interferon and genetic material in general is of 
particular interest (Smith, 1997; Courrier eta!., 2002).
1.3. Biophysical basis for pulmonary drug administration
The primary role of the pulmonary system is the oxygenation of the blood and 
the associated removal of carbon dioxide from the body. Breathing ventilates 
the respiratory tissue leading to gaseous exchange in the lungs. The two lungs 
of a human being are in slightly unequal proportions because of the asymmetric 
position of the heart (Figure 1.1). The right lung represents 56 percent of the 
total lung volume and is composed of three lobes separated by deep oblique 
fissures. On the other hand, the left lung has only two lobes separated by one 
oblique fissure.
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Figure 1.1. Structure of the lungs (Washington et al., 2001).
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The respiratory tract is a strongly branched system designed to avoid 
penetration of particles into the lungs. It can be divided into two major domains: 
the conducting and the respiratory region. The conducting airways (comprising 
the basal cavity and associated sinuses, the nasopharynx, larynx, trachea, 
bronchi and the first 16 generations of airway bronchioles) are responsible for 
the filtration, humidification and warming of the inspired air. The respiratory 
region is composed of the bronchioles, alveolar ducts and alveolar sacs where 
rapid gas exchange with the venous blood occurs. The widely used morphologic 
model to describe the structures within the lungs given by Weibel (Weibel, 
1963) is shown on Figure 1.2. In this tracheobronchial classification, the lungs 
are represented by a highly bifurcated system. Successive branching from the 
trachea (or generation 0) to the alveoli (or generation 23) reduces the diameters 
of the tubes but markedly increases the surface area of the airways (120-160m^ 
in total); with a network of over 2000 km of capillaries. The conjunction of the 
large surface area, the thickness of the alveolar epithelium (approx. 0.1-0.5pm 
thick) and the extended capillary network makes the alveoli a target for systemic 
drug absorption.
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Figure 1.2. Schematic of Weibel lung morphology model (Weibel 1963).
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At generation 17, the function of the tissue changes from conducting airways to 
gas exchange. The pulmonary parenchyma, consisting of approximately 
130,000 lobules (each containing 2,200 alveoli), is the tissue responsible for the 
gas exchange. The alveoli are very small porous air sacs that use passive 
osmotic diffusion mechanisms. Once a drug aerosol deposits in the deep lung, 
the major barrier to entering the body is the 0.1 pm layer of type I alveolar cells 
that cover 95 % of the alveolar surface. These cells, also described as 
squamous epithelial cells, are covered by a thin layer of surfactant (produced by 
type II cells) whose role is to lower the surface tension at the air/alveolar 
interface. Lung surfactant consists of 90 % lipids (of which there are 70 % of 
saturated and non saturated phosphatidyl choline, 10 % of neutral lipids, 5 % of 
phosphatidyl glycerol, 3 % of phosphatidyl ethanol amines and 2% of other 
phospholipids), 8 % proteins and 2 % carbohydrates (Lopez-Vidriero, 1984). 
Alveolar cells have “tight junctions” acting as barriers to the absorption of 
macromolecules and as a way to prevent pulmonary oedema by keeping the 
oncotic pressure gradient constant. The type II pneumocytes differentiate into 
type I cells to maintain the type I cell population and to repair the alveolar 
surface after damage from a virus or chemical agent (Washington et a/., 2001). 
In addition to epithelial cells, the alveoli contain macrophages that phagocyte 
particles and migrate either in the ciliated airways where the particles are 
cleared by mucociliary clearance or into the interstitial space.
1.3.1. Aerosol deposition in the respiratory tract
1.3.1.1. Mechanism of deposition
An aerosolised medication is designed to be delivered through the airways 
within ventilated gas and then be deposited at sites in the lung through inertial 
impaction, gravitational sedimentation, and diffusion onto lung surfaces (Brain 
and Valberg, 1979) as shown in Figure 1.3.
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Figure 1.3. Particle deposition mechanisms (Schulz, 1998).
1.3.1.1.1. Inertial impaction
Impaction is the major mechanism of deposition in the upper airways: the 
probability of particle deposition is related to the mass and density of the 
individual particle. Deposition also depends on the velocity of the particle, which 
itself depends on the respiratory flow (Schlesinger, 1985). It is more likely to 
occur in the extrathoracic (i.e. naso-pharyngeal and oro-laryngeal) and large 
conducting airways in which flow velocities are high and airflow direction 
changes often. For a particle travelling in an airway, the probability of its 
deposition by impaction is a function of a dimensionless parameter involving the 
air velocity, known as Stokes’ number (Stk), which may be calculated using the 
following equation:
Stk = P pd ^V
8 # [Equationl.1]
where pp\s the particle density, d the particle diameter, V the air velocity, p the 
air viscosity and R the airway radius.
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The higher the value of Stokes’ number, the more readily particles will deposit 
by impaction.
1.3.1.1.2. Sedimentation
Gravitational settling by sedimentation is the major deposition mechanism in the 
deeper airways where the airstream velocity is relatively low. The fraction of 
particles depositing by this mechanism is dependent upon their residence time. 
The distance at which a particle settles within a given time increases with its 
mass (i.e. with its density and with its diameter). For instance, a unit-density 
sphere of 1 pm diameter settles at a distance of 35 pm in Is, whereas a unit- 
density sphere of 10 pm diameter settles at a distance of 3000 pm in the same 
time (Schulz, 1998).
The rate of sedimentation is governed by the particle density as expressed in 
the form of Stoke’s law as Equation 1.2:
U , = D ^ g ^  [Equation 1.2]
' 18y
Where Ut is the terminal settling velocity, cr the particle density, p  the density of 
air, g the gravitational constant, D the particle diameter and /  the viscosity of 
air.
1.3.1.1.3. Diffusion
For particles with a diameter less than 0.5pm, particle displacement is governed 
mainly by diffusional transport. The random displacement or Brownian motion 
that a particle will cover by diffusion increases with elapsed time and decreasing 
particle diameter. Hence the highest probability of particle deposition due to a 
diffusional displacement occurs for very small particles inhaled into the lung 
periphery with its small airways dimensions. It is thought that 80 % of particles 
with a Mass Median Aerodynamic Diameter equal or less than 0.5 pm are 
eliminated during exhalation (Courrier et al., 2002).
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1,3.1.2. Factors influencing the deposition
The amount of aerosolised medication that deposits via the above mentioned 
mechanisms in a given region of the lungs depends on the physical properties 
of the aerosol particles, the patient (i.e. ventilation factors) and the device used.
1.3.1.2.1. Physical properties of the aerosol
The variable most frequently used to describe the deposition of the aerosol in 
the respiratory tract is the aerodynamic diameter. The motion of dispersed 
particles in a gas stream depends on the size, shape and density of the aerosol 
particles. The aerodynamic diameter combining these three properties is given 
by Equation 1.3:
da = dyfp [Equation 1.3]
Most aerosol devices available in respiratory medicine produce polydispersed 
aerosols, meaning that they contain particles that are of widely different sizes. 
Such an aerosol is frequently characterised by the Mass Median Diameter 
(MMD), the Geometric Standard Deviation (GSD) and the Mass Median 
Aerodynamic Diameter (MMAD).
• The MMD corresponds to the diameter of a particle such that 50 % of the 
mass lies below and 50 % above;
• The MMAD corresponds to the diameter of a sphere of unit density that 
has the same aerodynamic properties as a particle of median mass from 
the aerosol;
• The GSD in a log-normal distribution is defined as the square root size 
ratio of dg4% to the die% on the cumulative frequency curve; ds4% 
corresponding to the diameter for which 84 % of the particle mass lie 
below. A therapeutic aerosol typically exhibits a GSD of approximately 2. 
If the GSD is smaller than 1.2 then an aerosol is considered as 
monodispersed (Schulz, 1998).
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Aerosol particles that can traverse the pharynx and upper airways are generally 
below 5 pm MMAD (Figure 1.4). Particles between 2 pm and 5 pm deposit in 
the central airways, and particles below 2 pm deposit at the peripheral airways, 
if there is a percentage of particles within the aerosol that is finer than 1 pm, a 
portion of these will be exhaled or will be trapped in the residual air and 
eventualiy deposit on the respiratory bronchioles and perhaps on alveolar 
surfaces. The fraction of the aerosol containing particles below 5 pm in diameter 
is termed the fine particle of respirable fraction (FRF). This parameter is widely 
used both to describe the characteristics of the aerosol and its potential for 
delivery to the lower respiratory tract and as a quality control parameter for 
inhalation product.
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Figure 1.4. Particle deposition mechanisms at an airway branching site 
(Washington et ai., 2001).
1.3.1.2.2. Ventilation factors
While particle size criteria must be met to ensure efficient lung delivery, other 
variables that influence deposition include ventilation factors. Particle velocity, 
inspired voiume, inspiratory time, breath-holding duration and timing of aerosol 
delivery during inspiration all influence deposition. Particle velocity is 
determined by the aerosol generator and is influenced by the patient inspiratory 
flow of aerosol-laden air. Typical adult inspiratory flows during quiet tidal 
breathing are approximately 0.25-0.5 Us.
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Faster inspiratory flows increase oropharyngeal and upper airways deposition 
by inertial impaction, while slower inspiratory flows enhance more distal delivery 
and deposition through sedimentation and diffusion. Faster inspiratory flows 
(e.g. 0.5-2 Us) may be necessary with some dry powder systems to 
disaggregate and disperse the dry powder. The size of the inspired volume 
influences deposition by affecting both the amount of aerosol that enters the 
lung and the depth of penetration of the aerosol into the lung. Breath-holding 
after inhalation enhances deposition by facilitating sedimentation and diffusion 
(Pavia ef a/., 1977).
1.3.1.2.3. Device
Dry powder inhalation is a breath-actuated system requiring sufficient energy to 
be generated in order to effectively detach the adhesive therapeutical fine 
particles from their coarse carrier particles in the formulation (see point 1.4.1.3.) 
and disaggregate cohesive actives. If a patient inhales with a low flow, the 
efficacy of the separation process will therefore be reduced, the extent of which 
will be device and formulation dependent. One of the intrinsic characteristics of 
any DPI device is its resistance to airflow, which normally results in the flow 
through the DPI being restricted compared to that which is generated by the 
patient. Increasing resistance to airflow generally reduces the velocity of inhaled 
particles, reducing impaction and therefore increasing lung deposition. 
However, increasing the resistance of the device makes it more difficult for 
some patients to generate a sufficient airflow for an optimal aerosolisation. This 
is particularly true for children and geriatric patients who may be unable to 
generate high inhalation flows.
In pMDIs, a large proportion of the inhalable dose impacts and deposits in the 
oropharynx due to the velocity and the dispersion of the jet fired from the 
canister.
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1.3.2. Absorption
The importance of lung clearance and absorption mechanisms relate to the 
action of the drug. For local therapy involving bronchodilators or anti­
inflammatories, an extended residence time in the lung may be beneficial, 
whereas for systemic delivery (such as insuiin for the treatment of diabetes) a 
rapid absorption is desirable. The alveolar epithelium and the capillary 
endothelium have a high permeability to water, gases and lipophiiic substances. 
90 % of the absorptive area of the lung is therefore attributed to the alveolar 
epithelium, which primarily consists of type I pneumocytes. Soluble 
macromolecules can be absorbed following two mechanisms: trancytosis 
(passage through the cells) or paracellular transport (between the cells). Two 
types of trancytosis are known: adsorptive or non specific (through the type I 
alveolar epithelial cells and capillary endothelial cells) and specific receptor 
mediated, for example in the case of albumin (Kim et al., 2003). Three types of 
paracellular transport are known: bi and trijunctional transports, both occurring 
at the circumference of both endothelial and epithelial cells, and a transport 
through pores (Patton, 1996). The effects of the molecular weight, partition 
coefficient, pH and osmolarity on the kinetics of adsorption have been studied. 
Enna and Schanker (Enna and Schanker, 1972) showed that the adsorption of 
saccharides and urea was inversely proportional to the molecular weight. Effros 
and Mason (Effros and Mason, 1983), back in 1983 found a rough inverse 
relationship between the logarithm of the molecular weight and that of the 
clearance rate. It was also demonstrated that more lipophilic and non ionised 
drugs were absorbed better than their more hydrophilic and ionised 
counterparts (Schanker and Less, 1977).
1.3.3. Clearance
The clearance of inhaled particles deposited in the lower airways is 
accomplished by a self-cieaning mechanism known as the mucociliary escalator 
(in addition to coughing and alveolar clearance). The mucociliary clearance is a 
physiological function of the respiratory tract and is meant to remove dusts, 
excess of secretion and inhaled particles. It is one of the most important non­
specific defence mechanisms of the airways.
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The conducting airways, which in Weibel’s model comprise airway generations 
0 to 16 (trachea to terminal bronchioles), are lined with ciliated epithelium. The 
coordinated movement of the cilia propels the mucus lining (consisting of lower 
periciliary layer (sol) and upper mucus (gel)) and deposited foreign materials 
outwards towards the pharynx where they are swallowed (Wanner et al., 1996) 
(Figure 1.5). Mucociliary transport in the conducting airways is thought to take 
approximately 24 hours from the lung periphery to the epiglottis.
For an optimal clearance the epithelial cells should be intact, the mucus 
rheology and the ciliary’s activity normal. Limitations have been found for 
smokers (Foster et a!., 1985), patients with chronic bronchitis (Svartengren et 
a!., 1996) or with chronic asthma (Oberdorster, 1988).
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Figure 1.5. Schematic representation of the mucociliary clearance.
Particles deposited in the nonciliated region of the lung i.e. the terminal airways, 
will be subjected to alveolar clearance: the particles are phagocytosed by 
alveolar macrophages and subsequently transported to the ciliated bronchial 
airways (a non absorptive process) or into the alveolar interstitial space (an 
absorptive process). The absorptive process involves entering the alveolar wall. 
Once the particles leave the alveolar surface and penetrate below the epithelial 
barriers (type I and II cells), their removal occurs at a slower rate by both 
interstitial and intravascular macrophages. The rate of phagocytosis depends 
on the chemical composition, size and number of particles. Optimally the 
particle should be between 2 and 3 pm. The site of initial deposition of the drug 
particle is therefore an important parameter to consider in determining its 
resident time within the lung.
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1.4. Aerosol therapy
1.4.1. Aerosol generators
Different devices generate therapeutic aerosols: nebulisers, pressurised 
metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). The available 
evidence supports the safety and efficacy of these devices at the recommended 
drug doses. Tablel.1 summarises the advantages and disadvantages of these 
formats.
Advantages Disadvantages
Nebuliser
Jet
No patient coordination 
High dose possible 
NO CFG release 
Suitable for both 
solutions and suspensions
Expensive 
Not portable (bulky) 
Contamination possible 
Device preparation required 
before treatment
Ultrasonic
+ Faster delivery than 
jet nebuliser
MDIs
Conventional
Convenient 
Less expensive and 
more efficient than 
conventional nebulisers 
Portable 
Difficult to contaminate
Patient coordination and 
actuation required 
Cool feeling after actuation 
(Cold Freon effect) 
Large pharyngeal deposition 
CFC propellants
With spacer
Less pharyngeal 
deposition 
Less patient coordination 
required
More expensive and less 
portable than conventional 
MDI
DPIs
Passive
Propellant free 
Less problem of drug 
stability 
Less contamination
Dependent on patient's 
inspiratory flow rate 
More expensive
Active
Less dependent on 
patient breathing patterns Not on the market
Tabie 1.1. Advantages and disadvantages of the different inhaier devices, 
modified from Pierson (Pierson, 2000).
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1.4.1.1. Pressurised metered-dose Inhalers
Introduced in the mid-1950s pressurised metered-dose inhalers (pMDIs) are still 
the most commonly prescribed inhalation system for therapeutic aerosol 
delivery. A schematic representation of a pMDI is given in Figure 1.6. Eighty 
percent of the different inhaled medications (bronchodilators, anticholinergics, 
anti-inflammatory agents and steroids) are delivered in the US using this 
delivery system (International Pharmaceutical Aerosol Consortium, 1997). A 
pMDI contains the drug either as fine powder particles either dispersed or 
solubilized in propellants. Since propellants are poor solvents for most drugs 
and surface-active agents, co-solvents such as ethanol are required even if 
their low volatility may retard evaporation. The mixture contained in a 
pressurised canister is released upon actuation through a metering valve that is 
fitted into an actuator boot. After undergoing volume expansion in the passage 
within the valve, the droplets emerge into the air at high speed where the 
propellants evaporate, leaving free particles to be inhaled.
L>nig Sub'it.w^ 'c Isuspension 
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Figure 1.6. Schematic representation of a pMDI (Smyth, 2003).
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Despite being the most commonly used device, there are inherent problems 
with this technique as shown in Table 1.1. Major drawbacks include large 
oropharyngeal deposition (Morén, 1981) and inefficient drug delivery stemming 
from lack of coordination between actuation and inspiration (Crompton, 1990). 
The introduction of large-volume spacers in the 1980s improved the efficiency 
by reducing both the importance of the inhalation/actuation coordination and the 
early deposition of large propellant droplets in the oropharyngeal areas, by 
allowing time for propellant evaporation and deceleration of the aerosol cloud. 
On the negative side, using a large-volume plastic spacer may be encumbering 
for the paediatric population.
Major challenges faced by pMDI technology are reformulation issues with the 
newly approved HFA propellants (McDonald and Martin, 2000) following the 
phase-out of the traditional chlorofluorocarbon (CFC) propellants as decided by 
the United Nations in 1987 (Montreal Protocol on substances that deplete the 
ozone layer). Even if specific exemptions for “essential uses” ( metered dose 
inhalers (MDIs) used in the treatment of asthma and chronic obstructive 
pulmonary disease (CORD) were agreed for pharmaceutical aerosols, annual 
renewal is still required with decrease in allowances as alternatives become 
available (D'Souza, 1995). Much needed alternatives to CFCs may be found in 
the hydrofluoroalkanes (HFAs), especially tetrafluoroethane (HFA 134a) and 
heptafluoropropane (HFA 227), which do not contain chlorine and therefore 
have no ozone-depleting potential. Nevertheless, HFA and CFC propellants 
possess different physical and chemical properties leading to surfactant 
solubility problems in the new propellants (Byron et al., 1994). The use of HFA 
propellants in pMDIs developed for CFC propellants may cause unwanted water 
uptake from valves (Williams and Tcherevatchenkoff, 1998).
1.4.1.2. Nebulisers
Although the first choice of aerosol generator for the delivery of bronchodilators 
and steroids is the pMDI (O'Donohue, 1996), this format has high innovative 
potential due to developments in liquid spray delivery systems. In nebulisers, 
the drug is solubilised or suspended in aqueous solutions and possibly with co­
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solvents and surfactants. The active is inhaled during normal tidal breathing 
over several minutes through a mouthpiece or facemask.
Thus, nebulisers can be employed to deliver medications to populations such as 
children or elderly patients. Moreover, they are frequently used as an alternative 
to pMDIs or DPIs in patients who experience difficulties using these delivery 
devices.
There are two categories available depending on the energy type needed for 
the aerosol generation: the most commonly used jet nebuliser, relying on 
compressed air, and the ultrasonic nebuliser relying on a piezoelectric crystal 
(Figure 1.7). In a jet nebuliser, compressed air continuously enters the chamber 
through a narrow Venturi nozzle, creating an area of negative pressure at the 
outlet of the adjacent capillary feed system. This results in the fluid being drawn 
up into fine filaments according to the Bernoulli effect as shown in Equation 1.4.
P  + + pgh =  consiànt [Equation 1.4]
Where P is the pressure in the tube, p  the gas or liquid density, v the gas or 
liquid velocity, g is the gravitational acceleration and h the height above some 
reference level.
These fine filaments collapse into droplets under the influence of surface 
tension. Small enough droplets are carried away by the inhaled airstream, 
whereas the large, non-respirable ones impact on the walls of the chamber and 
baffles. The impacted large droplets are hence returned for recycling to the bulk 
solution kept in the chamber. The droplet size is mainly governed by the rate of 
incoming gas flow. Clay et al. (Clay et al., 1983) in a laser diffraction analysis of 
four jet nebulisers, showed a 50 % reduction in the MMAD when increasing the 
flow rate from 4 to 8 L/min. Droplets size was largely independent of the fill 
volume.
The ultrasonic nebulisers use a piezoelectric crystal vibrating at a frequency of 
1-3 MHz to produce particles (Taylor and McCallion, 1997). The vibrations are 
transferred from the crystal to the surface of the solution, generating a "fountain"
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from which large and small droplets are emitted. The droplet size is inversely 
proportional to the frequency and, as for the jet system, baffles remove large 
droplets by allowing them to fall again in solution. Most of energy is converted to 
heat as only a fraction is utilised in the formation of the aerosol droplets. This 
causes the temperature of the liquid within the nebuliser to increase, modifying 
the surface tension and viscosity of the liquid.
Despite the new developments including new designs, the use of nebulisers, 
traditionally a “hospital-focused therapy”, to administer pharmaceutical agents 
has many important limitations such as a large amount of drug wastage (over 
50 % with continuously operated ones (O'Callaghan and Barry, 1997), 
heterogeneous droplet population and dead volume (referring to the amount of 
solution trapped inside the device, usually in the range of 1 to 3 m l, that cannot 
be nebulised) (Dalby etal., 1996).
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Figure 1.7. Schematic representations of jet nebuliser (A) and ultrasonic 
nebuliser (B) (O'Callaghan and Barry, 1997).
1.4.1.3. Dry Powder Inhalers
In the 1970s, the first single dose dry powder inhaler with a hard gelatine 
capsule technology (Fisons Spinhaler®) was initially developed for the inhalation 
of relatively large amounts of disodium cromoglycate, a low potency non-steroid 
used in the treatment of allergic asthma. Since then, this niche has been
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extensively studied and the single-dose DPI technology expanded with the 
introduction of the Rotahaler® (GSK) for both salbutamol sulphate (SS) and 
beclomethasone dipropionate (BDP) and the Aerohaler® (Boehringer Ingelheim) 
for ipratropium bromide.
In 1987, the first multiple-dose DPI, the Turbuhaler® developed by Astra Zeneca 
was introduced on the market and quickly followed by the eight-blister 
Diskhaler® and later by its successor, the Acculaher® (GSK products). One of 
the strengths of the Turbuhaler system is it’s ability to deliver drug particles in 
the absence of any excipients, except in the case of formoterol, a highly potent 
drug that is diluted using “microfine” lactose (Oxis® (formoterol) and Symbicort® 
(formoterol/budesonide). The loss of patent protection on some key drugs for 
the treatment of asthma (i.e. S3, terbutaline sulphate, BDP and budesonide 
(BUD) was concomitant with the emergence of generic DPIs (e.g. Clickhaler® 
and Easyhaler®). Most currently marketed DPIs rely on the patient’s inspiratory 
effort to generate the aerosol. Difficulties can arise in producing sufficient a air 
flow, which has lead the industry to develop new “active devices” utilising an 
additional source of energy. The Spiros® DPI from Dura Pharmaceuticals, for 
example, applies electro-mechanical energy to disperse and aerosolise the 
formulation: battery-powered energy is converted into mechanical energy 
through a motor, which drives an impeller to create a high shear zone through 
which the powder must pass to exit the device. The patient’s gentle inhalation 
through the mouthpiece triggers the impeller, which causes the drug powder to 
aerosolise.
1.4.2. Choice of the device
In general the pMDI is seen as the most convenient and cost effective way to 
deliver an aerosol (Clark, 1995). The very extensive spectrum of delivery 
formats particularly with the emergence of novel DPIs, may result in confusion 
for both the prescriber and the patient (Lenney et al., 2000). In a study by 
Morice et al. (Morice et al., 2002), it has been shown that patients may prefer 
the DPI to the conventional pMDI. The acceptability of the Clickhaler® (as a DPI 
model) and the Becotide® plus Volumatic® (as a pMDI device) for the delivery of 
BDP to adult and paediatric patients with asthma was studied: 67 % of the
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patients found the DPI easier to use than the pMDI (22 %, p<0.01) and 
significantly more patients preferred the DPI (63 %) to the pMDI (28 %, p<0.01). 
An extensive review (Barry and O'Callaghan, 2003) compared the clinical 
efficiency of pMDI with or without spacers, DPIs and nebulisers. The available 
technology platforms should be chosen wisely, taking into consideration the 
characteristics of the different systems, the clinician and also the patient to 
ensure an optimal compliance and competence. For instance, young children 
and elderly patients may have difficulties coordinating pMDI actuation and 
inhalation, and devices requiring a high inspiratory flow rate may be not suitable 
for severe asthmatics. Table 1.2 summarises the device to be used for children 
with asthma.
Age (years) First Choice Second choice
0-3 pMDI + spacer + facemask
Nebuliser
3-5
pMDI + spacer
5-12
(bronchodilators)
pMDI + spacer, or DPI
DPI
5-12 (steroids) pMDI + spacer
12+
(bronchodilators)
DPI or breath actuated pMDI -
12+ (steroids) pMDI + spacer
DPI or breath actuated 
pMDI
Acute asthma (all 
ages)
pMDI + spacer Nebuliser
Table 1.2. Choice of inhalation device for children with asthma, adapted from 
Barry et al. (Barry and O'Callaghan, 2003).
1.5. Formulating dry powder inhalation systems
1.5.1. Production of micronised drugs
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In dry powder inhalation, one of the first requirements is to use micronised 
drugs. There are classically three methods used to generate respirable 
particles: supercritical fluid precipitation, spray drying and milling.
Supercritical fluid precipitation (SCFP) is a relative newcomer in the production 
of micronised particles. One of the main methods used is termed Solution 
Enhanced Dispersion by Supercritical Fluids (SEDS). This one-step process 
involves the use of liquid carbon dioxide as a medium, which is being pumped 
at the required flow rate and being passed through a heat exchanger 
maintained at a constant temperature.
The drug is subsequently mixed and dispersed with the supercritical fluid in the 
nozzle before being precipitated in the particle formation vessel. This solvent 
free technology also enables the formation of uniform particles (with identical 
particle size, morphology and crystal Unity). Velaga et al. (Velaga et al., 2004) 
used this technique to produce particles of BUD and flunisolide with suitable 
characteristics for inhalation. In another study, Steckel et al. (Steckel et al., 
2004c) also showed the possibility of obtaining micronised BUD by precipitation 
in supercritical carbon dioxide. The authors also stressed the importance of the 
process conditions on the aerodynamic properties of the obtained particles.
Spray drying is a well established method for respirable particle production. This 
technique is fully described in chapter 3 and will therefore not be subjected to 
any further explanation here. Application of spray drying has been described in 
various reports, for instance disodium cromoglycate (Vidgren et al., 1987; 
Chawla et al., 1994; Steckel and Brandes, 2004); however, no spray-dried 
products are currently marketed for respiratory drug delivery.
Finally, air-jet milling (Figure 1.8) is the traditional method used to produce 
active particles in the micrometer region. High velocity compressed air is 
introduced as a high pressure jet through opposite nozzles at the bottom of the 
milling chamber. The high velocity creates zones of turbulence into which bulk 
crystals are fed. The mill contains no grinding parts so the particle fracture is 
due to the collision of one into another. The particles are retained in the mill and 
remain entrained in the airstream until sufficient particle size reduction is 
achieved (below 10pm). Upon completion of this step, the fine material is
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removed by centrifugal flow into a collection vessel. Intense milling by fluid 
energy mill (also called air-jet mill) can induce particle changes such as 
variations in the surface area, crystallinity or polymorphic form, level of 
amorphous content and batch content uniformity. Those changes can lead to 
formulation problems in processing and redispersion, because of electrostatic 
(Byron et al., 1999), van der Walls, capillary and mechanical forces that lead to 
increased energies of association.
Airflow Ce ntrifugal re moval o f 
micronised material to 
collection vessel
chamber
Opposing jetInlet feed jet
impact region
Figure 1.8. Schematic of air-jet mill (adapted from Hickey, 2003).
1.5.2. Examples of drugs administered via the pulmonary route 
• Bronchodilators
Acute bronchospasm contributes to the characteristic wheezing of asthma. It is 
commonly treated by the utilisation of two different classes of drugs: P2 agonist 
and anticholinergics. Mild to moderate symptoms of asthma respond rapidly to 
the inhalation of short acting p2 agonists such as SS (Asmasal®, Ventodisks®) 
or terbutaline sulphate (Bricanyl®). These cause relaxation of bronchial smooth 
muscle through the activation of adenylate cyclase and thus allow the airway to 
dilate. Longer acting ^ 2  agonist such as salmeterol (Serevent®) or formoterol 
fumarate (Foradil®), useful in noctural asthma, should be intended for long-term 
prevention of asthma attacks and added to existing corticosteroid therapy. 
Muscarinic receptor antagonists block the action of acetylcholine released from
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parasympathetic nerves and thus prevent bronchial muscles from being 
constricted. Anticholinergics do not therefore prevent all types of 
bronchospasm, but are effective against irritant-induced changes in respiratory 
function. Ipratropium bromide (Atrovent®) is used to provide short-term relief in 
chronic asthma.
• Corticosteroids
By reducing airway inflammation and subsequent excessive secretion of mucus, 
corticosteroids are very effective in asthma. They inhibit inflammatory cell 
infiltration into the airways. They are recommended for prophylactic treatment of 
asthma when a p2 agonist is already administered more than once daily. BDP 
(Becodisks®, Asmabec®), BUD (symbicort®) and fluticasone propionate 
(Fixotide®) appear to be equally effective.
• Cromoglycate and related therapy
The asthmatic response triggered by an external allergen causes constriction of 
smooth muscle via the H1 receptors. This reaction can be prevented by using 
nedocromil sodium (Tilade®) and sodium cromoglycate (Spincaps®), which are 
the only non-steroid anti-inflammatory agents available for treating asthma.
• Mucolytics
Their role is to modify the rheological function of the mucus to aid in its 
clearance from the bronchi. It is particularly important in cystic fibrosis. A 
recombinant human deoxyribonuclease 1 is administered by inhalation using a 
jet nebuliser (Pulmozyme®).
1.5.3. Coarse carrier system
In most dry powder formulations, the micronised drug is blended with an inert 
excipient, usually a lactose monohydrate (in the size range of 70 to 120 pm) 
(Ganderton, 1992). The sugar is included in the formulation as a diluent and 
dispensing aid. The carrier’s purpose is to convey surface-adhered drug 
particles into the air stream as controlled aggregates where they are stripped off 
as individual respirable particles. Lactose is a natural disaccharide of glucose
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and galactose (as shown in its structural formula in Figure 1.9). It is obtained 
from the whey of cow’s milk; whey being the residual liquid of the milk following 
cheese and casein production (Kibbe, 2000). It exists naturally as two optical 
isomeric forms, a and (3, depending on the orientation of the hydroxyl group in 
position T.
It can also exist in a free aldehyde form qualifying lactose as a reducing sugar. 
This aldehyde form (open form) is observable during the interconversion of a 
and (3 lactose. For example, (3-lactose mutarotates to a-lactose under the 
influence of water vapour.
4-0-^D«6alaetopyranosyl-D*slucopyrano6e
6'
CHaOH
6 TT HCHaOH I
”  ÇHaCH
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Figure 1.9. Molecular structure of a and (3 lactose (Byron et al., 1996).
The most commonly used form of lactose in industry is crystalline a-lactose 
monohydrate (C12H22O11.H2O), which is prepared by crystallisation from a 
supersaturated solution below 93.5®C (Olano et al., 1983), whereby each 
unstable a anhydrous molecule absorbs a molecule of water. Alpha lactose 
monohydrate is a white to off-white crystalline powder, practically insoluble in 
ethanol at room temperature and soluble 1 to 4 in water at 25®C. Various 
grades of lactose are commercially available which have different physical 
properties such as particle size distribution and flow characteristic (Kibbe, 
2000). Adverse reactions to lactose are largely attributed to lactose intolerance, 
which occurs when intestinal enzyme lactase is deficient. The resulting 
indigestion of large quantities of lactose (over 12 g) may cause abdominal
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cramps, flatulence or diarrhoea (Savaiano and Levitt, 1987). This is due to the 
increase in water and sodium following an osmotic effect in the lumen. At 
pharmaceutical dosage level, lactase deficient patients should feel no 
discomfort.
The advantages of lactose monohydrate reside in its large availability, low price, 
toxicity profile, smooth crystal surface and good flowability. Nevertheless, 
despite being overwhelmingly used as a carrier material, this disaccharide is not 
the ideal and universal carrier for all active materials. For example, its reducing 
sugar function may interact with peptide or protein functional groups. In 
addition, the possible presence of endotoxin (referring to the lipopolysaccharide 
complex associated with the outer membrane of Gram-negative bacteria) and 
additives of bovine source drove scientists to look for alternative carriers. Tee et 
al. (Tee et al., 2000) investigated the dispersion and deaggregation of SS from 
mannitol and sorbitol carriers using a Rotahaler® coupled to a twin stage 
impinger (TSI). The authors showed that in binary systems, i.e. those without 
added fine sugars, formulations using mannitol as the carrier exhibited a higher 
fine particle dose (40.9 ± 4.4 pg) and higher fine particle fraction (9.0 ± 0.9 %) 
than those from a lactose based carrier (29.7 ± 4.3pg and 6.4 ± 1 . 0  % 
respectively). Using sorbitol as the carrier resulted in similar deposition pattern 
with a fine particle dose of 30.5 ± 3.0 pg and a fine particle fraction of 6.5 ± 0.6 
%. It was concluded that both sugars might be employed as alternatives to 
lactose. In another study Steckel et al. (Steckel and Bolzen, 2004) confirmed 
the promising potential of mannitol as a drug carrier for DPI formulation. Other 
tested sugars including sorbitol, maltitol and xylitol were barred due to their 
sensitivity to humidity, which is likely to increase the drug-to-carrier adhesion 
and therefore show poor dispersibility.
1.6. Particle interactions in dry powder inhalation systems
The adhesion between two micronised particles or a micronised particle and a 
solid surface is complex to describe. Particulate interactions may result from a 
combination of physical forces including electrostatic or Coulombic forces, 
capillary forces, solid bridge formation, and van der Waals forces.
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1.6.1. Electrostatic forces
In the gas phase, electrostatic forces can arise either from particle-charge 
interaction, image-charge effect, or electrostatic contact potential difference 
(Masuda and Gotoh, 1997).
• Particle-charge interaction
Particle-charge or Coulombic forces between two charged particles can be 
expressed mathematically by Coulomb’s law:
 ^ [Equation 1.5]
Where Qi and O2 are the charges on the two particles, R the interparticle 
separation, and eq the permittivity (or dielectric constant) of vacuum.
• Image-charge effect
When a negatively or positively charged spherical particle comes in contact with 
an uncharged surface, such as the walls of the container, an image charge 
results on the plane surface with the same magnitude but opposite sign as the 
particle charge. The resulting image force of attraction is given by the equation:
^  [Equation 1.6]
(2H)
Where Q is the particle charge, R the particle radius, H the separation distance 
and € 0  the permittivity of vacuum.
• Electrostatic contact potential difference
The contact between two uncharged, different solids results in an electrostatic 
contact potential difference being established. Electrons from the material with 
the lower work function are transferred to the material with the higher one.
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The work function of a material can be defined as the difference in energy 
between the energy of an electron occupying the highest energy level (the 
Fermi level) and the energy of an electron at the vacuum level (point in space 
where the electron can no longer feel the potential of the surface). Thus it 
corresponds to the minimum energy required to remove the weakest bound 
electrons from a material. The two work functions will eventually be similar and 
equilibrium established (Stewart, 1986). This electrostatic force of attraction can 
be calculated using the following equation (Visser, 1989).
[Equation 1,7]
M
Where R is the particle radius, H the separation distance, A l/ the potential 
difference arising from the difference in work functions, and £o the permittivity of 
vacuum.
If one or both of the materials are poor conductors, static charges can 
accumulate on the surfaces for long periods of time (i.e. insulators prevent 
redistribution of electrical charge). As electrostatic forces dependent upon the 
physical and chemical states of each material, contact between varying 
materials will result in the generation of different electrostatic charges.
1.6.2. Capillary forces
Water is easily adsorbed to a wide range of surfaces. Adsorption of water 
molecules on dry powders results in the condensation of water vapour in the 
interstices between adjacent particles. If enough condensation occurs, the 
surface tension of the liquid may result in the formation of a liquid bridge or 
liquid annulus between adjoining particles. Capillary condensation normally 
occurs at high relative humidities, usually in excess of 60 % (Hiestand, 1966). 
The magnitude of the capillary forces will depend on the surface tension of the 
liquid, the particle size and the wettability of the particles. When a liquid bridge 
forms between two particles the magnitude of the van der Waals force is much 
less than what it would be for two particles separated by air. As a result, at high 
relative humidity, the overall force responsible for particle adhesion is
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predominantly due to the capillary force and not the van der Waals force 
(Rabinovich et a i, 2002).
1.6.3. Solid bridge formation
Solid bridge interactions can occur between particles in a stationary particulate 
system in different ways. These includes mineral bridges between particles of 
the same material, direct chemical interactions between particles, partial melting 
of low melting point solids caused by friction, and shrinkage of the liquid film 
separating powder particles followed by crystallisation of the liquid bridge 
(Farber at a i, 2003).
1.6.4. Van der Waals forces
The principal attractive forces between neutral molecules, at a separation 
distance of the order of the molecule size, are named after the dutch physicist 
Van der Waals, who was the first to point out that deviations from the ideal gas 
law (PV=nRT) at high pressures were due to the gas molecules attracting each 
other, according to the following equation:
(v -  bn) =  nRT  [Equation 1.8]
Where P is the pressure, V the volume, n the number of molecules, R the gas 
constant, T the absolute temperature, a a constant whose value depends on the 
gas considered, and b the volume per mole occupied by the molecules.
Van der Waals forces are electromagnetic in nature, arising from the various 
interactions of the nuclei and electrons of one molecule or particle with the 
nuclei and electrons of another body. These low energy interactions, comprising 
the dispersion (London), orientation (Keesom) and the induction (Debye) 
interactions, are of greatest relevance to interfacial phenomena (Buckton, 
1995). Higher energy short-range interactions, i.e. chemical bonding, are not 
important for the adhesion of aerosol particles, because water or other organic
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molecules are usually adsorbed to the particles, thereby creating a physical 
shield or barrier to chemical bond formation.
• Keesom interaction (dipole-dipole interaction)
This type of van der Waals interaction occurs between polar molecules. These 
molecules possess a permanent dipole moment, because the centre of charge 
of the electrons does not correspond to the centre of charge of the nuclei. 
These interactions are due to the attraction between the negative and positive 
poles of nearby molecules combined with the repulsion between like-charged 
poles. Dipole-dipole interactions make, at most, a small contribution to surface 
and interfacial tension. One particular type of Keesom interaction is hydrogen 
bonding. This type of specific short-range interaction occurs between a 
hydrogen atom on one molecule and a more electronegative atom (usually 
oxygen, nitrogen, sulphur, or, less predominantly, a halogen atom) on a 
neighbouring molecule. The hydrogen atom acts as a proton donor (electron 
acceptor site), while the other atom has a lone pair and acts as a proton 
acceptor site (electron donor) (Zeegers-Huyskens and Huyskens, 1991).
• Debye interaction (dipole-induced dipole interaction)
This attractive interaction occurs when the permanent dipole (i.e. permanent 
electric field) on a molecule A induces a dipole moment on a neutral polarisable 
molecule B.
• London interaction (dispersion forces)
London interactions are the only van der Waals forces for molecules that have 
no permanent dipole or higher order moments. These are universally attractive 
and occur between all molecules. Of quantum mechanical origins, London 
interactions originate from correlation between instantaneous fluctuations in the 
charge distributions p"^  and p® of molecules A and B (due to rapid movement of 
their electrons).
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Quantitatively, the van der Waals force can be determined by two theories, 
either the London-van der Waals or the Liftshitz-van der Waals theory (Fan and 
Zhu, 1998). The former is a microscopic theory, which takes as a starting point 
the interaction between two symmetrical molecules. The latter is a macroscopic 
theory that is better suited to the description of the interaction between two 
macrobodies (i.e. two particles), making this approach more appropriate in the 
case of dry powder formulations. In the London-van der Waals theory the 
approximated potential energy between two molecules is calculated using the 
following equation:
E = - ^  [Equation 1.9]
Where A12 is a constant that depends on the characteristics of the molecules 
and r is the separation between the centres of the molecules.
Based on the concept of additivity, Hamaker postulated that the van der Waals 
interaction between two solids could be taken as the integration of all the 
interactions between all pairs of molecules making up the solids. The resulting 
equation for the interaction of a spherical particle and a plane surface is:
F = 4 î 2l [Equation 1.10]
6r
Where ai is the radius of the particle, r  the separation distance, and A 12 the 
Hamaker constant given by:
[Equation 1.11]
Where qi and Q2  are the atom/molecule density of the materials.
However, for closely packed atoms or molecules in a condensed body, the 
pairwise additivity approximation does not hold. The macroscopic Liftshitz-van 
der Waals approach solves this problem by modifying the expression of the 
Hamaker constant (Visser, 1989).
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Instead of depending on the characteristics of the individual molecules, it 
depends on the bulk properties of the materials themselves:
A = -^hOJ [Equation 1.12]
Where hœ is the Lifshitz constant, depending only on the material. For the 
interaction of two materials 1 and 2 separated by a medium 3, this constant is:
^ ^ 1 2 3  = ^ f  I
A ~^3 
.^1+^37
2^ ~^3 
V^ 2 +^3 7
d (  [Equation 1.13]
Where h is Planck’s constant and f/ the dielectric constant of material / along 
the imaginary frequency axis f.
1.7. Factors influencing particulate interactions
The performance of carrier-based and agglomerated dry powder aerosol 
formulations is predominantly influenced by drug and carrier properties such as 
size, shape, surface morphology, chemical composition, hygroscopicity, surface 
energy.
1.7.1. Particle size and the use of ternary components
It is easily understandable that van der Waals forces increase with particle size. 
Therefore it appears logical to decrease the particle size in order to decrease 
the particulate interaction. Staniforth etal. (Staniforth et al., 1982) confirmed this 
theory by studying two size fractions, 250-500 and 500-710 pm of recrystallised 
lactose. Interparticle adhesion forces, measured using the ultracentrifuge 
method, were much higher in ordered mixes based on the larger carrier 
particles (10.6 10'  ^ N vs. 2.3 10'^ N). Indeed, increased drug deposition is 
generally observed with smaller carrier size (Steckel and Müller, 1997) and 
increased proportion of fine particles (Lucas et al., 1998b; Zeng et a!., 1999; 
Zeng et a!., 2000b), as these factors may limit the adhesive forces occurring 
between the drug and carrier particles or the internal cohesive drug-drug
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interactions. One of the possible explanations was given by Staniforth 
(Staniforth, 1996b) and was based on the theory of active and passive adhesion 
sites on particle surfaces (first proposed by Mersey (Mersey, 1975)). In this 
theory, there is a variable pattern of particle-particle adhesion forces at different 
surfaces sites. The fines would occupy the high-energy “active” adhesion sites 
before the carrier powder is exposed to the drug particle fraction. This leaves 
only the lowest energy sites available for the adhesion of drug particles (Figure 
1.10). These are expected to be liberated from the carrier surface more 
completely upon application of a removal force.
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Figure 1.10. Possible model for the action of fine particle lactose (FPL) (Lucas 
etal., 1998b).
Another explanation might be that the lactose is intercalating between the drug 
particles, hence reducing the stability of the agglomerates. In the case of 
nedocromil sodium, which spontaneously exhibits agglomeration tendency, due 
to their high surface energy, high-shear mixing techniques physically disrupt 
drug-drug contact and promote deaggregation (Clarke et al., 2001).
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1.7.2. Particle shape-surface texture
Elongated carriers increase aerosol dispersibility and drug FRF, possibly 
because of the increased duration in the air stream drag forces. Manipulation of 
the shape and texture of the carrier can also improve the efficiency. Zeng et al. 
(Zeng at a!., 2000a) studied the influence of different morphological features 
(including shape and smoothness) with similar particle size on drug delivery. 
One of their conclusions was that increasing the surface smoothness of lactose 
crystals led to increased respirable fraction of SS. Clefs or pits on the surface of 
carrier particles provide areas within which drug particles are “hidden” from 
aerosolisation shear forces, whereas particles adhered to “flat” areas are more 
exposed. Higher rugosity of carrier and a more irregular drug particle shape can 
also reduce the flow and ease of dispersion by increasing the area of 
interparticle contact (Larhrib etal., 1999).
1.7.3. Surface energy
Solid surfaces possess a net imbalance of surface forces and consequently 
have a surface energy. The surface energy is not evenly distributed over the 
solid surface: plane surfaces have lower surface energy than surface asperities 
for example. Surface free energy (ys^°^) essentially refers to the attraction force 
between the surface solid molecules, which hold the molecular lattice together. 
It is usually described as the additive contribution from polar and non-polar 
forces as described in point 2.3.6. The minimum work necessary to separate 
two surfaces (and therefore the energy bonding them together) is equal to the 
difference in free energy before and after separation. The work of adhesion, Wg, 
between two different materials A and B is given by:
+ [Equation 1.14]
Where /  and f  are the dispersive components of the two solids and is the 
free energy of the interface.
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Thus, for a single material C, the work of cohesion, Wc, is given by:
W ^=ly^  [Equation 1.15]
Where f  is the dispersive component of the solid.
It is now clear that both adhesion and cohesion of solids are related to the 
surface energies of the interacting objects. Since drug particle detachment from 
the carrier is only possible if the drag force overcomes the adhesion forces and 
the weight of the particles, the predominant role of surface energy is obvious. 
The most common ways of determining surface energy have been reviewed by 
Buckton (Buckton, 1997) and comprise contact angle techniques, isothermal 
microcalorimetry, gravimetric sorption and inverse gas chromatography. 
Contact angle techniques have been the traditional method of surface energy 
assessment, even if some difficulties persist. For example it has been shown 
that the solid surface free energy is dependent on the liquids used for its 
calculation. A difference in liquid contact of 1® modifies the solid surface energy 
value, the variation being dependent on the choice of the combination of liquids 
(Planinsek et al., 2001). The method used in this study is inverse gas 
chromatography (IGC), which is described in detail in chapter 2. This technique 
provides important information about the surface chemistry of the substrate. 
This technique has been used to detect batch to batch variability both in term of 
excipients (a lactose monohydrate) (Ticehurst et a/., 1996) and active (SS) 
(Ticehurst et a!., 1994). It has also been used to assess differences in surface 
energy due to milling (Feeley et a!., 1998; Newell ef a!., 2001a; Ohta and 
Buckton, 2004) and different relative humidities (Newell et a!., 2001b; Ohta and 
Buckton, 2004). Furthermore, differences of surface free energy for two isomers 
have been studied (Grimsey et a/., 1999). In 2002, a paper published by Cline 
and Dalby (Cline and Dalby, 2002) correlated the surface energy of active and 
carrier components (converted from mJ/m^ to mJ/g by dividing by the surface 
area) to in vitro performance of a dry powder inhaler.
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1.7.4. Relative humidity
Relative humidity has an impact on interparticulate forces. This can occur by 
two different mechanisms, causing an increase due to capillary forces at high 
humidities or a decrease due to an increase in the conductivity of both the 
particle and the surrounding atmosphere. Braun et al. (Braun et ai., 1996) 
studied the influence of storage humidity on the aerosol deposition of disodium 
cromoglycate (DSCG). Deposition (measured as fine particle fraction of DSCG 
from formulations containing either lactose or dextrose as carriers) was studied 
at 55 % RH and 33 % RH. After storage at 55 % RH only 47.2% of the DSCG 
that was delivered by the same mixture stored at 33 % RH was determined in 
the stage 2 of the TSI. In a humid environment, capiliary condensation 
generates capiilary forces that increase the total adhesion forces. Finot et ai. 
(Pinot et al., 1996) determined that above 50 % RH the capillary forces 
dominate. In a study using the atomic force microscopy (AFM) (Berard et al.,
2002), adhesion between micronised zanamivir crystals and lactose 
monohydrate was measured at different RH. The authors concluded that from 0 
to 32 % RH and from 32 to 85 % RH, the adhesion values were multiplied by 
two at each step. In another study, Young et al. (Young et al., 2003) studied the 
effect of humidity (ranging from 15 to 75 %) on separation energies for SS using 
AFM. They claimed that the increase in particle cohesion at higher humidities 
(due to capiilarity forces) led to an increase in energy required for 
deagglomeration. This may well result in a decrease in the aerosol efficiency. 
The effect of humidity should also be taken into account in the selection of a 
suitable salt for a drug. In two studies, Jashnani et al. (Jashnani et al., 1995; 
Jashnani and Byron, 1996) investigated the dry powder aerosol performance of 
salbutamol and different related salts. In the first study, they showed that FPF of 
both salbutamol and salbutamol sulphate, at any temperature, decreased with 
increasing RH (FPF dropping from 59.4 % at 43 % RH to 35.8 % at 85 % RH for 
the saibutamol sulphate). In the second study, FPF for all compounds studied 
was humidity dependent at 45°C aithough the sulphate and the free base 
showed more drastic changes as RH increased compared to the other salts. 
Uncontrolled high humidities have been shown to decrease the FPF of BDP 
from a lactose based formulation (Geuns etal., 1997). Harjunen etal. (Harjunen 
et al., 2003) investigated how both the drug to carrier ratio and the storage
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condition (40®C / 75 % RH) were affecting the deposition of both SS and BUD 
using different sugars as carriers: a lactose monohydrate, mannitol and glucose 
anhydrate. Irrespective of the chemical nature or the concentration of the 
carrier, the respirable fraction of SS decreased after storage. On the other 
hand, the effect of storage on the respirable fraction of BUD was dependent on 
the carrier and drug to carrier ratio. It has to be mentioned that ambient humidity 
can be particularly important as hygroscopic particles will increase in size as 
they flow through a high air stream (approximately 99 % relative humidity) due 
to condensation of water onto the particle surface (Perron, 1977). Hygroscopic 
growth is therefore likely to increase the deposition in the upper airways.
1.7.5. Electrical properties - triboelectrification
During powder handling processes such as grinding, sieving, pneumatic 
conveying or mixing, electric charges arise from interparticulate friction and 
collision as well as collisions between the particles and the contact surface. The 
resulting effect is a net charge on the particle, which is either electronegative or 
electropositive. Charge accumulation is influenced by many factors including 
particle shape and size, nature and work function of the contacting surface, 
surface purity as well as atmospheric conditions (Bailey, 1984). Eilbeck et al. 
(Eilbeck at a!., 1992) charged a range of a lactose monohydrate particles 
(ranging from 125 to 1000 pm) against rough steel insert, and showed that the 
specific charge values increased in negativity with a decrease in particle size. 
Carter at al. (Carter at al., 1992) investigated the triboelectrification process of a 
lactose monohydrate, SS and BDP. Different lactose size fractions were tested 
and their specific charge values (ratio of total charge to mass) were measured. 
This work showed that decreasing the particle size of the excipient led to an 
increase in the specific charge value due to an increase in particle number 
density of the smaller size fraction (resulting in a bigger surface area for charge 
transfer). Electrostatic interactions play a significant and important role in dry 
powder inhalation since they not only influence the stability of ordered mixes of 
drug and carrier particles but also the passage through the inhalation device 
and the particle separation upon actuation. In another study. Carter at al. 
(Carter at al., 1998) studied the charge accumulation and decay on compacts of 
lactose, SS and polyvinyl chloride (used as a device material) using a Faraday
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well method and a capacitive probe method. Using a corona electrode, SS 
retained a significant charge after 120 min. One possible way of modifying the 
charges within a binary system is by adding fine particles consisting of lactose 
(Bennet et al., 1999), magnesium stearate (Staniforth, 1996a) or L-leucine 
(Staniforth, 2000). All additions resulted in a change in the attraction and 
detachment of the drug particles.
1.8. Aims of the thesis
In this study some factors influencing dry powder inhalation have been 
examined. Both the formulation and the device employed were investigated. 
Two model drugs: SS and BDP were chosen to represent a hydrophilic and 
hydrophobic active substance respectively. Two types of inhalers were also 
used: a metered reservoir device (Clickhaler®) and a capsule pre-metered 
inhaler device (Aerolizer®). The principal objective of this work was to rationalise 
the approach for dry powder inhalation systems and limit as much as possible 
the aerosol deposition variations induced by the different parameters.
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2
Materials and methods
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2.1. Materials
2.1.1. Source of materials used
Lactose monohydrate from the following three sources were evaluated as 
carriers for DPIs in chapter 3: (1) Pharmatose 325M (B.N. 10007701) from DMV 
International (The Netherlands), (2) Aero Flo 65 (B.N. 8500122121) from 
Foremost Farms (USA), and (3) Lactohale LH 100 (B.N. 314039/S) from 
Borculo Domo Ingredients (The Netherlands).
In addition, crystalline a-lactose monohydrate (B.N. 23416) obtained from 
Borculo Whey Products (UK) was used as a reference material for the solution 
calorimetry study described in chapter 3. It was also used for the different spray 
drying experiments to produce either 100 % amorphous material or different 
lactose/PEG 4000 systems. PEG 4000 (B.N. 565220442049) was purchased 
from Prolabo (France). Microfine Pharma 201 (B.N. E949423) from Borculo 
Domo Ingredients (The Netherlands) was used for inverse gas chromatography 
analysis described in chapter 4. A mixture of 80 % p-lactose and 20 % a- 
lactose (B.N. A010045201) was obtained from Acros Organics (Belgium). This 
mixture was to be used as a reference material for the X-ray diffraction analysis 
in chapter 3.
Methanol used for the BDP analysis was HPLC grade and purchased from 
Fisher Scientific, UK. Analytical grades of ethanol (96 %) and hydrochloric acid 
solution (5 M) were provided by BDH and VWR respectively. Deionised water 
was obtained from a DV 25 water purification system (Elga Ltd, UK).
Materials used for inverse gas chromatography were all HPLC grade or 99 %+.
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2.1.2. Drug models
2.1.2.1. Beclomethasone dipropionate
Beclomethasone dipropionate (BDP) was chosen as a representative 
hydrophobic drug model. This drug is a synthetic steroid used for the 
prophylaxis of asthma (British National Formulary, 2004). It reduces broncho- 
constriction by decreasing the airway hyper-response and mucus secretion. The 
high topical anti-inflammatory activity of BDP with a lower systemic activity, due 
to metabolic inactivation of the swallowed portion of the dose, appears to be the 
principal reason why beclomethasone controls asthma at doses that do not 
cause important glucocorticoid effects. Once inhaled, BDP is transformed in the 
lung to the monopropionate form through enzymatic hydrolysis. Due to its 
chemical structure (Figure 2.1), its solubility in acetone is high but sparing in 
alcohol. Three different forms of BDP are known: the anhydrate, the 
monohydrate and the organic solvate (Parmar, 1997). The crystal form of BDP 
used throughout was the anhydrous form used micronised (with a volume mean 
diameter of 1.7 pm) and supplied as a gift from Sicor (Italy, B.N. 6661/MI).
OCOEt
•OCOEt 
V—Me
Me
Figure 2.1. Chemical structure of BDP.
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2.1.2.2. Salbutamol sulphate
Salbutamol sulphate (SS), also known as albuterol sulphate, was chosen as the 
hydrophilic drug model. This drug is a short acting (32 adrenoceptor agonist, 
which is probably the most common medication group used in respiratory 
practice. It is generally used for its bronchodilator properties in the management 
of bronchospasm in bronchial asthma (reversible airways obstruction). The 
smooth muscle relaxation follows the stimulation of the (32 receptor in the cell 
membrane (activating the adenylate cyclase). This leads to a decrease in 
intracellular calcium levels essential for actin-myosin cross linkage. SS is a 
white, crystalline powder, freely soluble in water and slightly soluble in alcohol 
or ether. No solvate or hydrate forms have been reported. The micronised form 
of SS (Figure 2.2) was supplied as a gift from Medeva Pharma Ltd (UK, BN 
15732) with an average volume mean diameter of 2.3 pm.
H OH
NHBu-t
i
CFLOH
and enanîiomer
Figure 2.2. Chemical structure of SS.
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2.1.3. Inhalation devices
2.1.3.1. The Clickhaler'.©
The Clickhaler (Figure 2.3) is a multi-dose dry powder inhaler developed by 
Innovate Biomed Limited (St. Albans, UK) and is commercially available as 
Asmabec™ (BDP 50, 100 and 250 pg per dose) or Asmasal™ (88 114 pg per 
dose) (British National Formulary, 2004). The Clickhaler® is a reservoir device 
metered inhaler containing a drug hopper and dose metering mechanism. 
Pressing the dosing push button causes the dosing cone to rotate and 
transports one metered dose into the inhalation channel, and allows the dose 
consisting of approximately 3 mg of the lactose blend to be presented for 
inhalation (Mantel and Newhouse, 1999).
Hopper plug
Ratchet
Compression spring
Cono support cover
Figure 2.3. Schematic view of the Clickhalef® (Parry-billings et al., 1999).
The Clickhaler® device was selected because it has reported delivered dose 
uniformity, even at low nominal doses (Fukunaga et a/., 2000). It also produces 
efficient in vitro aerosol generation (30 to 60 % fine particle fraction (FPF) over 
a range of drug formulations and flow rates), whereas other recent passive DPI 
devices (Diskus® / Accuhaler®) have a lower efficiency (around 20 % in vitro). 
The performance of older DPIs may also be more flow rate sensitive.
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Furthermore, the Clickhaler is able to provide a comparable bronchodilator 
response in patients with moderate to severe asthma when compared to a 
pMDI used optimally (Newhouse etal., 1999).
Empty devices were received as a gift from Innovata Biomed Ltd. The different 
formulations were introduced into the reservoirs of the empty Clickhaler® and 
plugged with caps. The reservoirs were filled to two thirds to allow enough 
headspace for device shaking prior to actuation. Each formulation was tested 
three times. Between two sets of experiments, the device was cleaned and ten 
waste shots fired. A new device was used for each separate formulation.
2.1.3.2. The Aerolizer®
The Aerolizer® (Figure 2.4) is a single-dose dry powder inhaler, developed by 
Novartis Pharmaceuticals Corporation (USA), commercialised to deliver the 
selective P2 adrenergic drug formoterol fumarate. In the Aerolizer®, the capsule 
containing the single dose is pierced in the device by a set of four pins after 
depressing two buttons on each side of the capsule chamber. On inhalation, the 
capsule caused to lift out the capsule chamber into the inhalation spin chamber 
where it rotates. The device resistance is low (0.06 cm H2O (L/min). Even if in 
vivo studies showed no impact of different flow rates on clinical effect using the 
similar device Cyclohaler® (Zanen et ai., 1992), in vitro studies pointed out the 
necessity to test DPIs at different flow rates depending on their resistance. 
Chew et ai. (Chew and Chan, 2000) showed that the performance of the 
Aerolizer® was slightly dependent on the air flow rate, whereas there was no 
significant variability over a range of inspiratory flow rates (15, 30 and 60 L/min) 
observable with the Clickhaler®. All in vitro studies involving the Aerolizer® were 
performed at an airflow of 60 L/min.
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Figure 2.4. Schematic view of the Aerolizer®_
In order to load the Aerolizer® with a capsule containing the formulation to be 
tested, the body of a size 3 gelatine capsule was filled manually with 30 mg of 
powder accurately weighed using a micro-spatula. The capsule was then closed 
by placing and locking the cap and placed in the capsule chamber. The devices 
used were supplied by Novartis (Basel, Switzerland). Each device was used for 
only one measurement.
2.2. Methods
2.2.1. Production of particles by spray drying
Particles prepared by spray drying were examined throughout this dissertation. 
The production of particles by this process has gained considerable attention in 
recent years. By definition it is “the transformation of a given feed stock from a 
fluid state into a dried particulate form by spraying the feed into a hot drying 
medium” (Masters, 2002). The feed stock can be a solution, a suspension or an 
emulsion. One of the biggest advantages of spray drying over other drying 
techniques (such as tray-drying and freeze-drying) is the possible control over 
the final particle morphology, which is of the biggest importance within the 
pharmaceutical industry.
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One of its biggest drawbacks, however, is the deposition of the product on the 
walls of the drying chamber and on the different ducts. This leads to poor yields 
and hence makes this technique quite costly, especially for expensive products. 
Four main stages are generally involved in this method: atomisation, spray-air 
contact, drying of feed material and separation of the dried product.
The formation of a spray (atomisation) and its contact with the drying medium 
are important characteristic features. Elversson et al. (Elversson et a/., 2003) 
studied the influence of spray drying parameters on the produced lactose 
particle characteristics. A higher atomisation airflow (at constant feed rate) 
resulted in smaller droplet size, whereas increasing the orifice diameter of the 
nozzle from 1.5 to 2.0 mm resulted in doubling the size of the particles. The 
feed solid content also influences the atomisation since an increase in feed 
concentration increases the feed viscosity, which in turn produces coarser 
sprays on atomisation. In the same study, the particle size distributions of 
lactose particles spray-dried from different feed solutions (1, 5, 10 and 20 % 
w/w) were investigated. Only a moderate size difference in particles was 
observed when lactose solutions of 5 to 20 % (w/w) were employed, whereas 
particles from 1 % solution appeared far smaller.
After atomisation, the second step is the spray-air contact. Three different types 
of contact can be encountered:
• Co-current flow where the feed and the drying air flow in the same 
direction;
• Counter-current flow where the material is sprayed in the opposite 
direction of the flow of hot air;
• Combined co/counter-current flow, combining the advantages of the two 
pre-mentioned methods.
The work described in this dissertation is focused on the operational 
characteristics of two laboratory scale spray dryers: the Büchi 191 mini spray 
dryer used for the production of lactose/PEG 4000 systems (see chapter 4 and 
5) and the Niro SD MICRO™ for the production of SS/PEG 4000 systems (see 
chapter 6). Both spray dryers operate in a co-current manner.
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Evaporation is rapid and the duration of exposure short. This is particularly 
important for heat sensitive materials such as proteins. Maa et al. (Maa et a!., 
1997) investigated the effect of drying conditions and formulation variables on 
the morphology of spray-dried proteins. They stated that the droplets along the 
drying chamber were exposed to a temperature dominated by the outlet 
temperature rather than by the inlet temperature. They also showed that, based 
on the spray drying of water, an increase in the outlet temperature was directly 
proportional to an increase in the inlet temperature and/or the drying air flow 
rate. The outlet temperature decreased in a linear way with increasing liquid 
feed rate and/or atomizing airflow rate. Generally, particles reach a maximum 
temperature which is 15 to 20°C below the outlet temperature of the co-current 
dryer (Masters, 2002)
The drying of a wet droplet (Figure 2.5) corresponds to the double transfer of 
mass and heat after coming into contact with the drying air. The drying of a 
spherical droplet of liquid containing solid can be divided into 3 different stages.
• Stage 1 (sections A-B): In contact with the air, evaporation takes place 
from the saturated vapour film at the droplet surface. The temperature of 
the droplet surface approaches the wet-bulb temperature of the drying 
air. The wet-bulb temperature corresponds to the temperature at which 
evaporated water brings the air to saturation at the same temperature.
• Stage 2 (sections B-C): The drying rate is constant. There is sufficient 
moisture and molecular mobility within the droplet to replace lost 
moisture from the surface. The particle experiences shrinkage with a 
negligible temperature change.
• Stage 3 (sections C-E): At point C, the droplet moisture level is too low to 
compensate that which is lost. This results in the formation of a crust on 
the droplet surface (point D). The thickness of this crust increases with 
time, resulting in the slowing of the evaporation rate. Evaporation 
continues until the droplets or now the particles acquire a moisture 
content that is in equilibrium with the surrounding air.
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Heat
Shrinkage
Dr>'ing with droplet 
shrinkageDroplet heated to air 
wet-bulb temperature
Droplet at initial 
temperature
Crust
Progressing
End of dr>'ing Drying with 
crust formation
Figure 2.5. Different drying stages involved in spray drying modified from 
Farid (Farid, 2003).
The final stage involves the separation of the solid product from the air stream. 
A cycione separator, through which product and air pass after exiting the drying 
chamber, enables a separation from the drying medium. The material 
accumulates in a collecting vessel at the base of the cyclone. It has to be 
mentioned that separation is not 100 % efficient and that some fines may be 
iost through the exhaust air. in the case of the Niro SD MICRO™ some back 
filters ensure a full recovery of the product.
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2.2.1.1. Spray drying using the Büchi 191
The Büchi 191 (Figure 2.6) uses a two-fluid pneumatic nozzle (0.5 mm 
diameter). The feed concentration is pumped to the nozzle by a peristaltic pump 
using silicon tubing and then atomized using compressed air from an in-house 
supply (100 psi).
• Production of amorphous lactose
In order to investigate the amorphous content of different batches of lactose 
using solution calorimetry, a calibration curve had to be established beforehand, 
requiring the production of amorphous lactose material. This was achieved by 
spray drying a 10 % (w/v) solution of a-lactose monohydrate following 
parameters shown in Table 2.1. The experiments were performed at constant 
process conditions and only the feed rate was slightly modified in order to 
minimise outlet temperature fluctuations.
Parameters Settings
Inlet temperature (®C) 185-190
Outlet temperature (®C) 85-90
Aspirator dial 60%
Pump 18%
Atomiser airflow rate (Normliter/h) 400
Table 2.1. Spray drying parameters used to obtain amorphous iactose and 
crystaiiine iactose/PEG 4000 particles.
• Production of crystalline lactose/PEG 4000 systems
Three different 50.0 g blends consisting of lactose/PEG 4000 systems 
(containing 1, 5 and 10 % PEG 4000 by weight of solids) were dissolved at 
room temperature in 500 mL deionised water. This ensured full dissolution of 
lactose monohydrate in water (solubility at 25°C of 1 in 4.63 (Kibbe, 2000)). The 
spray drying parameters employed were identical to the ones set out in Table 
2.1 above.
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•  Production of partially amorphous lactose/PEG 4000 system
A formulation comprised of 10 % PEG 4000 by weight of total solid, was spray- 
dried as a 10 % (w/v) aqueous solution using the parameters shown in Table
2.2.
Parameters Settings
Outlet temperature (®C) 120-125
Inlet temperature (°C) 76-80
Aspirator 80%
Pump 14%
Atomiser airflow rate (Normliter/h) 600
Table 2.2. Parameters used to obtain partially amorphous iactose/PEG 4000 
co-spray-dried system.
• SS/PEG 4000 and SS/lactose/PEG 4000 systems
For these systems involving a much larger number of experiments, the detailed 
methodology will be fully described in the relevant chapter.
All product powders were removed from the collecting vessel as soon as the 
spray drying process was over and stored in a desiccator over silica gel, at 
room temperature.
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Figure 2.6. Outline of the Büchi 191 spray dryer (left) and photograph of spray drying in operation (right): A=feed pump, 
B=compressed air inlet, C=pneumatic nozzle, D=primary drying chamber, E=control panel, F= sample feed holder,
G=spray drying cyclone, H= collection vessel and l=aspirator.
2.2.1.2. Spray drying using the Niro SD MICRO™
Unlike the Büchi, the process gas employed in the Niro SD MICRO™ (Figure 
2.7) is compressed filtrated nitrogen, which is heated by means of an electrical 
air heater in order to evaporate the liquid contents of the feed solution. It 
enables the operator to use flammable solvents and, in our study, to spray dry 
organic suspensions consisting of SS suspended in an ethanolic solution 
containing PEG 4000. Prior to start up, it was important to determine and set 
the temperature safety class for the solvent employed. For ethanol a heater 
element surface temperature limit of 300®C was adopted since the auto-ignition 
temperature for this solvent was found to be 363°C (Niro Manual). The hot 
process gas enters the chamber through the process gas disperser and is 
immediately mixed with the atomized suspension coming from the two-fluid 
nozzle. The liquid is evaporated and the remaining dry particles leave the 
chamber through the outlet duct together with the process gas. The powder 
passes through the cyclone and is collected in a glass jar. Smaller fines 
accompanying the process gas may be collected within a bag filter. The process 
requires that gas flow and nozzle flow are obtained by opening the nitrogen 
main valve followed by adjustments with flow controllers. The inlet process gas 
temperature was set as shown in Table 2.3 and the heater switched on. When 
the inlet reached 10® C over the set value, the peristaltic pump controlling the 
feed rate of the ethanolic solution was turned on. The ethanolic solution was 
sprayed until the atomisation of liquid was constant. When all parameters were 
stabilised for ten minutes the hose of the pump was transferred to the feed 
suspension. Once finished, the hose from the peristaltic pump was transferred 
back to the clean solvent, and the jar containing the product was removed from 
the system and stored in a desiccator at room temperature.
Parameters Setting
Chamber inlet gas flow (kg/h) 20
Atomiser gas flow (kg/h) 2.0
Inlet temperature (®C) 85-90
Outlet temperature (®C) 60-65
Feed pump 28%
Table 2.3. Spray drying parameters used on the Niro SD MICRO TM
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Figure 2.7. Outline of the Niro SD MICRO spray dryer (left) and photograph of spray drying in operation 
(right): A=nitrogen main valve, B=feed pump main air valve, C=feed pump air filter, D=drying chamber,and E=spray 
drying cyclone. N.B. The schematic is a mirror image of the photograph.
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2.2.2. Preparation of powder blends
Mixing is an intermingling of two or more dissimilar fractions of material. The 
primary objective of powder mixing is to obtain dose uniformity. It is necessary 
for the active ingredient to be homogeneously mixed with the carrier excipient. 
Different factors influence the quality of a blend, including the order and length 
of time of mixing, type of mixer used, blender loading, and the physico-chemical 
properties of all active and excipients (size, shape, density and surface 
properties).
The best obtainable mixture would be one in which there was the least variation 
in composition for any given sample size. Two types of blend exist: random and 
ordered. Random mixes involve particles of equal size and weight with little or 
no surface effects, whereas ordered mixes do not require equally sized or 
weighted particles. Ordered mixes are therefore formed when a fine component 
has sufficient intrinsic cohesiveness to adhere to the surface of a coarser 
component. This involves the types of particle interaction, which were described 
in detail in chapter 1.
Experimentally, all blends were mixed in a 14 m l glass container with 
approximately 50 % of the blending vessel being filled. Lowering the fill volume 
would increase the space for powder movement and allow a greater degree of 
interaction, which in DPI formulation would be detrimental. On the other hand, 
increasing the powder volume would decrease the particle interaction, but also 
might decrease the mixing efficiency by decreasing the space for powder 
homogenisation. Blending was carried out in a three-dimensional Turbula T2C 
mixer (Glen creston UK). Adhesion to the vessel was regarded as insignificant 
by comparing the theoretical to the measured drug content in the sample. The 
drug powder was mixed with the carrier so that the final concentration of drug in 
the formulation ranged from 1.0 to 4.0 % (w/w). Each blend was prepared in 5.0 
g quantities. A sieving process was required to deaggregate the raw materials. 
Due to the cohesive nature of SS and BDP, the deaggregation required manual 
pressure using a spatula for its passage through a 355 pm sieve screen.
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When stated, an air-jet sieve (Alpine, Germany) was used to effectively remove 
any present particle below 45 pm in size. The air-jet method is a single-sieve 
system for dry powders. In this technique, the sieve is mounted in a sealed 
chamber and the air is drawn upwards through the sieve from a rotating slotted 
nozzle to fluidise the sample. Undersized particles are carried downward 
through the sieve to a collection canister. Each carrier was sieved for 15 
minutes using a sieve aperture of 45 pm (Endecotts, UK).
2.2.3. Assessment of content uniformity
One of the issues in pharmaceutical formulation is to achieve a high drug 
content uniformity. Therefore, prior to the study of in vitro deposition patterns, 
the content uniformity must be assessed. Both SS and BDP were quantified by 
UV spectrometry.
Calibration curves for both drugs were determined by a procedure described in 
the British Pharmacopoeia (BP) under their respective monographs. A 0.008 % 
(w/v) solution of SS in 0.1 M hydrochloric acid (HOI) was prepared following the 
method outlined in the BP. This solution was analysed over a range of 200 to 
400 nm using a Cary 3E, UVA/is spectrophotometer. A Amax of 276 nm was 
obtained and all analyses conducted with SS were therefore performed at this 
wavelength. A range of concentrations varying from 0.0002 % (w/v) to 0.0010 % 
(w/v) was then prepared from a stock solution of 0.1 % (w/v) SS in 0.1 M HCI. 
Samples were analysed using an Ultrospec 2000 spectrophotometer 
(Pharmacia Biotec, UK) at 276 nm. A good linear correlation between UV 
absorption and SS concentration was found within this region (r^= 0.9987). The 
gradient of the solid line in Figure 2.8 was found to be equal to 61.5, with a y- 
axis intercept of 0.0003. BDP was also analysed over the range of 200 to 400 
nm, using a Cary 3E, UV/Vis spectrophotometer. For this purpose, a 0.002 % 
(w/v) solution of BDP in methanol was prepared following the method outlined in 
the BP. A Amax of 238 nm was obtained for the hydrophobic drug and all 
subsequent analyses were therefore performed at this wavelength. The same 
concentration range as that for SS was prepared and the calibration curve 
established.
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A good linear correlation between UV absorption and BDP concentration was 
also found within this region (r^= 1 ). The gradient of the dashed line was equal 
to 284, with a y-axis intercept of minus 0.0064.
y = 284x- 0.0064
0.25 -
0.2 -
0.15 -
y = 61.5k + 0.0003 
= 0.9987
0.05 -
0.0002 0.0004 0.0006 0.0008 0.001
Concentration (% w/v)
Figure 2.8. UV calibration curves for SS(solid line) and BDP (dashed line).
Neither PEG 4000 nor lactose interfered with the UV measurements since 
neither was absorbing alongside the drugs at these wavelengths.
Once the blending process was completed, ten samples of the powder bed (of 
approximately 10 mg each) were obtained and accurately weighed. Three 
samples were obtained from the top, four from the middle and three from the 
bottom of the powder bed, and each was finally transferred into a 100 mL 
volumetric flask. SS samples were dissolved in 0.1M HCI, while BDP samples 
were dissolved in a methanol-water mixture (70:30 (v/v)). The methanol-water 
mixture ensured that both lactose (hydrophilic) and BDP (hydrophobic) were 
fully dissolved. The solutions were subsequently analysed using UV 
spectroscopy. To eliminate the effect of weight variations between the individual 
samples, the drug content was normalised for each sample weight. The 
uniformity of the blend was characterised by the coefficient of variation of the 
samples. This parameter describes the standard deviation (o) of the ten 
samples as a percentage of the mean drug content (M). A coefficient of 
variation (C.V.) below 5 % corresponded to good blends. Only these blends with 
a good homogeneity were taken to the next stage of the investigation.
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2.2.4. Characterisation of aerodynamic properties of dry powder aerosols
A key pharmaceutical challenge for DPIs is to ensure that there is good dose 
uniformity. In vitro aerosol particle sizing methods have evolved in parallel to the 
increased interest in powders for inhalation. In all in vitro studies, the British 
Pharmacopoeia was followed, which adopts the TSI, Apparatus A, which was 
initially developed to assess pMDI performance (Hallworth et ai., 1978; 
Hallworth and Westmoreland, 1987). As illustrated in Figure 2.9, the aerosol 
cloud is introduced at the inlet (A) and passes through a glass tube containing a 
90® turn (B), designed to mimic the oropharyngeal region. It then passes the 
upper impingement chamber (D), which is filled with 7 mL of a suitable solvent 
(0.1M HCI in distilled water for SS and a 70/30 mix (v/v) methanol/water for 
BDP). The particles passing to stage 2, corresponding to the lower impingement 
chamber, containing 30 mL of suitable solvent, are considered to be respirable 
and below 6.4 pm (Miller et ai., 1992). This value corresponds to the 
aerodynamic cut-off diameter at a flow rate of 60 L/min.
• in vitro study using the Clickhaler®
To operate the TSI (Copley instruments, UK), the primed Clickhaler® was 
placed into an appropriate mouthpiece adaptor specially moulded by Copley, 
ensuring that a good seal was obtained. An adjustable pump (model T12, Nr 
65321, Erweka®, Germany) capable of maintaining an airflow of 60 L/min 
through the TSI, was connected to the outlet of the lower stage. A micro 
manometer ensured a 60 ± 5 L/min airflow during the entire process. The 
inhaler was then actuated for 5 seconds. The pump was then switched off, the 
inhaler removed and the mass change measured by comparing the initial and 
final weight of the inhaler. The procedure was repeated for a further nine 
discharges. Following these 10 actuations, the apparatus was dismantled.
Once completed, the mouthpiece and the different stages were rinsed with the 
suitable solvent for the drug to be assessed, and poured into volumetric flasks. 
The flasks made up to a volume of 100 mL each were then analysed using UV 
spectrometry as stated in Section 2.2.3. Each formulation was run at least three 
times. A new Clickhaler® device was used for each formulation tested.
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• In vitro study using the Aerolizer
A mouthpiece adaptor suitable for the Aerolizer® was obtained from Novartis 
Pharma and fitted to the glass part of the TSI. The pre-prepared capsule was 
placed into the capsule chamber. After checking that the capsule was correctly 
positioned, the inhaler was closed and the capsule perforated by pressing and 
releasing the two buttons simultaneously. The pump was switched on for 5 
seconds and then turned off. The impactor was then dismantled and the 
different parts washed as described earlier on.
Following the calculation of the concentrations from the UV data in the different 
stages, three different aerosol parameters were obtained:
- The emitted dose (ED) corresponding to the amount of drug (in pg) in 
stage 1 (A to D) and 2 (E to H);
- The respirable dose (RD) corresponding to the amount of drug (in pg) in 
stage 2;
- The fine particle fraction (FRF) corresponding to the respirable dose as a 
percentage of the emitted dose.
Experimental data sets were statistically analysed by using either the student t- 
test (for two data sets) or the analysis of variance (One-Way ANOVA for more 
than two sets). A “p-value” of 0.05 was taken as indicative of statistical 
differences. Furthermore, the standard deviations of the different measurements 
are also presented in parentheses in this work. These statistical methods were 
also applied to the physico-chemical data sets of the different formulations.
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Figure 2.9. Outline of the TSI (left) (modified from BP) and photograph of in vitro assessment in operation (right).
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2.3. Physico-chemical characterisation methods for the powder systems
2.3.1. Scanning electron microscopy
The morphology of the different carriers was studied using scanning electron 
microscopy (SEM). In this technique, a fine beam of medium energy electrons 
scans the sample in a series of parallel tracks. The interactions of these 
electrons with the sample generate different signals such as secondary electron 
emission, back-scattered electrons and X-rays. At magnification in the range of 
optical microscopy, a scanning electron microscope can give a depth focus 
several hundred times greater than that of an optical microscope. Particies 
generaliy greater than 1 pm can be imaged, making this technique particularly 
useful for the characterisation of dry powders.
SEM analysis was performed by Mr. McCarthy of the SEM department at the 
University of London, School of Pharmacy. The samples were mounted onto 
carbon disks attached to SEM stubs and coated with a thin layer (approximately 
20 nm) of gold under vacuum in an argon atmosphere for 4 min at 30 mA using 
a sputter coater, to improve the conductivity. The micrographs were obtained 
using a Philips L20 SEM (Philips, the Netherlands).
2.3.2. Particle size measurements
Laser diffraction is a popular method for determining the size distribution of 
powders. Its widespread use is mainly due to its advantageous fast 
measurements, high reproducibility and good reliability (XU and Di Guida,
2003). A Mastersizer X (Malvern Instruments, UK) was used to measure the 
particle size distribution of the different samples. This technique is based on the 
interaction of laser light with particles that are suspended in an appropriate 
solvent. The determination of particle size by light scattering is based on the 
Mie theory. This theory results in a value for the volume of the particle, with the 
assumption that the particies are optically homogeneous, spherical and dilute in 
a random arrangement (to give independent, incoherent scattering) (Allen, 
1997). The general diffraction principle relies on the fact that diffraction is 
inversely proportional to particle size.
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When light is directed at particles that are much larger than the incoming 
wavelength, it is scattered with an angle that is linked mathematically to the 
dimension of the particles: the scattering power increases with the square of the 
particles diameter. In the simplest description, small particles scatter weakly 
and principally to large angles away from the incident light beam, while large 
particles scatter strongly to smaller angles.
The measurements performed are based on the concept of the equivalent 
sphere. In the case of Malvern measurements, which are volume based, the 
equivalent sphere is that which would produce the same scattering intensities 
as the particle. This corresponds approximately to a sphere of equal volume. 
When particles are introduced in the suspension medium, both the light 
scattered by the particles and the unscattered remainder are incident on the 
receiver lens. This lens, acting as a Fourier transform lens, focuses the 
diffracted and transmitted light onto a series of photo-detectors at fixed 
positions.
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Figure 2.10. Schematic diagram of laser light diffraction particle sizer (modified 
from Aulton (Aulton, 2002)).
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The apparatus schematised in Figure 2.10 consists of the following different 
modules:
• The transmitter module containing the laser, power supplies and beam 
collimation optics;
• The sample area;
• The collection optics;
• The receiver module (detector of scattered light);
• The computer (to transform scattered light data into particle size data).
The amount of light scattering signal recorded is a function of the scattering 
power of the particles, which itself depends on the refractive index of both the 
solid and the medium. The refractive index of a substance is defined as the ratio 
of the speed of iight in vacuum to the speed of light in that substance. It is a 
complex spectral function with both real and imaginary (absorption) parts.
The instrument operated with a He-Ne 632.8 nm laser diffraction source, over a 
0.5 -  900 pm particle size range. A Malvern MS7 magnetically stirred small 
volume (15 mL) diffraction cell was used. In order to avoid cross contamination, 
the cell was first washed with distilled water and then filled with propan-2-ol. 
Approximately 10 mg of lactose crystals were suspended in 5 mL of the same 
solvent. Collection from the powder bed was crucial since the data obtained 
from this small sample was meant to be representative of the entire batch. Thus 
it was always insured that the material was thoroughly stirred with a spatula 
before taking samples for measurement. Each specimen was then added 
dropwise with a pipette into the cell until a 10 to 15 % obscuration value 
(corresponding to the fraction of incident light intensity that is not detected at 
zero angle detector) was achieved. It is important to use dilute suspensions, 
since in concentrated suspensions possible multiple light scattering may modify 
the angular distribution of light intensity (Guardani et al., 2002). The particle size 
distribution was generated from the diffraction data using a mathematical model 
or “presentation”. The measurements were repeated three times for each 
material and both the mean and standard deviation were reported. Different 
parameters were defined: dso%, also known as the volume median diameter, 
indicates the median particle size distribution where 50 % of the volume of all
82
particles resides below and above this value. dio% and dgo% indicate that 10 % 
and 90 % of particle volume lie below those values respectively. Calculating the 
coefficient of spread, called SPAN and corresponding to the ratio of d90% - 
d10% to d50%, assessed the width of the distribution.
2.3.3. Specific surface area
The surface topographies of the different lactose carriers can be further 
described quantitatively by the determination of the specific surface area (SSA). 
The measurement of the surface area is based on the fact that a solid, when 
exposed to a gas, adsorbs a proportion of the gas at its surface. The BET 
isotherm, derived by Brunauer, Emmett and Teller, is widely used to determine 
the surface area of solids. An adsorption isotherm can be defined as the 
relationship between the amounts of gas adsorbed on a solid at a constant 
temperature and the gas pressure. It was realised only in the 1930s that 
multilayer adsorption could occur at liquid nitrogen temperature (Sing, 2001). 
Assuming the formation of a multilayer of adsorbed molecules, the three 
scientists modified the Langmuir approach (type I isotherms, in which the core 
assumption is that adsorption stops at monolayer coverage) by balancing the 
rates of adsorption and desorption for the various molecular layers. With the 
BET approach, the determination of adsorption isotherms of nitrogen (which has 
an effective area per molecule of 0.162 nm^) at the temperature of liquid 
nitrogen, approximately 77 K, is possible by a point-by-point procedure where 
successive amounts of nitrogen are introduced. At each stage the system is 
allowed sufficient time to reach equilibrium. The adsorbent surface is pictured 
as an array of equivalent sites on which nitrogen molecules are adsorbed in a 
random manner. The occupation probability of a site is assumed to be 
independent of the occupancy of neighbouring sites and the adsorbed 
molecules are assumed not to interact with each other (Sing, 2001). Since 
adsorption of gases onto pharmaceutical solids usually gives rise to type II 
isotherms, which may be considered as unrestricted monolayer/multilayer 
adsorption, the SSA of the different powders was calculated from the BET 
equation below:
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Where V corresponds to the volume of adsorbed vapour, Vm to the volume of 
gas adsorbed to form a monolayer, P to the partial pressure of the gas, Po to 
the saturated vapour pressure of the gas and c to the BET constant.
If a plot of PA/ (Po-P) is drawn as a function of P/Po. the slope of the line is 
equal to (c-1)/c\/m and the intercept is 1/cVm. Since the total volume of gas 
adsorbed by the sample (V) is measured, the volume of adsorbed gas required 
to form one complete monolayer on the solid (Vm) can thus be determined 
graphically. From this result, the total number of gas molecules adsorbed on the 
solid can be determined. Finally, knowing the area occupied by each nitrogen 
gas molecule, the totam surface area of the solid can be obtained.
Experimentally, an accurately weighed sample was transfered into a nitrogen 
BET surface area analyser tube fitted with a glass rod to minimise the overall 
free space. Each sample was then loaded in the outgas station of a SA 3100 
surface area analyser (Beckman Coulter ™). The instrument included a sample 
port, three outgassing stations, a vacuum and a built in data processor. The 
outgas time ensured a removal of free particles from the surface which would 
be able to adsorb nitrogen molecules. Upon increase of the sample outgas time 
from 2 to 4 hours no apparent increase in the SSA was detectable. Therefore, 
after outgassing for 4 hours at 30“C, it was assumed that all surface 
contaminants such as physically adsorbed gas and moisture, had been 
successfully removed and the true specific surface area could then be 
measured. Upon completion of the outgas step, the sample was removed and 
sealed with a rubber cap to prevent any mixing of the backfilled nitrogen in the 
sample tube with the ambient air. The dry sample was reweighed and loaded in 
the analyser port of the analyser and the underlying Dewar-vessel was filled 
with liquid nitrogen.
Helium free-space calculation was conducted to account for the free volume in 
order to accurately measure the volume of gas adsorbed. After the free space 
measurement was completed, the isotherm measurements were made, from 
which the specific surface area was calculated. All samples were tested in
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duplicate and then analysed using a Coulter® SA 3100 surface area and pore 
size analyser (Beckman Coulter™), as shown in Figure 2.11.
Figure 2.11. Photograph of a SA 3100 surface area analyser.
2.3.4. X-ray powder diffraction
X-ray powder diffractometry (XRPD) has been used for decades for the 
measurement of crystallinity (Saleki-Gerhardt et a!., 1994). Moreover, the 
existence of drug polymorphism is well characterised by means of XRPD 
(Brittain et a!., 1991). X-rays are a type of electromagnetic radiation, with a 
wavelength ranging from about 10'  ^ to 10  ^ A. They are a by-product of the 
sudden deceleration of electrons that had previously been accelerated to a high 
velocity. Within the X-ray tube, electrons emitted by the cathode are accelerated 
through a high-voltage field and a copper anode is bombarded at high potential 
(Figure 2.12). On impact, the electrons transfer their kinetic energy to the 
copper atoms, producing photon X-rays. As the target becomes very hot due to 
the collision of high-energy electrons, it must be cooled, typically by water.
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Figure 2.12. Schematic of an X-ray tube (Willard et ai, 1988).
The X-rays pass out of the tube via a beryllium window. As illustrated in Figure 
2.13, when the incident beam strikes a powder sample, diffraction occurs in 
every possible orientation of 20. Diffraction of an X-ray beam striking a crystal 
occurs because the wavelength of the beam is similar to the spacing of atoms in 
minerals (1-10 A). When an X-ray beam encounters a crystal, most of the X- 
rays will destructively interfere with each other (i.e. cancel each other out), but 
under some specific conditions they constructively interfere and reinforce one 
another. Constructive interference only occurs when Bragg’s law (Equation 2.2) 
is satisfied:
2d sin 0= nA [Equation 2.2]
Where n is an integer, A the wavelength of the incident beam, d the distance 
between atomic planes in the crystal, and 6 the angle of incidence of the X-ray 
beam on the atomic planes.
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Figure 2.13. Reflection of X-rays from two planes of atoms in a solid.
In order to scan the emission spectrum of a sample, the analysing crystal is 
mounted on a goniometer (to measure angles) that slowly rotates through the 
desired angular region. The powder pattern consists of a series of peaks 
detected at various scattering angles. Characteristic peak intensities, or 
integrated peak intensities, can be measured.
XRPD measurements were performed on a Philips PW 3710 diffractometer. 
The Cu anode tube was operated at 45 kV and 30 mA in combination with a Ni 
filter to give monochromatic Cu Kq X-rays. This filter is needed in order to 
reduce the intensity of the line with the shorter wavelength (K^). Experimentally, 
a sample of approximately 0.5 g was loaded in the sample holder, resulting in a 
powder bed of 2 mm thickness. The sample was scanned from 5 to 30® on the 
20 scale with a step size of 0.05® per second.
2.3.5. Solution calorimetry
Long-standing techniques such as XRPD but also differential scanning 
calorimetry (DSC) are known to quantify amorphous contents of 5 % and above 
(Saleki-Gerhardt et ai., 1994). It was established that solution calorimetry is 
useful for quantification of the amorphous content below this 5 % threshold
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(Gao and Rytting, 1997; Hogan and Buckton, 2000). In this thermal analysis 
technique, the temperature change produced by chemical or physical 
interactions in a liquid due to dispersion or dissolution of the investigated 
material, in a constant environment, is monitored as a function of time. The 
software then converts the temperature to heat. Enthalpy of solution of any 
particular solute in one of its solvents can thus be measured, enabling the 
detection of slight changes in the physico-chemical properties of a material. The 
net measured response for the enthalpy of solution results from the addition of 
different components: wetting of the powder and dissolution following the 
disruption of the bonding between the solid molecules and the formation of 
bonds between the solute and the solvent. Moreover, some rearrangement of 
bonding within the solvent will also occur.
All experiments were carried out using a Thermometric 2225 Precision 
Calorimeter (Thermometric AB, Sweden) mounted in one channel of the 
Thermometric 2227 Thermal Activity Monitor (TAM) (Thermometric AB, 
Sweden). The TAM was used as a precise temperature water bath, having a 
stability of ± 0.0001 ®C over 24 hours. The Precision Calorimeter consists of 
three main components: the calorimetric unit itself (Figure 2.14), the calorimetric 
cylinder that holds the calorimetric unit, and the solution calorimeter module that 
houses the electronic components. The calorimetric unit consists of a 100 mL 
Pyrex glass vessel and a stirrer unit. The vessel is fitted with a heater for 
calibration and a thermistor for measuring the temperature change when the 
reaction takes place. The vessel also contains a sapphire-breaking tip mounted 
on a pin at the bottom, which enables the ampoule holding the sample to be 
broken. The vessel is attached to the holder by an interlocking nut, acting as a 
thermal insulator. The stirrer unit, also acting as the ampoule holder, ensures a 
good mixing of the sample with the dissolving solvent. Data was collected by 
the “Software for Solution Calorimeter", Version 1.2 (Thermometric AB, 
Sweden).
100 mL pyrex 
-glass vessel
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ampoule
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Figure 2.14. Schematic diagram (Thermometric AB, 1997) and photograph of the calorimetric unit.
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All experiments were carried out with the TAM water bath set to 25.0000 ± 
0.0001 °C. A sample mass of approximately 200 mg was accurately weighed 
and filled into a 1.1 mL glass-crushing ampoule. The ampoule was then stored 
in a vacuum oven (Sanyo-Gallenkamp) between 40 and 50°C at -300 mbar, 
until complete dryness was achieved (no further weight loss recordable). It was 
subsequently plugged with a silicon bung before being sealed with molten bee’s 
wax in order to avoid any water vapour contact (Hogan and Buckton, 2000). 
The glass-crushing ampoules were always handled wearing latex gloves to 
prevent deposition of dirt on the outer surface of the ampoule. The sealed 
ampoule was then placed in the ampoule holder, which was then inserted in the 
stirrer unit containing 100 mL of distilled water. The complete unit was lowered 
into the equilibrium position of the solution calorimeter channel of the TAM. The 
stirrer was operated at 600 rpm. After immersion and achievement of thermal 
equilibrium, the glass ampoule was pushed down by hand. On achieving a 
steady baseline (corresponding to a standard deviation of the experimental data 
points of less than 5 pK), the ampoule was broken to initiate the reaction and 
allow the enthalpy of solution to be measured. Following the break, a second 
electrical calibration was carried out. This supplied information about the 
background thermal energy (heat evolved from the stirrer action for example) 
upon which it could base its calculation through direct comparison of heat 
involved.
Temp
offset
(mK)
EndP® Break
Tim e (min)
Figure 2.15. Analysis example of a crystalline lactose sample by solution 
calorimetry (P=pause, B=baseline, C=calibration).
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An example of experimental raw data can be seen in Figure 2.15. The 
experiment sequence included the following sections:
• Pause (P): the different pauses allowed verification that both the reaction 
vessel and the water bath were in thermal equilibrium.
Baseline (B): the different signals recorded resulted from stirring and 
noise. These baselines enabled the determination of parameters of the 
system such as the constant steady-state temperature (infinite 
temperature) and the calorimeter time constant.
Calibration (0): calibrations consisting of a heating period followed by a 
waiting period were performed to calculate the calibration constant, 
which is an expression for the heat capacity of the reaction vessel 
(including the sample and detectors). The heat evolved by the 
experimental reaction is obtained by multiplying the change in 
temperature by this constant. A known amount of energy was supplied to 
the system by the heater to duplicate the thermal energy accompanying 
the reaction. Post-reaction calibration (02) was regarded as more 
reliable than pre-reaction calibration (01), since it reflected the presence 
of the solute and broken glass.
Break: this section was automatically ended after 10 minutes and the 
instrument proceeded to the next section.
End: the experiment concluded automatically when the End event in the 
experiment was reached.
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2.3.6. Inverse gas chromatography
Inverse gas chromatography (IGC) is a direct extension of conventional gas 
chromatography. A common aim is to determine the composition of an unknown 
gaseous or liquid phase. In gas-solid chromatography, an unknown solute in a 
gas stream (corresponding to the mobile phase) passing over a known 
substrate (corresponding to the stationary phase) will adsorb and desorb 
repeatedly as it passes over the surface of the substrate. Gas separation occurs 
because of differences in the position of adsorption equilibriums between the 
gaseous components of the sample and the stationary phase. In recent years, 
IGC has been used in the study of batch to batch variability of both active and 
excipient (Ticehurst et al., 1994; Ticehurst et al., 1996; Feeley et al., 1998; York 
et al., 1998). The influence of milling (Ohta and Buckton, 2004) and that of 
humidity (Newell et al., 2001b) on surface free energy was also investigated 
with this technique.
To conduct an IGC experiment, the solid material to be investigated is packed 
within a glass column. Well-characterised volatile probe molecules of known 
properties pass through the column under the flow of an inert gas. The simplest 
type of study that can be undertaken is at low solute concentration and is 
termed infinite dilution IGC. This technique allows determination of the 
substrate/solute interactions in the absence of solute/solute interactions. In this 
concentration region, chromatographic peaks are essentially Gaussian in shape 
and the retention volume Vn is independent of the solute concentration. Infinite 
dilution is verified by injecting smaller amounts of probe until the probe retention 
time does not change significantly with the amount of probe injected. A solute 
molecule, even without interacting with the adsorbent surface, requires time to 
pass through the column. This dead time to is experimentally measured using a 
non-interacting standard such as methane.
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From the retention time (fr) of the probe, the net retention volume Vn can be 
determined according to Equation 2.3 developed by Schulz et al. (Schultz et al., 
1987):
V„ = JF(t^ -  r j  [Equation 2.3]
Where F is the carrier gas flow rate (in mL/min) and J the compressibility 
correction factor for the pressure drop over the column, taking account the 
compression of the gas.
This correction factor J is given by Equation 2.4 as follows:
J  = \  /  0* '/  [Equation 2.4]
out
where Pin is the pressure at the inlet and Poutthe pressure at the outlet (normally 
equal to the ambient pressure).
2.3.6.1. Determination of the dispersive component of surface energy
The free energy of adsorption, resulting from polar and non-polar interactions, 
for a gaseous probe molecule under isothermal conditions is given by the 
following equation:
AG°a = àG^A + àG^^A [Equation 2.5]
Where AG^a is the non-polar free energy of adsorption and AG^^a the acid/base 
or specific free energy of adsorption.
AG '^a is also expressed by the equation:
AG°a = R TInVn  + C [Equation 2.6]
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Where R is the ideal gas constant, T the absolute temperature and C an 
empirical constant that takes into account the weight, the surface area and the 
vapour pressure of the probes in the gaseous state.
The work of adhesion Wadh per surface area between an adsorbate and an 
adsorbent is related to AG°a by:
AG °a = N a Wadh [Equation 2.7]
where N is Avogadro’s number and a the cross sectional area of the adsorbed 
molecule.
In the case of a non-polar liquid (L) adhering onto a solid (s), the work of 
adhesion, Wadh, is generally expressed as the geometric mean of the dispersive 
components of the solid {/s^) and the liquid (Fowkes, 1964)
= 2 V Â V  [Equation 2.8]
Thus by combining Equations 2.6, 2.7 and 2.8 we obtain:
R T ]n V ,=  2 N ^ a ^  +  C  [Equation 2.9]
Typically, the free energy of adsorption of non-polar probes onto solid material 
is determined from a plot of RT In Vn as a function of the dispersive component 
of alkanes (Cio to Ce), as shown in Figure 2.16. The slope of the line is equal to 
2N from which the surface energy be calculated. The values for a
and yi^ were obtained from the literature (Schultz et al., 1987; Nardin and 
Papirer, 1990).
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Figure 2.16. Illustration of the free energy of adsorption of aikanes as a function
2.3.6.2. Determination of specific polar interactions
The total free energy of adsorption is the result of non-polar and polar forces. 
Polar probes can interact with a polar surface by both dispersive and polar 
interactions. To calculate the specific interaction, polar probes are plotted with 
the alkanes on a graph of RT in Vw versus Polar probes are located above 
the alkane line. The vertical difference between the polar probe and the alkane 
line gives the specific energy of interaction (AG°a (Figure 2.17). The 
difference in y-values between the polar probe and the x-axis is equal to the 
total free energy of adsorption.
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Figure 2.17. Determination of specific poiar interactions by iGC.
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The specific interactions of the polar molecules with the solid substrate can be 
used to determine the acid and basic constants. According to the Gutmann 
(Gutmann, 1978) acid-base concept, each probe is classified as either a Lewis 
acid (electron acceptor) characterised by a corrected acceptor number AN, or a 
Lewis base (electron donor) characterised by a donor number DN. Riddle and 
Fowkes (Riddle and Fowkes, 1990) corrected AN to AN* by taking into account 
the van der Waals force contribution. The specific free energy of adsorption can 
then be used for the determination of the surface acceptor {Ka)  and donor (Kb)  
parameters:
AG = K^DN + K^AN* [Equation 2.10]
Where DN and AN* are Gutmann’s numbers for the probes and Ka and Kb the 
acid and base parameters of the solid.
Plotting AG / AN* versus DN/AN* yields a straight line with a gradient of Ka 
and an intercept of K b . Thus, the acid and basic parameters can be obtained 
from the slope and intercept respectively.
2.3.6.3. Column preparation
In all IGC experiments pre-treated columns (6 mm outer diameter, 3 mm inner 
diameter, and 30 cm long) were used. Treatment with dimethyldichlorosilane 
(Re pel cote®, UK) was performed to ensure that the surface was hydrophobic 
and non interactive with any gaseous probe (Mohammad and Fell, 1982). Using 
a small funnel 300 to 500 mg of powder was poured into the column, whose 
bottom end had been previously plugged with DMCS silated wool (Chrompack). 
The powder within the column was packed by vertical tapping for 10 minutes 
(until no further settling was observable) using a tapping device supplied by 
Surface Measurement Systems. After completion, the top end of the column 
was plugged with more silated wool. The column was checked visually to 
ensure that no cracks or channels were present before being installed in the 
IGC.
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2.3.6.4. Apparatus
Experiments were performed using an inverse gas chromatograph from Surface 
Measurement Systems (UK). It is comprised of three modules: a flow control 
module, a probe oven module and a column module, as illustrated in Figure 
2.18. The flow control module consists of six flow controllers enabling the 
regulation of the relative composition of the different mixtures: a flow of dry 
helium as the reference and a mixture of helium and organic solvent vapours to 
produce the elutant gas mixture. The elution mixture (250 pL) is then injected by 
an automated valve into the reference gas flow and passes through the column 
to the two detectors, attached in series at the column outlet. A Hewlett Packard 
6890 series gas chromatograph (GC) was used to control the solvent 
temperature. The GC data acquisition system was used to record data from 
both the flame ionization detector (FID) and the thermal conductivity detector 
(TOD). This combination of detectors allows differentiation between organic 
solvent and moisture. A separate column oven was used to control the sample 
temperature. Data was analysed using the SMS /GO Analysis Software, Version 
1.6 .
2.3.6.5. Experimental
After equilibrium in the column oven for 4 hours, probes were injected at a 
concentration of 4 % (v/v) using headspace sampling and each column was 
tested three times. This equilibrium time enabled any weakly adsorbed 
contaminant to be removed from the sample surface. No humidity program was 
used and all experiments were performed at 0 % RH. Both the column oven and 
solvent oven temperatures were kept at 30‘’C. Methane was injected as the 
non-interacting reference probe. Depending on the shape of the peaks and the 
pressure drop along the column, the helium gas flow rate was adjusted. In most 
cases, a rate of 10 mL/min was chosen.
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The dispersive component and the specific interaction were determined using 
the different probes described in Table 2.4.
Vapour
probe
Cross sectional 
molecular area a (m^) (mJ/m^)
AN*
(kcal/mol)
DN
(kcal/mol)
Decane 7.5E-19 0.0234 0 0
Nonane 6.9E-19 0.0227 0 0
Octane 6.3E-19 0.0213 0 0
Heptane 5.73E-19 0.0203 0 0
Hexane 5.15E-19 0.0184 0 0
Acetone 3.4E-19 0.0165 2.5 17.0
Chloroform 4.4E-19 0.0250 5.4 0
Ethanol 3.53E-19 0.0211 10.3 19.6
Ethyl acetate 3.3E-19 0.0196 1.6 17.1
Table 2.4. Properties of vapour probes required for IGC anaiysis.
AN* is the corrected acceptor number (Mukhopadhyay and Schreiber, 1995), 
DN is the donor number (Schultz et ai., 1987), a is the cross sectional area 
(Schultz et ai., 1987; Nardin and Papirer, 1990) and is the dispersive 
component of surface energy of the liquid probes (Schultz et al., 1987; Nardin 
and Papirer, 1990).
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As previously described, IGC is gaining popularity as a method for assessing 
powder surface energy. Nevertheless, some points of caution should be noted 
in order to understand the results. Mukhopadhyay et al. (Mukhopadhyay and 
Schreiber, 1995) pointed out the dependence of the ys^  on the choice of the 
molecular cross sectional areas (a) for the alkanes. For a non-spherical 
molecule, the correct choice of the molecular area will depend on the orientation 
of the molecule. Moreover, “a” values are assumed to be constant regardless of 
the experimental temperature.
Probe conformation may change both due to changing kinetic aspects of the 
adsorbed molecule and temperature dependence of the force exerted by the 
adsorbing solid. At high temperatures the choice of “a” appears critical.
A second complication arises from the principle of operation: by injecting probes 
at infinite dilutions, it is assumed that adsorbate-adsorbate interactions can be 
ignored and only adsorbate-adsorbent interactions are involved. However, solid 
surfaces are known to be heterogeneous with broad site energy distribution. 
Vapour probes will therefore preferentially interact with the most energetic 
dispersive sites on the powder surface (Planinsek and Buckton, 2003). IGC 
determinations will therefore lead to higher values of y$^  than those obtained 
from conventional contact angle measurements. A relevant confirmation of this 
was given by Dove et al. (Dove et al., 1996) who studied the surface energies of 
both caffeine and theophylline using IGC and two contact angle measurement 
methods.
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Figure 2.18. Schematic diagram (Sing, 2001; Newell et al., 2001b) and photograph of the IGC apparatus.
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2.3.7. Dynamic vapour sorption (DVS)
Vapour sorption studies employing humidity controlled ultra-sensitive recording 
microbalance systems are often used to study the sorption/desorption of a 
solvent to a powder. Buckton et al. (Buckton and Darcy, 1995) studied 
gravimetrically the process of crystallisation of lactose, demonstrating the 
usefulness of this technique in detecting the presence of amorphous material at 
a concentration as low as 0.05 % (w/w). Columbano et al. (Columbano et al., 
2002), Hogan et al. (Hogan and Buckton, 2001 ) and Ticehurst et al. (Ticehurst 
et al., 2000) respectively studied the recrystallisation of amorphous SS, 
amorphous raffinose and micronised revatropate hydrobromide using this 
technique. Many amorphous materials are plasticized by absorbed water, 
causing the glass transition temperature to drop below the experimental 
temperature. This newly acquired mobility allows rapid crystallisation. Upon 
crystallisation, the absorbed water is displaced and the resulting mass loss at 
elevated RH monitored.
The DVS system (Service Measurement Systems, UK) is based on a Cahn D- 
200 microbalance, which is able to detect weight variations of ± 1.10^ mg. The 
sample and the reference empty glass pans are located on opposite sides and 
are attached to the microbalance by hand down wires. Each pan is enclosed in 
a glass tube and can be accessed by lowering the inferior part of the tube, after 
removing the metal clip holding the two parts in place. This microbalance is 
enclosed in an incubator in which the temperature (ranging from 25 to 80®C) 
and humidity (ranging from 0 to 98 %) are controlled. A schematic 
representation and a photograph are shown in Figure 2.19. Humidity is 
controlled by flow of dry nitrogen through switching valves, which regulate the 
total amount of gas passing through the humidification stage. This is enabled by 
the presence of two flow controllers that produce the required relative humidity. 
The sample and reference pans are exposed to a continuous gas flow set to 
200 m l /min. The reference pan counteracts any effect on the sample pan and 
therefore any change in the weight of the sample, recorded as a function of time 
and humidity, represents the change due to the powder only.
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Prior to an experimental run, the sample pan was cleaned using distilled water 
followed by absolute alcohol. To remove any residual solvent, the sample pan 
was allowed to dry at 0 % RH before being exposed to 90 % RH for 10 minutes 
to remove any static which may have developed during the cleaning process. 
The RH was then returned to 0 % and the balance zeroed until a steady 
baseline was observed. The criterion used to define the steady baseline was 
the % ûfm/cff value. The dm/df value represents the rate of change of the sample 
mass as the percentage of the initial mass of the sample per 20-second time 
interval. The sample was considered dry when the dm/dt value was less then 
0.0001.
Once this had been achieved, samples of 30 mg (± 10 %) were loaded onto the 
glass pan of the DVS. All experiments were performed at 25°C. The 
programme, which can be divided into three different sections, was then 
initiated.
• Initial drying step (0-6h) by exposing the sample to dry nitrogen (0 % 
RH);
• Exposition to 80 % RH to allow water uptake and crystallisation (6-16h);
• Final drying step (16-22h) by reexposing the sample to dry nitrogen (0 % 
RH).
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Figure 2.19. Schematic diagram taken from Ahfat, 1998 and photograph of a DVS.
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3.1. Summary
The source, quality and inter-batch control of lactose monohydrate is of utmost 
importance for the reproducibility of dose delivery performance of DPIs. 
Different qualities of lactose monohydrate are likely to influence the 
performance of a DPI (Steckel and Bolzen, 2004). This chapter describes first a 
blend homogeneity characterisation study for a formulation containing 4 % BDP 
using the Clickhaler® reservoir device, and then a comparative study of the 
influence of the surface characteristics of three different commercially available 
sources of a lactose monohydrate for inhalation purposes using the two 
selected drug models, SS and BDP. The first part of the study showed that the 
formulation complied with acceptance criteria according to compendial 
requirements. In the second part of the study, the measurements displayed a 
significant lactose dependence on the deposition of the BDP based 
formulations. In contrast, there was less variation in performance with the 
formulations using the hydrophilic drug model SS. Physico-chemical 
characterisation was undertaken in an attempt to correlate the in vitro 
performance with surface properties of the lactose. The findings of this study 
indicate that the presence of fine lactose particles on the carrier surface exerts 
a major influence on aerosol dispersion of BDP whereas deposition of SS is 
more dependent on the surface energy properties of the carrier surfaces.
3.2. Introduction
Steckel et ai. (Steckel et ai., 2004a) investigated the aerosol behaviour from the 
Flowcaps® inhaler using five different batches of lactose monohydrate from 
three different manufacturers (Meggle, Borculo and DMV). BUD and SS were 
chosen as a hydrophobic and a hydrophilic drug respectively. Fine particle 
fractions were obtained using a multistage liquid impinger at an airflow of 30 
L/min. They concluded that the average particle size of the different lactoses 
had a significant influence on the emptying behaviour of the capsules. For 
example, the gravitational force in the case of Pharmatose 110 or Inhalac 70, 
with an average particle size above 100 pm, was too high to obtain an optimal 
particle entrainment for this particular type of capsule-based DPI.
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Reproducible delivery from the capsule was achieved using Lactohale LH 200 
and Pharmatose 325M. Lactohale LH 200 was found to be more efficient than 
Pharmatose 325M for both drugs (43.6 vs. 14.6 % for SS and 20.8 vs. 12.3 % 
for BUD). The particle size distribution data revealed that the Lactohale LH 200 
had a higher fine content (dio%=12 pm) compared to the Pharmatose 325 M 
(dio%=31 pm). Passivation by the fines of the high-energy sites of the lactose 
surface was put forward to explain those observations. In another study, 
Podczeck (Podczeck, 1998) examined ten batches of medium grade lactose 
monohydrate from three different manufacturers and salmeterol xinafoate as a 
drug substance. The author stated that a simple interchange of the carrier in 
terms of brand or grade appeared impossible due to the inherent physico­
chemical properties of the different lactose used.
To obtain the required particle size distribution for the carrier, the crystals are 
fractionated by means of mechanical sieving procedures. This process may 
have an impact on the amorphous content on the surface of the lactose 
crystals, leading to performance differences. Processes such as drying and 
milling can induce disorder in the resulting apparent crystalline material 
(Buckton, 1997). The presence of a small amount of surface disorder may 
influence the product performance. The amorphous regions can take up more 
water than the crystalline regions. Ahlneck et al. (Ahlneck and Zografi, 1990) 
have shown that, assuming that essentially all water (e.g. 0.5 % (w/w)) is 
preferentially taken up by these amorphous regions (e.g. 0.5 % (w/w)), the 
associated water content would represent a huge amount of water for these 
small areas of the sample (i.e. 50 % (w/w)).
Prior to characterising the different carriers it is essential to describe briefly the 
different possible states of pharmaceutical materials.
• Crystalline state
A crystalline material can be characterised by repetitive spacing of constituent 
molecules in a regular three-dimensional array. Four main types of crystalline 
solids can be differentiated depending on the type of forces holding the crystals 
together: (1) ionic crystals (e.g. sodium chloride), composed of charged species 
held in place in the lattice by electrostatic forces; (2) covalent crystals (e.g.
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diamond) in which atoms are connected by a framework of covalent bonds 
(atoms sharing their valence electrons); (3) metallic crystals (e.g. copper) 
comprising ordered arrays of identical cations and (4) molecular crystals 
(organic crystals), which are held together by non-covalent interactions 
including hydrogen bonds and non-covalent attractive forces. The latter depend 
on the polarisability, electronic distribution and dipole moments of the 
molecules.
Periodicity and symmetry characterise the crystalline state. Seven different 
types of crystal systems have been described: cubic, monoclinic, triclinic, 
orthorhombic, trigonal, hexagonal and tetragonal. During crystallisation, if the 
rate of growth is equal in all three directions, then a cubic shape will be formed. 
If the growth is limited to one or two directions, the crystal will be either a 
needle-shaped or a plate-shaped respectively. These differences in crystal 
morphologies will have large repercussions on dry powder inhalation systems. 
For example, most commercially available lactose crystals used as carriers in 
DPI formulations present irregularities on their surface (Tee et al., 2000). In a 
recent study, Larhrib at al. (Larhrib at a/., 2003) investigated the potential use 
for DPI technology of engineered lactose crystals, using a one-step 
crystallisation process from acetone/water co-solvent mixtures. Depending on 
the water/acetone ratio, different crystal morphologies were obtained, from 
needle to tomahawk like shape, and different elongation ratios (defined as 
length expressed as a function of the width) calculated. The impact on the in 
vitro deposition of SS varied from 29.2 (2.2) % FPF to 5.1 (1.6) % FPF 
depending on the type of lactose crystals chosen.
The relative size of the faces of a particular crystal can vary considerably giving 
rise to different habits. Crystal habits are crystals with the same chemical 
composition and crystal structure but with different general shapes obtained 
during its growth. A substance capable of crystallising into different, but 
chemically identical, crystalline forms is said to exhibit polymorphism (e.g. 
graphite (hexagonal) and diamond (regular) forms of carbon). Polymorphism 
can be a result of different crystallisation conditions such as the crystallisation 
solvent, temperature and rate of cooling. Polymorphism is of utmost importance 
since different polymorphs will exhibit different fundamental characteristics (i.e. 
flowability, compression properties, solubility and solid-state stability). During 
crystallisation, solvent molecules may be entrapped with molecules of the given
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sample into a unique structure. The solvent may be either in stoichiometric or 
non-stoichiometric proportion. If the solvent is organic, the crystals are called 
solvates; if the solvent is water, then the solvate is specifically called a hydrate. 
An interaction between the host molecule and the solvent molecule in the form 
of hydrogen bonding leads to the incorporation.
• Amorphous state
As in a crystalline solid, an amorphous solid may have short range molecular 
order (including hydrogen bonding) but no long range three dimensional order 
of molecular packing (Yu, 2001). As a result, amorphous solids have a lower 
energetic barrier to overcome in order to enter solution than a regularly 
structured crystalline solid. Amorphous materials have been therefore widely 
used to improve the dissolution of poorly soluble compounds and accelerate the 
dissolution of others. The amorphous material is usually described by the 
process of supercooling from the melt (Craig et al., 1999) as seen in Figure 3.7. 
When the temperature is decreased from the liquid state to the melting point 
(Tm), an exothermic crystallisation occurs. This is followed by a sudden 
reduction in the free volume (defined as the difference between the total volume 
and the actual volume displaced by the constituent molecules) and in the 
enthalpy of the system. For a glass-forming material, the rapid cooling (>10®K s' 
)^ of the liquid below its melting point (Tm) creates a metastable state, also 
called “rubbery state”, in which the molecules within the liquid do not have 
enough time to orientate themselves into the crystal lattice formation.
The typical viscosity of supercooled liquids is in the region of 10'^ to 10^  ^Pa.S. 
Upon further cooling, the viscosity of the liquid increases and a temperature is 
reached at which the molecular mobility is so low that the rearrangement to 
achieve equilibrium state before further cooling does not occur. This 
temperature is known as the glass transition temperature (Tg) and the 
dynamically relaxed solid (“rubbery state") undergoes a transition to the 
dynamically “kinetically frozen” solid (“glassy state”). The glassy state 
possesses an elevated amount of enthalpy, entropy and a higher specific 
volume than the rubbery state. The critical temperature at which the 
configurational entropy of a system is zero is called the Kauzmann temperature 
(T k).
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Figure 3.1. The process of glass transition by cooiing the liquid melt, 
reproduced from Ahneck (Ahlneck and Zografi, 1990).
The glass transition temperature is characteristic of each system and its 
knowledge is really important since it can be used to predict the storage 
conditions. The addition of certain plasticizers (e.g. water) can lower the Tg. 
Plasticization at a molecular level increases the molecular space, leading to a 
change in apparent viscosity. Water with its very low Tg (-136®C) (Johari et ai., 
1987), small molecular size and hydrogen bonding ability can be absorbed 
within the amorphous material. However, a recent paper (Yue and Angell, 2004) 
concluded that the glass transition of water could not be directly probed.
The effect of water plasticization on the Tg of an amorphous material can be 
predicted using the equation developed by Gordon and Taylor (Gordon and 
Taylor, 1952).
Tgmix =
w\Tg\ +  kwiTgi
w i  +  kW 2
[Equation 3.1]
Where Tgmix is the Tg of the mixture, Tgi and Tg2  the glass transition 
temperatures of component 1 (solid) and component 2 (water), wi and W2  the 
weight fractions of the solid and water respectively
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k \s a constant calculated from the density (p) and the Tg of the components 
according to:
j _Tgipi
k - —-----  [Equation 3.2]Tgipz
• Transition from amorphous to crystalline state
Amorphous forms are less thermodynamically stable than crystalline forms and, 
given the opportunity, will eventually recrystallise after nucléation and growth of 
crystals. Different factors can affect the rate of crystallisation such as 
temperature and the presence of plasticizers (Yu, 2001). For amorphous 
materials, this transition is only possible if the mobility of the molecules is 
sufficient to allow the rearrangements to take place. In fact, crystallisation 
occurs once the experimental temperature is above the Tg. Nucléation, which 
can be defined, as the formation of a small amount of crystalline material, may 
be either spontaneous or artificially induced. For spontaneous nucléation a 
group of constituent molecules must coagulate and orientate in a fixed lattice. 
Artificial nucléation occurs when seed crystals or impurities are included in a 
supersaturated system. The formation of these initial or primary nuclei is the 
first step that initiates the crystallisation process. Crystal growth takes place 
once stable nuclei are formed. Controlled crystallisation is a potential method 
for engineering carrier (Larhrib et al., 2003) or drug microcrystals (Ikegami et 
a/., 2002) through manipulation of the crystallisation process.
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3.3. Aims of the study
In the present study, the presence of a correlation between the in vitro 
deposition of DPI formulations and the physico-chemical properties of the 
chosen lactose carriers was investigated. The main objectives were to:
• Evaluate the Clickhaler® as a reservoir device;
• Compare the deposition performances of three different marketed grades 
of lactose blended with SS or BDP;
• Examine the physico-chemical properties of the lactose carrier particles 
to correlate to the aerosol deposition from the two drug models.
3.4. Materials and methods
Regarding the reproducibility study with the Aero Flo 65 as a carrier, this grade 
of lactose was blended with BDP so that the final concentration of the drug was 
4 %. Typically, 4.8 g of lactose was mixed with 0.2 g BDP in a 14 m l glass 
container. This was carried out using a Turbula mixer for 30 minutes at 42 rpm. 
Figure 3.1 is an image of the binary mixture consisting of the coarse lactose and 
BDP. After content uniformity assessment, the formulation was tested in the 
Clickhaler® as previously described in chapter 2.
Ten consecutive runs were tested. In the second part of the work, three different 
lactose grades (Aero Flo 65, Pharmatose 325M and Lactohale LH 100) were 
blended with 4 % of the two model actives. The same blending conditions were 
used throughout.
I l l
Figure 3.2. Co-processed coarse carrier with an active.
The physico-chemical properties of the different carriers and active compounds 
were characterised using the techniques described in chapter 2.
3.5. Results and discussion
3.5.1. Deposition study
3.5.1.1. Repetability study with BDP
A primary requirement for a dry powder formulation is the necessity for dose 
uniformity. Regulatory bodies have progressively increased the specifications 
for this requirement. In the European Pharmacopoeia (2002), test B is applied 
to the uniformity of pre-dispensed dose of powders for inhalation which states: “ 
The preparation complies with the test if not more than one individual content is 
outside the limits 85 per cent to 115 per cent of the average content and none is 
outside the limits of 75 percent to 125 percent of the average content.
The preparation fails to comply with the test if more than three individual 
contents are outside the limits 85 percent to 115 percent of the average content 
or if one or more individual contents are outside the 75 per cent to 125 percent 
of the average content. If two or three individual contents are outside the limits 
85 per cent to 125 per cent but within the limits of 75 per cent to 125 percent, a
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second tier test is required where one determines the individual contents of 
another twenty dosage units taken at random. The preparation complies with 
the test if no more than three individual contents of the thirty units are outside 
the limits of 85 per cent to 115 percent of the average content.”
The measured ED was normalised to the average of the 10 single delivered 
doses and the limits of ± 25 % of the average delivered dose were calculated. 
The data for the aerosol deposition study is listed in Table 3.1 and shown in 
Figure 3.2.
BDP deposition patterns from 
a Foremost Aero 65 carrier
ED (pg) RD (pg) FPF (%)
Run 1 1010 449 44.5
Run 2 910 342 37.59
Run 3 942 373 39.7
Run 4 707 218 30.92
Run 5 727 227 31.3
Run 6 874 335 38.3
Run 7 1097 433 39.5
Run 8 878 310 35.34
Run 9 980 328 33.45
Run 10 1014 367 36.2
Table 3.1. In vitro BDP deposition patterns from ten repetitive actuation runs 
using Foremost Aero 65 as lactose carrier.
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Figure 3.3. Repetability assessment of the BDP emitted dose following 10 
runs (each corresponding to 10 actuations).
As shown in Figure 3.2, all actuations for this formulation complied with the set 
criteria for content uniformity, indicating that the flow properties of the carrier are 
suitable for the Clickhaler®. The doses were not delivered particularly 
consistently (especially run 4 and 5 which are both below the average) but still 
within the regulatory requirements. One possible explanation may be that the 
highly cohesive behaviour of BDP led to agglomeration, causing poorer 
flowability and increased variations in the delivered dose.
3.5.1.2. Results for aerosol deposition studies of SS and BDP formulations
The data for the evaluation of the influence of the lactose carrier on the 
deposition pattern of BDP and SS using the TSI are listed in Tables 3.2 and 3.3.
Material ED (pg) RD (pg) FPF (%)
Aero Flo 65 954 (52) 388 (55) 40.6 (3.5)
Pharmatose 325M 1108 (35) 205 (35) 18.4 (2.7)
Lactohale LH 100 1292 (10) 201 (10) 15.6 (0.8)
Table 3.2. Influence of the different lactose qualities on the BDP deposition 
patterns expressed as means (n=3).
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Different BPD deposition profiles were obtained depending on the grade of 
lactose chosen as the carrier (Table 3.2). It was found that the EDs of BDP of 
the different formulations were greatly influenced by the type of lactose carrier 
used. In particular, the ED for the Aero Flo 65 was 954 (52) pg, which was 
significantly lower than that for Pharmatose 325M, 1108 (35) pg, which was also 
lower than that for Lactohale LH 100, 1292 (10) pg. The differences in EDs may 
be attributed to one of many factors such as different densities or powder flow 
properties which could have resulted in different packing extents in the device 
reservoir and measuring cups. Changes in the grade of lactose chosen also 
influenced the mass of respirable BDP released from the different formulations. 
The RD was greater for the Aero Flo 65 (388 (55) pg) compared to both 
Pharmatose 325M (205 (35) pg) and Lactohale LH 100 (201 (10) pg). The 
differences between the carriers were further highlighted in the calculated FPF 
of BDP. The Aero Flo 65 displayed a FPF that was double that of the other 
grades of lactose (40.6 (3.5) % vs. 18.4 (2.7) % or 15.6 (0.8) %). The low 
fractions indicate that the drug does not separate well from those surfaces.
For SS formulations (Table 3.3), it was found that the EDs were less dependent 
than BDP on the type of lactose carrier used. The ED for the Aero Flo 65 was 
1271 (61) pg, comparable to that of Pharmatose 325M, 1219 (125) pg, and 
slightly lower than that of Lactohale LH 100, 1477 (127) pg. The trend seen in 
the ED values for the SS formulations was also seen in the different RD values, 
with values ranging from 303 (53) pg for the Pharmatose 325M based 
formulation to 414 (37) pg for the Lactohale LH 100 based one. With respect to 
the FPF of SS deposited from the formulations under study, differences 
between grades are less marked with values ranging from 24.9 (3.2) % to 31.2 
(0.9) %.
Material ED (pg) RD (pg) FPF (%)
Aero Flo 65 1271 (61) 395(12) 31.2 (0.9)
Pharmatose 325M 1219(125) 303 (53) 24.9 (3.2)
Lactohale LH 100 1477(127) 414(37) 28.1 (0.2)
Table 3.3. Influence of the different lactose qualities on the SS deposition 
patterns expressed as means (n=3).
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This study highlighted the extreme importance of the lactose grade in DPI 
performance. It also showed clearly that a formulation performance is carrier 
and drug dependent. For example, using a cohesive drug such as BDP may 
affect the ED from Aero Flo 65 based formulation, whereas no apparent effect is 
noticeable when using SS. Such differences are not straightforward to explain 
and more thorough characterisation of the physico-chemical properties of the 
different lactose grades employed was needed to help in drawing hypotheses.
3.5.2. Physico-chemical properties of the different carriers
3.5.2.1. Particle morphology and size, and specific surface area of the different 
lactose carriers
The different lactose grades were characterised by SEM with a method identical 
to that described in Section 2.3.1. The individual crystalline coarse carrier 
particles adopted the characteristic tomahawk shape (Figure 3.3). The images 
are of carriers alone without the presence of the micronised drugs. The 
presence of clefts and fine particle lactose caused the surface to be regarded 
as rough. Close analysis of the SEMs suggested adherence of the small lactose 
particles on the coarse surface. The small particles were present to different 
extents in the samples used. Small differences in the surface texture and crystal 
form of the lactose particles could be seen: the Pharmatose 325M and the Aero 
Flo 65 appeared to be smaller than the Lactohale LH 100. Particle size 
measurements and specific surface area determination were performed to 
confirm these visual observations.
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Figure 3.4. Scanning electron micrographs of the different grades of lactose: 
Pharmatose 325M (A), Aero Flo 65 (B),and Lactohale LH 100 (C).
The particles were sized by laser diffraction using a Mastersizer X (Malvern 
Instruments, UK). Particle sizing was carried out in accordance with Section
2.3.2. The results of particle size analysis of the lactose carriers are presented 
in Figure 3.4 and Table 3.4.
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Figure 3.5. Particle size distribution of the three different grades of lactose.
Lactose grade d io % dso% dgo% SPAN
Lactohale LH 100 
Pharmatose 325M 
Aero Flo 65
57.8 134.8 238.4 1.35
(1.5) (2.2) (3.2) (0.02)
44.1 68.3 100.0 0.82
(0.7) (0.9) (3.4) (0.05)
15.0 64.6 137.4 1.90
(3.1) (1.8) (2.6) (0.1)
Table 3.4 Particle size distribution parameters expressed as mean values 
(n=3).
The lactose carriers all displayed bimodal distributions with narrow spans. 
Lactohale LH 100 had the largest volume median diameter (VIVID 141 (2) pm). 
Pharmatose 325M and Aero Flo 65 exhibited the same VIVID (70 (1) pm and 69 
(1) pm). The wider particle size distribution of the Aero Flo 65 (SPAN of 1.90 
(0.1)) compared to Pharmatose 325M (0.82 (0.05)) or Lactohale LH 100 (SPAN 
of 1.35 (0.02)) was mostly due to the large amount of fines in the Aero Flo 65 
(dio% =15 pm). Moreover the Aero Flo 65 had a large proportion of particles 
below 5 pm (4.8 %) whereas no such small particles were detectable in either 
Pharmatose 325M or Lactohale LH 100. Interestingly, this grade was also the 
most efficient in dispersing BDP particles, highlighting the role played by small 
fines. This type of effect of carrier on drug deposition efficiency in DPIs has 
been demonstrated previously (Zeng etal., 1998; Louey et al., 2003).
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A trend was observed where the FPF of BDP increased as the carrier dio% 
decreased (Figure 3.5 A) whereas SS deposition tended to be independent of 
the dio% of the carriers (Figure 3.5 B). This confirmed that a carrier presenting a 
large amount of fine lactose particles was better at dispersing and 
deaggregating BDP than a carrier without fines. Such an improvement could not 
be confirmed with the hydrophilic drug model.
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Figure 3.6. Mean FPFs (n=3) of BDP (A) or SS (B) vs. mean dio% values 
(n=3) of carrier.
One possible explanation is that small Aero Flo 65 particles may, as well as 
possibly occupy the drug-binding sites on the coarse particle, disturb the BDP- 
BDP particle interactions and weaken the agglomerates, enabling more “single 
BDP particles” to be released from the carrier surface during inhalation.
The differences observed in the particle size measurements were supposed to 
be reflected in the specific surface areas (SSAs) of the different lactose carriers. 
This can be easily seen by considering both the area (A) (Equation 3.3) and the 
volume (V) of a sphere of diameter d (Equation 3.4).
A= Tcd^  
V= 7cd^ /0
[Equation 3.3] 
[Equation 3.4]
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Combining Equations 3.3 and 3.4 we obtain the surface area per volume 
[Equation 3.5]
AA/=6/d [Equation 3.5]
The SSAs of the different lactose grades were determined by the gas 
adsorption method based on the BET equation and performed on a Surface 
Area Analyser (SA 31000, Beckman Coulter UK) following the procedure 
described in chapter 2.
The results (Table 3.5) were in accordance with the particle size 
measurements: the Lactohale LH 100 displayed the largest VMD and therefore 
had the smallest surface area: 0.133 m^/g. The Aero Flo 65 and Pharmatose 
325M presented the same VMD but the Aero Flo 65 had the largest proportion 
of fines. Since those fines are likely to present a large surface area, the overall 
Aero Flo 65 surface exhibited a higher value (0.291 m^/g) than Pharmatose 
325M (0.218 m^/g). The impact of SSA on the drug deposition is taken further 
into account in chapter 5.
Formulation SSA (m^/g)
Lactohale LH 100 0.133 (0.001)
Pharmatose 325M 0.218(0.009)
Aero Flo 65 0.291 (0.001)
Table 3.5. Specific surface areas of three different grades of lactose expressed 
as means (n=3).
As already outlined in Figure 3.5 with the dm% parameter, a correlation between 
BDP deposition and some characteristics of the carrier could be observed. A 
trend (r^ = 0.7989) between SSA of the carrier particles and FPF of BDP can be 
seen in Figure 3.6 A. The correlation for SS was difficult to find with a revalue of 
0.223 (Figure 3.6 B).
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Figure 3.7. Correlations FPFs of BDP (A) and SS (B) expressed as mean 
values (n=3) vs. SSAs (m^/g) of carrier (n=3).
3.5.2.2. Determination of crystallinity in the different materials
Pharmaceutical solids rarely exist as 100 % crystalline or 100 % amorphous 
states, so it was necessary to quantify the purity of the grade of lactose (e.g. 
traces of beta lactose) or the presence of amorphous material, generated during 
air-jet milling for example. X-ray diffraction was used in order to detect the 
presence of p-lactose, whereas solution calorimetry experiments were 
undertaken to measure the extent of crystallinity of the different carriers.
3.5.2.2.1. X-ray diffraction
Drapier-Beche et al. (Drapier-Beche et al., 1997) recorded the X-ray peaks 
obtained by diffraction of two crystalline forms of lactose (a-lactose 
monohydrate and (3-lactose). They located significant diagnostic peaks for each 
form. Presence of a-lactose monohydrate was characterised by intense peaks 
at diffraction angles 20 of 12.5® and 16.4®, whereas |3-lactose was characterised 
by such peaks at a diffraction angle 20 of 10.6®.
The X-ray diffraction patterns of the three grades of lactose were measured at 
room temperature with an X-ray powder diffractometer as described in chapter 
2. The XRPD scans (Figure 3.8) were all indicative of crystallinity and the peaks
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at 12.6 were attributed to the presence of alpha lactose monohydrate. No traces 
of beta lactose were detectable in any grade of available lactose since no 
specific peaks at 10.6° were detectable. An X-ray diffraction scan of (3-lactose is 
shown in Figure 3.9 as a reference control scan. All lactose grades used in this 
study were hence solely composed of a-lactose monohydrate.
 Foremost Aero Flo
65
 Pharmatose 325M
Lactohale LH 100
20 
[“2 0]
Figure 3.8. X-ray diffractograms of the three different grades of lactose 
monohydrate.
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Figure 3.9. X-ray diffractogram of (3-lactose.
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3.5.2.2.2. Solution calorimetry
The enthalpy of solution for each lactose sample of approximately 200 mg was 
measured using the Thermometric 2225 Precision Solution Calorimeter 
(Thermometric AB, Sweden) and the water bath of the Thermometric 2227 
TAM. Details of the experimental set-up are described in Section 2.3.5. All data 
here refers to the values calculated using the post-break calibration. A 
calibration curve had first to be established with 100 % pure amorphous and 
100 % pure crystalline lactose standards. Crystalline a-lactose monohydrate 
was as supplied by Borculo Whey Products UK (B.N 23416). Production of 
amorphous lactose was prepared by spray drying, following the parameters 
outlined in Section 2.2.1.1. Confirmation of the amorphous nature of the yield 
was obtained by the XRPD pattern (Figure 3.10). Dried amorphous and 
crystalline lactose were accurately weighed and blended in 14 mL glass 
container to produce powder mixes of 1.0 %, 5.0 %, 10.0 %, and 20.0 % 
amorphous lactose (w/w). The samples were mixed for 20 minutes in a Turbula 
mixer at 42 rpm to ensure a homogeneous amorphous content. The sample 
mass (200 mg) was accurately weighed and filled into a 1.1 mL glass-crushing 
ampoule and the methodology explained in point 2.7.5.2 employed. The 
enthalpies of solution for lactose mixes of various amorphous contents 
(between 0 and 20 %) were calculated to provide the necessary calibration 
curve (Table 3.6 and Figure 3.11).
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Figure 3.10. X-ray diffractogram of spray-dried lactose.
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% of amorphous material Enthalpy of solution (J/g)
0 55.99 (0.4)
1 55.67 (0.17)
5 52.43 (0.16)
10 44.62 (0.49)
20 34.41 (0.26)
100 - 48.26 (0.83)
Table 3.6. Enthalpies of solution of different partiaily amorphous mixes 
expressed as mean values (n=3).
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Figure 3.11. Calibration curve for the determination of the iactose amorphous 
content by solution calorimetry (n=2)
The enthalpy of solution decreased in a linear fashion with increasing 
amorphous content (Figure 3.11). As anticipated, the heat of solution of 100 % 
crystalline material was endothermie (55.99 J/g) whilst the heat of solution for 
100 % amorphous lactose was exothermic (-48.26 J/g). This is due to the fact 
that amorphous lactose is more readily soluble in water than the crystalline 
form. For all blends, a net endothermie response was observed since the 
majority of the sample was crystalline in nature. The good linear correlation (r^= 
0.9994) proved that by using the technique with the sample parameters used, a 
quantification of about 1 % (w/w) amorphous content was possible. These 
findings were in agreement with a study by Hogan et al. (Hogan and Buckton, 
2000) who investigated the use of solution calorimetry to quantify the 
amorphous content of lactose.
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Differences in the amorphous content of the three grades of lactose under 
investigation were determined (Table 3.7) and the amorphous content 
calculated using the established calibration curve.
Grades of lactose
Enthalpy of solution (J/g) 
(mean ±
Pharmatose 325M 57.06 (0.22)
Aero Flo 65 56.48(0.55)
Lactohale LH 100 55.86 (0.09)
Table 3.7. Enthalpies of solution of different grades of lactose. Values are 
mean and (standard deviation)
Pharmatose 325M exhibited the largest enthalpy of solution, 57.06 (0.22) J/g, 
and Lactohale LH 100 the smallest, 55.86 (0.09) J/g. A fully crystalline sample 
used for establishing the calibration curve had an enthalpy of solution equal to 
55.99 J/g. The values for the different grades are close to this value. Based on 
a sensitivity of 0.5 %, we can conclude that all three samples were totally 
crystalline. A possible explanation of the higher values obtained for Pharmatose 
325M and the Aero Flo 65 may be due to accuracy problem in the ampoule 
weight or to sorption of water prior to enthalpy of solution measurement even 
though crystalline samples are not so hygroscopic and therefore not likely to 
have remaining absorbed water.
Another possibility is the possible contamination of the lactose used for the 
calibration curve. However, no (3-lactose was detectable in the starting material 
(Figure 3.12). A more sentive method such as gas chromatography may have 
been employed to corroborate the findings of the XRPD.
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Figure 3.12. X-ray diffractogram of starting lactose material used for the 
solution calorimetry calibration curve.
3.5.2.3. Surface properties
To further evaluate the surface properties of the different lactose grades, IGC 
experiments were conducted. Columns were packed with the lactose samples 
and tested following the methodology described in Point 2.3.6. The dispersive 
components of the free energy and the specific polar interactions are presented 
in Tables 3.8 and 3.9.
Formulation Ys^  (mJ/m^)
Aero Flo 65 42.9 (0.3)
Pharmatose 325M 40.1 (0.2)
Lactohale LH 100 42.5 (0.8)
Table 3.8. Dispersive component of free energy for three different grades of 
iactose. Values are mean and (standard deviation).
The Ys^  of coarse Pharmatose 325M was found to be 40.1 (0.2) mJ/m^, which is 
slightly lower that the Ys^  of coarse crystalline Aero Flo 65 (42.9 (0.3) mJ/m^) or 
that of Lactohale LH 100 (42.5 (0.8) mJ/m^). Aero Flo 65 was expected to 
present a slightly higher Ys^  due to the important presence of fines which are 
known to be more energetic. However, the size range under investigation may 
have been too narrow for changes in the dispersive component to be observed
126
and any straightforward conclusion was difficult to formulate. Consideration of a 
relationship between dispersive energy and SS FPF showed that an increase in 
the dispersive energy was associated with an increase in FPF. However, for 
BDP, the correlation between the two factors was limited. BDP tends to form 
cohesive aggregates whereas SS tends to bind to the lactose surface. It was 
therefore expected that BDP deposition data would be less linked to the surface 
properties of the lactose grade.
The probes that were used for the acid-base anaiysis of the different lactose 
grades were ethanol and chloroform, which are considered to be acidic probes, 
and acetone and ethyl acetate, which are considered to be basic probes. Using 
the method based on the Gutmann electron-donor acceptor numbers, Ka and 
Kd values were determined (see Tabie 3.9). The Kd value was found to be 
negative for Pharmatose 325M. This is a difficult concept to explain 
theoretically. Nevertheless, the determination of acid-base properties was 
clearly a better tool in investigating the different lactose batches compared to 
the dispersive nature. This was in accordance with the work of Ticehurst et al. 
(Ticehurst et al., 1996) who found large differences in the specific interactions 
between four batches of a-lactose monohydrate with equivalent Ys^  values.
Carrier
Specific polar interactions (J/mol)
Acetone Chioroform Ethanol Ethylacetate
Acid-base
characteristics
K a Kd Kd/Ka
Aero Flo 65
Pharmatose 
325M 
Lactohale 
LH 100
7830 1968 12478 10929
(46) (52) (95) (59)
7134 -405 8188 7642
(191) (109) (156) (203)
8088 1295 10781 9760
(84) (82) (61) (65)
0.141 0.007 0.05
0.108 -0.108 -0.26 
0.129 0.01 0.08
Table 3.9. Specific polar interactions and acid-base properties of the different 
lactose carriers using a (mJ/m^). Values are mean and (standard deviation).
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It was also difficult to interpret the experimental data below the alkane linear 
plot. In Figure 3.13, chloroform clearly lies below the non-polar line.
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Figure 3.13. Example of chloroform lying below the alkane line (obtained with 
Pharmatose 325M as the investigated carrier).
Other physical criteria can be plotted against RTinVn to determine the specific 
interaction. Chehimi et ai. (Chehimi and Pigois-Landureau, 1994) assessed the 
acid-base properties of solid surfaces by using the dispersive contribution to the 
enthalpy of vaporisation (AH^vap). This method of analysis required values for 
(AH^vap) the test probes, taking into account the percentage of self-association 
of the probes. Unfortunately, no data for AH^vap of ethanol is available and 
therefore all calculations were based on three probes, i.e. acetone, chloroform 
and ethyl acetate. Plotting only three polar probes was considered insufficient 
to provide a confident reflection of the surface energetic properties of a powder 
surface. A third method was therefore used: the boiling point (Tp) of the liquid 
probes (Sawyer and Brookman, 1968). This approach might be the most 
convenient since Tp of most widely used probes are readily available in the 
literature. Table 3.10 summarises the different physical properties of the probes 
required for analysis.
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Boiling point (°C) AH^ap (kJ/mol)
Decane 174.15 51.4
Nonane 150.82 46.4
Octane 125.67 41.5
Heptane 98.5 36.5
Hexane 68.73 31.5
Acetone 56.05 22.4
Chloroform 61.17 30.4
Ethanol 78.29 *
Ethyl acetate 77.11 29.3
Table 3.10. Boiling point and heat of vaporisation data of the different vapour 
probes required for IGC anaiysis.
No literature data available
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Figure 3.14. Plot of RT in Vn against boiling point of the probes (A) and against
à f r vap (B ).
The K d/K a  ratios as determined by the enthalpy of vaporisation approach are 
presented in Table 3.11. From these values, the Aero Flo 65 and Pharmatose 
325M surfaces were shown to have approximately as many basic as acidic 
sites. Lactohale LH 100 was found to have twice as many basic sites compared 
to acidic sited (K q/K a  of 1.53). IGC was carried out at infinite dilution which 
relates to approximately 1 to 3 % coverage of the surface by the probe
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molecules (Ticehurst et al., 1996). It is therefore sensitive to high surface 
energy sites. Minor differences in the surface crystallinity of Lactohale LH 100 
may be responsible for “hot spots” of high energy, which could be detected by 
IGC. This explanation would contrast with the conclusions obtained with the 
solution calorimetry measurements described earlier. It is more likely that K°/K^ 
determination based on three probes was not entirely accurate.
Enthalpy of vaporisation approach
K a K d K d/K a
Aero Flo 65 0.18 0.209 1.16
Pharmatose 325M 0.146 0.154 1.057
Lactohale LH 100 0.185 0.284 1.53
Table 3.11. Acid-base parameters based on A G values obtained using the 
AH^ vap approach.
The Kd/Ka ratios determined by the boiling point approach showed a different 
pattern, as presented in Table 3.12. Pharmatose 325M surface appeared to be 
nearly four times more acidic than basic, mainly due to the small Kq value. The 
Aero Flo 65 appeared to have more basic sites than acidic, whereas a more 
homogenous distribution appeared on Lactohale LH 100.
Boiling point approach
Ka Kd Kd/K a
Aero Flo 65 0.047 0.07 1.57
Pharmatose 325M 0.018 0.039 2.12
Lactohale LH 100 0.036 0.07 1.97
Table 3.12. Acid-base parameters based on AG values obtained using the 
boiling point approach.
Attempts to correlate the acid-base properties to in vitro deposition patterns of 
both drugs are presented in Figure 3.15 and 3.16. The Ka and Kd values were 
chosen as obtained by the boiling point approach. Despite only three lactose 
carriers being examined, a correlation was found between an increase in Ka 
and Kd and an increase in the SS FPF (Figure 3.16). However, for BDP no 
obvious correlation could be found between the surface energy data and the 
deposition profiles.
130
0.08 n r  0.08
0.07 - A A - 0.07
a KA
0.06 - - 0.06
a KD
0.05 - A “- 0.05
j  0 .04-
A ^
- 0.04 Q
0.03 - - 0.03
0.02 - A - 0.02
0.01 - - 0.01
Q 0
14 18 22 26 30 34 38 42
BDP FPF (%)
Figure 3.15. Relationship between BDP FPF and acid-base properties of the 
different carriers.
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Figure 3.16. Relationship between SS FPF and acid-base properties of the 
different carriers.
An alternative representation of the data to illustrate the relationship between 
individual probe interaction and FPF for both drugs is shown in Figure 3.17. As 
previously mentioned, the individual polar probe interaction values displayed 
significant variance over the grades of lactose considered. Graphical 
representation of the specific free energy of adsorption (AG '^^a) for all polar 
probes is presented in Figure 3.17.
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Figure 3.17. Relationship between BDP FPF, SS FPF and the individual polar 
probe interactions (in J/mol) Values are mean and (standard deviation).
Several observations based on the specific free energy of adsorptions as 
presented in Figure 3.17, can be drawn:
Basic probes interactions:
- Ethyl acetate: Aero Flo 65 > Lactohale LH 100 > Pharmatose 325M
- Acetone: Lactohale LH 100 > Pharmatose 325M > Aero Flo 65
Acidic probes interactions:
- Chloroform: Aero Flo 65 > Lactohale LH 100 > Pharmatose 325M
- Ethanol: Aero Flo 65 > Lactohale LH 100 > Pharmatose 325M
In vitro deposition:
- SS FPF: Aero Flo 65 > Lactohale LH 100 > Pharmatose 325M
- BDP FPF: Aero Flo 65 >Pharmatose 325M> Lactohale LH 100
The IGC data showed a correlation between the dispersive component of the 
surface energy and the FPF of SS. It also showed a relationship between the 
polar strength of interaction and the deposition patterns of both drugs. Aero Flo 
65 may contain more acidic and basic sites at the highest energy states
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responsible of the strong binding of polar probes to the surface. This could be 
associated with a greater interaction between this grade and the active, in 
comparison with other grades. Interestingly, the hydrophilic drug model SS 
deposition follows the same order as the interaction: the stronger the interaction 
the higher the FPF. This apparent contradiction was explained by the theory 
developed by Cline and Dalby (Cline and Dalby, 2002). The authors claimed 
that a minimum surface energy was required to pull highly cohesive drug 
particles apart during blending and aerosolisation. Any remaining agglomerates 
would not disperse upon actuation of the device, leading to poor deposition. 
IGC was also used to examine the surface properties of the two drug models. It 
became clear that the intrinsic characteristics of BDP and SS played a role in 
the deposition differences. The different drugs were packed into IGC columns 
(n=2) and analysed following the method described in Chapter 2. The 
examination of the dispersive component of the two materials did not explain 
directly the differences in deposition profiles. The ys^  of SS was found to be 50 
(3.9) mJ/m^, which was slightly lower that the ys^  of BDP (53.1 (3.0) mJ/m^). The 
dispersive component was high compared to the ys^  of the coarse lactose 
carriers. This was expected since the micronised drugs present a high surface 
area to volume ratio. York et al. (York et al., 1998) plotted ys^  of five batches of 
dl-propanolol against their median particle size. This study showed that as the 
particle size decreased during milling, the surface of the powder became 
increasingly more energetic. The acid and basic parameters of the drugs were 
also determined from the method involving the boiling point as previously 
described, since using the cross sectional method gave negative K d/K a  values 
(Table 3.13).
Drug
model
Specific polar interaction (J/mol) Acid-base characteristics
Acetone Chloroform Ethanol Ethylacetate K a K d K d/K a
QQ 7980 1052 11506 10396 0.137 -0.011 -0.079Oo (155) (58) (117) (112) (0.002) (0.002) (0.011)
6610 826 9194 8476 0.114 -0.011 -0.091DUr (108) (14) (34) (66) (0.001) (0.001) (0.001)
Table 3.13. Specific polar Interactions and acid-base properties of SS and 
BDP determined using the cross sectional method. Values are mean and 
(standard deviation).
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The results, presented in Table 3.13, displayed a stronger interaction between 
the probes and the hydrophilic drug model compared to BDP. Here again, 
stronger interactions were associated with increased in vitro performances. 
Determination of the Kq/K a using the boiling point approach (Table 3.14) 
indicated that BDP might contain more basic sites compared to acidic sites with 
a Kq/K a ratio of 5.3. SS displayed a Kq/K a ratio of 1.7. Kq/K a ratios were chosen 
instead of either Kq or Ka as both parameters were found to be independent of 
each other. For example, SS exhibited a much larger Ka value (0.0352) 
compared to BDP (0.0116) but had identical Kq values.
Drug
model
Specific polar interaction (J/mol)
Acetone Chloroform Ethanol Ethylacetate
Acid-base characteristics
Ka Kq Kq/K a
SS
BDP
2430 1997 5545 3172 0.0352 0.060 1.7
(217) (79) (168) (173) (0.003) (0.003) (0.07)
1178 1787 3299 1331 0.0116 0.061 5.3
(75) (14) (27) (25) (0.001) (0.001) (0.23)
Table 3.14. Specific polar interactions and acid-base properties of S3 and 
BDP determined using the boiiing point method. Values are mean and 
(standard deviation).
Based on the strength of interaction between acidic and basic probes, a 
material possessing a greater amount of acidic sites on its surface would have a 
greater affinity for a material exhibiting a large amount of basic sites. Based on 
the results presented in Table 3.12, the Aero Flo 65 would therefore develop a 
better interaction with BDP compared to the other grades. Further studies are 
described in chapter 5 to assess the impact of surface energies on the 
deposition patterns of both drugs.
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3.6. General conclusions
Lactose monohydrate is the most commonly used carrier in dry powder 
inhalation. A vast variety of suppliers and different grades leave the formulator 
with a large panel of possibilities. The main aim of this study was to assess the 
impact such a choice could have on the deposition of different model drugs. In 
addition, a great endeavour has been put on the characterisation of the physico­
chemical properties of the three different lactose carriers under investigation, in 
an attempt to correlate the observed depositions to the carrier characteristics. 
The specific results of the different studies are summarised with respect to the 
original objectives.
Evaluation of the Clickhaler® as a reservoir device
In the first part of this chapter, aerosol deposition was carried out on a 
formulation containing Aero Flo 65 as a model carrier and BDP as a model 
drug. The device employed was the reservoir Clickhaler® The results of ten 
actuations showed that reproducibility was obtained with this particular device 
and this particular formulation, so that the regulatory requirements were met.
Impact of the choice of the carrier on the deposition patterns of SS and BDP
Three different coarse lactose grades (Aero Flo 65, Pharmatose 325M and 
Lactohale LH 100), all commercially available as carriers for DPI formulations, 
were used for both SS and BDP using the Clickhaler® as a model device. The 
results showed that the hydrophobic drug deposition was profoundly affected by 
the type of lactose chosen. The formulation containing the Aero Flo 65 was 
found to emit a lesser amount of BDP than that which contained other lactose 
grades. However, more BDP particles were able to reach the lower stage of the 
impinger, resulting in a significantly greater FPF. For SS formulations, the 
selection of a lactose carrier over another did not seem to result, to the same 
extent as BDP, in major in vitro differences.
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Overall, this study highlighted that the importance of the carrier was drug- 
related, the most noticeable effect being for the hydrophobic and cohesive BDP. 
This suggests that each drug requires different carrier properties for an optimal 
deaggregation and aerosol deposition.
Determination of correlations between the ohvsico-chemical properties of the 
lactose carrier particles and the aerosol deposition of two drug models.
In order to correlate some solid state properties of the lactose used to the 
deposition patterns of the drugs, different methods and parameters were used. 
All samples under investigation were considered as fully crystalline a-lactose 
monohydrate following X-ray diffraction and solution calorimetry studies. 
Differences in particle size distribution and specific surface areas were linked to 
differences in the proportion of fine lactose particles present in the different 
samples. The presence of those fines seemed to play a vital role in the drug 
deposition profile of BDP, whereas SS appeared to be less sensitive to the fine 
concentration. Further evaluation of the exact role played by fine material and 
other factors governing the deposition patterns is presented in chapter 4.
Surface energy, being one of the most important factors governing adhesion 
between particles, was also considered. The surface energy data obtained by 
IGC enabled a better differentiation of the carrier materials. Despite similar 
dispersive components of free energy, the determination of the polar 
components gave more insight into the intrinsic differences of these lactose 
grades. Despite the limited number of carriers being tested (n=3), a correlation 
was found between an increase in Ka and Kd and an increase in the SS FPF. 
No obvious trend could be found between the surface energy data and the 
deposition profile of BDP. As previously stated, the hydrophobic drug model 
tends to form cohesive aggregates whereas SS tends to bind to the lactose 
surface. It was therefore predictable that SS deposition data would be linked to 
the surface energy of the lactose grades, whereas BDP would be more 
influenced by the presence of small particles, which may affect the stability of 
those aggregates.
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Chapter
4
Crystalline lactose/PEG 4000 
co-spray-dried systems used 
as fines for DPI
137
4.1. Summary
The previous chapter has focussed on the importance of lactose fines on the 
deposition pattern of micronised drugs. Numerous papers are related to the 
influence of adding a ternary component to improve DPI performances. 
Examples of adding different types of lactose fines, sugars, amino acids or 
lubricant are available in the literature. However, recent investigations 
conducted at the School of Pharmacy did not show any deposition improvement 
when adding crystalline lactose fines at 5, 10 or 15 % (w/w) to a coarse carrier 
(Al-Hadithi, 2004) Described in this chapter is a new type of fines consisting of 
crystalline lactose/poiyethylene glycol (Corrigan et al., 2002) co-spray-dried 
systems. Different such systems were produced by varying the lactose to PEG 
ratio. After characterisation of their physico-chemical properties, these systems 
were used as fines for DPI formulations. The impact of the nature of the fines 
and other formulation parameters, such as mixing sequence, fine concentration 
and drug concentration, were investigated.
4.2. Introduction
Chidavaenzi et al. (Chidavaenzi et al., 2001) investigated the effect of spray 
drying lactose and a fixed proportion of PEG 4000 at levels of 12,4,2 and 1 % 
by weight of solid using different feed concentrations of solid (10 % (w/w) and 
higher). While lactose alone appeared to be completely amorphous after the 
process, all lactose/PEG 4000 systems were crystalline. This unexpected 
property for these systems to crystallise could be explained by the high affinity 
with which water binds to PEG, causing a reduction in water evaporation during 
spray drying. The slower solidification rate of lactose/PEG particles (compared 
to that of lactose alone) enables the organisation of the lactose molecules in a 
three-dimensional crystal structure. The crystallisation effect may also be 
associated with the low Tg of PEG 4000. PEGs exhibit a Tg which depends on 
the molecular weight of the sample (Craig, 1995). In the molecular weight range 
of 10^ to 10\ the Tg varies from approximately -98 to -17°C. The low Tg of PEG 
4000 indicates that this material is likely to act as a pure plasticizer and 
therefore promote crystallisation.
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Gilani et al. (Gilani et al., 2004) studied the aerosol performance of binary 
mixtures composed of BDP and different lactose/PEG processed carriers. They 
used different molecular weights of this polymer (i.e. 400, 3000 and 6000 Da), 
which was mixed with lactose in aqueous media before being spray-dried using 
a Büchi 191. The resulting co-spray-dried products all appeared to be 
crystalline. These systems were used as carriers for BDP in a ratio of 67.5 to 1 
(w/w). The deposition pattern was assessed using a Spinhaler® connected to a 
TS. Using these new lactose/PEG carriers showed a general improvement 
compared to conventional lactose carriers. For example, the FPF of BDP using 
spray-dried lactose/PEG 3000 was greater than for BDP using Pharmatose 
325M (25.8 (5.3) % compared to 6.7 (1.1) %). The authors concluded that this 
improvement might result from the smaller asperities on the surface of the 
lactose/PEG particles compared to the bigger asperities on particles of 
conventional grades of lactose such as Pharmatose 325M. The larger asperities 
are likely to be responsible for the entrapment of the drug particles, which are 
dislodged, more difficultly, by the drag force generated by the inhaler, resulting 
in poor aerosol properties.
As described above, since the presence of PEG caused lactose to crystallise 
during the spray drying process, it is important to describe the characteristics of 
this polymer and in particular the molten state properties of PEG 4000, since 
the outlet temperature in the spray drying process was higher than the melting 
point of the polymer (Tm: 50-58"C)
PEG is a hydrophilic synthetic polymer, with the general structure H0-[-CH2- 
CH2-0]n-H where n is the average number of oxyethylene groups (Kibbe, 2000). 
Depending on the molecular weight, these materials can exist at room 
temperature either as liquids (PEG 200-600 Da), semicrystalline solids (PEG 
3000-20000 Da and above) and resinous solids for much higher molecular 
weights (>100000 Da). PEGs have a helical conformation consisting of seven 
monomers of repeat units and two turns in a fibre identity period of 20 (1.3) A. It 
crystallises forming lamellae with chains fully extended or folded (once or twice) 
(Craig, 1995). In both cases the terminal hydroxyl groups protrude from the 
surface (Kovacs et al., 1975).
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The most stable form is the extended chain form, while the once or twice folded 
forms are the metastabie ones. These metastabie forms have been shown to 
unfold to form the extended chain form over a period of time (Chatham, 1985). 
As previously mentioned, the outlet drying temperature was higher than the 
melting point of the polymer (Tm 50-58°C). The crystallisation from a PEG melt 
can occur by one of two mechanisms: homogeneous or heterogeneous 
nucléation, as described in chapter 3. The polymer chains in the melt are 
randomly orientated and may experience spontaneous aggregation below the 
melting point. When a critical nucleus size is reached, the subsequent addition 
of chains is irreversible and growth occurs. This phenomenon is called 
homogeneous nucléation. Heterogeneous nucléation occurs from nuclei 
already present in the melt. However, the mechanism of crystallisation is not 
clearly understood, since the added material can also act as an inhibitor for 
crystallisation by limiting chain diffusion and packing.
PEG is widely used in pharmaceutical formulations including parenteral, topical, 
ophthalmic, oral and rectal preparations (Kibbe, 2000). Although PEGs have no 
special indications for use in the lungs, considerable attention has been put on 
their use for the controlled release of bioactive compounds within this organ. Fu 
et al. (Fu et a/., 2002) synthesised new polymeric carriers for controlled drug 
delivery following inhalation. The polymers were composed of sebacic acid and 
PEG monomers. PEG was incorporated into the polymer backbone in order to 
reduce the interparticulate adhesion forces and decrease the density of the 
subsequent polymer aerosol. This occurs because the polymer encourages 
water uptake and thus swelling of the particles, which are subsequently frozen 
and lyophylised. The authors stated that PEG may gain approval in pulmonary 
applications due its wide use and proven safety in other clinical applications. 
Other workers (Fiegel et a/., 2004) recently published in vitro deposition data of 
poly(ether-anhydride) microspheres from a Spinhaler® using an Andersen Mark 
II Cascade Impactor. Particles containing 10 % PEG 8000 into the polymer 
blackbone exhibited significantly higher FPF (16.1 %) than those made with 0 % 
PEG (9.1 % FPF).
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French et al. (French et al., 1996) used different florescently marked PEGs 
(obtained by rapid cooling of a solution containing calcein blue solubilised in 
molten PEG 6000 and 8000) directly as carriers to study the influence of 
formulation parameters (i.e. flow rate, active carrier mass ratio and carrier 
particle size) on the deposition of mannitol or mannitol with recombinant human 
granulocyte-colony stimulating factor (GIVI). The study emphasised the 
importance of the drug component properties in emission, deaggregation and 
deposition from the Spinhaler®. Besides being used as a coarse carrier, PEG 
has also been studied as microfine particles. Lucas et al. (Lucas et al., 1998a) 
investigated the influence of PEG 6000 fines on the deposition of bovine serum 
albumin from a Rotahaler® attached to a TSI. Micronised PEG 6000 (VMD of
4.0 pm) was mixed with a coarse lactose carrier (63-90 pm size). The modified 
carrier containing 5.0 % (w/w) micronised PEG was blended with the drug (2 % 
(w/w)). The mean fine particle fraction was found to be 33.5 (4.5) % for the 
PEG-treated formulation, whereas formulations based on untreated lactose or 
treated lactose with 5 % fine lactose exhibited an FPF of 24.4 (4.1) % and 36.8 
(6.9) % respectively. These results showed the possibility of using alternatives 
to lactose fines to improve the in vitro deposition of DPI formulations.
4.3. Aims and objectives
The main aim of the work described in this chapter was to examine different 
lactose/PEG 4000 co-spray-dried systems as a new type of ternary material for 
DPI formulations. The impact of such additives on the aerosol performance of 
modified carriers was evaluated.
The main objectives were to:
• Examine the fabrication of lactose/PEG fines by spray drying;
Determine the physico-chemical properties of these systems to be used 
as fines for DPI formulations;
Examine the influence of the lactose to PEG ratio in the spray-dried 
product on the deposition pattern of the drugs;
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• study the effect of the blending sequence on the performance of a DPI 
formulation;
• Examine the influence of varying the amount of fines and drug on the 
aerosol performance of different coarse lactose carriers.
4.4. Materials and methods
4.4.1. Preparation of the particles by spray drying
The different feed samples containing of the various desired a-lactose 
monohydrate to PEG 4000 ratios were prepared and spray-dried using the 
conditions described in Chapter 2. Solutions with 20 % PEG 4000 and above, 
produced particles, which appeared to be fused together (Figure 4.1), giving low 
yields. This was due to the powder sticking to the walls of the cyclone. 
Therefore PEG concentrations higher than 10 % were not evaluated any further.
Concerning the possible degradation of PEG during the different drying stages, 
Corrigan et al. (Corrigan et a/., 2002) examined the molecular weight 
characteristics of PEG 4000 upon spray drying by gel permeation 
chromatography. No significant differences were found in molecular weights 
before and after processing the PEG. The authors concluded that this technique 
did not result in polymer degradation. No degradation studies were therefore 
performed during this phase of research.
In addition to the crystalline lactose/PEG fines, crystalline lactose fines (B.N. 
E949423) and amorphous lactose fines (obtained by spray drying following the 
parameters described in Chapter 2) were also studied as references. PEG 4000 
was also investigated for comparative surface energy studies. In order to obtain 
the desired particle size distribution, PEG 4000 flakes were ground manually 
and sieved to obtain particle size fraction of 45 to 90 pm. Adequate brass sieves 
were positioned in the sieve shaker (Copley, UK) and the system allowed to be 
shaken for 30 minutes.
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4.4.2. Preparation of the different formulations
Due to the numerous formulation parameters investigated, all detailed 
preparation methods for the different carriers are described under the 
appropriate sections (Sections 4.5.2.1 to 4.5.2.4). All in vitro assessments were 
performed using the TSI and the Clickhaler®.
4.5. Results and discussion
4.5.1. Characterisation of the lactose/PEG 4000 fines
The methods of scanning electron microscopy, particle size determination by 
the Malvern Mastersizer X, X-ray diffraction, dynamic vapour sorption and 
inverse gas chromatography were employed here as described in chapter 2.
4.5.1.1. Scanning electron microscopy
Microscopic examinations were undertaken on the different types of fines 
obtained. The scanning electron micrographs are shown in Figure 4.1. The 
crystalline lactose fines (image A) appeared to be of irregular morphology with 
individual particles appearing to be less than 10 pm in diameter. Image B shows 
the smooth surface of amorphous lactose produced by spray drying. Images C, 
D and E show the different lactose/PEG 4000 co-spray-dried systems. The 
products consist of particles with a particle size of roughly 2 to 10 pm in 
diameter. This was consistent with the work of Chidavaenzi et al, (Chidavaenzi 
et al., 2001). On the surface of the particles evidence of asperities could be 
seen at all lactose to PEG ratios employed. Asperities were present on these 
particles due to the crystallised PEG at the surface. Increasing the PEG 
concentration to 20 % (w/w) had an effect on the particle structure, with 
apparent loss of the integrity of the primary particles due to irreversible fusion of 
adjacent particles.
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Figure 4.1. Electron micrographs of (A) crystalline lactose, (B) amorphous 
lactose, (C) lactose/PEG 1 %, (D) lactose/PEG 5 %, (E) lactose/PEG 10 %,and 
(F) lactose/PEG 20 %.
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4.5.1.2. Particle sizing of the different co-spray-dried systems
The particle size of the different systems was measured using a laser diffraction 
particle analyser (Mastersizer X (Malvern Instruments, UK) as described in 
chapter 2. Propan-2-ol was used as the suspension medium. Each sample was 
analysed separately at least three times and the results are shown in Figure 4.2 
and Table 4.1.
- Lactose/PEG 5 %
- Lactose/PEG 10 % 
Lactose/PEG 1 %
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Figure 4.2. Particle size distribution of the three different grades of lactose.
Formulations
1 % PEG 4000 
5 % PEG 4000 
10% PEG 4000
dio% dso% dgo% SPAN
7.4 15.7 28.0 1.30
(1.1) (1.1) 016) (0.1)
5.0 9.4 15.9 1.16
(0.3) (0.6) (1.2) (0.06)
4.6 10.6 20.5 1.49
(0.3) (0.5) (2.3) 012)
Table 4.1. Particle size distribution of the different co-spray-dried systems. 
Values are mean and (standard deviation).
The spray drying process produced micronised particles with a volume median 
diameter (VMD) ranging between 9.4 and 15.7 pm (Table 4.1). Such a 
difference in particle size was interesting since all samples were spray-dried 
using similar conditions. The particle size analysis results indicated that the 
distribution of the particle was quite narrow whichever lactose to PEG ratio was 
considered.
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The volume mean diameter of the lactose/PEG 4000 particles containing 1 % 
PEG was 15.7 (1.1) pm with a narrow span of 1.3 (0.1). This VMD appeared to 
be bigger than for particles containing a higher percentage of PEG. Particles 
containing 5 or 10 % (w/w) PEG appeared to have similar VMD (9.4 pm and 
10.6 pm respectively). These systems were considered to be of intermediate 
size.
4.5.1.3. X-ray diffraction
The X-ray diffraction patterns of pure a-lactose monohydrate and pure PEG 
4000 are shown in Figure 4.3 and 4.4. The diffraction spectrum shows the 
characteristic peaks corresponding to PEG 4000 (20 = 19.2 and 23.4°).
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Figure 4.3. X-ray diffractogram of the reference a-lactose monohydrate.
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Figure 4.4. X-ray diffractogram of the PEG 4000 reference material.
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Figure 4.5. X-ray diffractogram of the 10% PEG/lactose spray-dried system.
The X-ray diffraction data for the lactose/PEG co-spray-dried system containing 
10 % PEG (Figure 4.5) showed composite diffraction peaks at 10.6° and 12.6°. 
These were attributed to the presence of (3-lactose and a-lactose monohydrate 
respectively (Drapier-Beche et al., 1997). The diffraction peaks for PEG were 
similar to that of the reference material, indicating that the sample presumably 
consisted of the extended chains. These findings were consistent with 
Chidavaenzi et al. (Chidavaenzi et al., 2001). Regarding the 1 % and 5 % PEG 
systems (data not shown), the XRPD data were similar to the 10 % PEG. This 
was unexpected since the same workers showed that spray-drying solutions of
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lactose/PEG consisting of a small amount of polymer resulted in the production 
of a-monohydrate, anhydrous a-lactose but no (3-lactose. The mechanism by 
which lactose crystallises in the presence of PEG is not clearly understood.
4.5.1.4. Dynamic vapour sorption
Lactose monohydrate, despite being soluble in water, is not hygroscopic. 
Buckton etal. (Buckton and Darcy, 1995) showed as little as 0.02 % weight gain 
when subjecting the sample up to 80 % RH. Data for the water sorption of the 
different lactose grades under investigation (i.e. Lactohale LH 100, Aero Flo 65, 
and Pharmatose 325M) also confirmed this low affinity of the powder for water 
with weight gains varying from 0.039 % to 0.076 % at 80 % RH, making 
gravimetric sorption studies difficult to interpret. No DVS isotherm for the a- 
monohydrate is therefore presented here. Moisture sorption / desorption of PEG 
4000 and the different co-spray-dried systems was studied in a dynamic vapour 
sorption apparatus. The method used was as described in chapter 2. Moisture 
uptake/loss (M) was calculated by Equation 4.1
M= (W-Wd)/WdX 100 [Equation 4.1]
where W is the weight of the exposed sample and Wd the weight of the dry 
sample.
In the case of PEG 4000 and lactose/PEG 4000 system containing 1 % PEG 
(w/w), the humidity stage was increased from ten to fifteen hours for PEG on its 
own, and from ten to twenty hours for the co-spray-dried system since 
preliminary experiments showed that no equilibrium was reached within ten 
hours.
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Figure 4.6. DVS mass plot of PEG 4000 as a function of time and % RH.
Gravimetric sorption data for a PEG 4000 sample is presented in Figure 4.6. 
The different relative humidities are illustrated by the blue line, whereas the 
corresponding changes in mass of the sample are represented by the red line. 
As the % RH was decreased to 0 %, water molecules evaporated from the 
sample surface, resulting in a recorded weight decrease. As the humidity of the 
system was raised to 80 % RH, no lag time was observed and the sample 
gained mass rapidly. The mass increase started to tail off after around 1000 
minutes. This was indicative of saturation of the sample with sorbed water. At 
this point the mass had increased by 2.3 %. When the humidity of the system 
was reduced to 0 %, the mass of the sample was seen to decrease rapidly and 
then followed a slower rate of change. This mass loss took place within 220 
minutes and returned to the original dry weight, indicating that reversible water 
sorption and desorption occurred with PEG 4000.
The water vapour sorption profile of lactose/PEG 4000 containing 10 % PEG 
(w/w) is presented in Figure 4.7. The mass gain reached a plateau (3.2 % mass 
increase). The result, showing the absence of mass loss during the 
humidification step, confirmed the initial XRPD data, indicating that no 
crystallisation occurred.
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The mass increase can be attributed to the water uptake due to the PEG and 
also the transformation of anhydrous a-lactose, present in the initial product, as 
described by Chidavaenzi et al., to the monohydrate form. During the final 
drying step, a quasi-instant loss in mass was observed with a residual mass 
gain of 0.8 % due to the expected formation of the hydrate.
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Figure 4.7. Water sorption for lactose/PEG 4000 co-spray-dried system 
containing 10% PEG (w/w).
The water vapour sorption data of lactose /PEG 4000 product containing 5 % 
PEG is presented in Figure 4.8. The material was dried and subjected to the 
same RH as previously described. The sorption of water, illustrated by the 
increase in sample mass, was comparable to the one described for the 10 % 
PEG system shown in Figure 4.7. The increase in weight at the equilibrium 
corresponded to 2.9 % mass gain. The rate of desorption was also really fast 
with a final mass gain equal to 1.6 %.
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Figure 4.8. Water sorption for lactose/PEG 4000 co-spray-dried system 
containing 5 % PEG (w/w).
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Figure 4.9. Water sorption for lactose/PEG 4000 co-spray-dried system 
containing 1 % PEG (w/w).
The sorption kinetic profile was different for the formulation containing 1% PEG 
(Figure 4.9) in comparison to the other lactose/PEG formulations (Figure 4.7 
and 4.8). Following a rapid water uptake for 40 minutes, a far slower rate of 
sorption occur for 980 min before reaching equilibrium with a water level peaked 
at 0.74 % mass gain. The final drying step resulted in a 0.27 % mass increase. 
This was attributed to the formation of some a-lactose monohydrate.
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4.5.1.4. Inverse gas chromatography
In addition to the different lactose/PEG systems, PEG 4000 and crystalline 
lactose (Microfine) were also studied as reference materials. The influence of 
different powder masses of PEG 4000 was also studied as Planinsek et al. 
(Planinsek and Buckton, 2003), had shown a dependence of the acid/base 
terms on the sample mass. The authors investigated the acid and base 
properties of different excipients including Methocel K4M and Pharmacoat 606. 
The K d/K a  ratio of these two materials was seen to be influenced by the powder 
mass. Increasing the sample mass from 250 mg to 500 mg resulted in an 
increase in Kd/Ka value (1.02 to 1.36 for the Methocel and 1.66 to 2.14 for the 
Pharmacoat sample). Access to more of the material or an artefact of the 
retention of vapours was presented as a possible explanation for this 
observation. Three silanized columns were packed with three different masses 
of PEG and the surface energies determined using the parameters described in 
chapter 2. The Ka and Kd were determined using the cross section method. 
Linear regression between the data values for the acid-base analysis is critical. 
The coefficient of correlation indicated a poor fit with the boiling point method (r  ^
below 0.6). The acid-base values obtained with this method were disregarded 
and are not shown here. The dispersive component of free energy, the specific 
surface energies of adsorption and the resulting Ka and Kd are listed in Table
4.2.
Mass
(mg)
Specific polar interaction (J/mol) c h a S s L  j ù )
Acetone Chloroform Ethanol aggtate Kd/Ka
319.6
402.6
494.6
9536 7608 12904 10115
(109) (165) (168) (173)
10042 8069 13639 10509
(68) (46) (67) (52)
9885 8017 13315 10435
(21) (42) (28) (34)
0.118 0.197 1.68
0.122 0.214 1.75
0.121 0.208 1.72
32.9
(0.9)
33.3
(0.4)
33.2
(0.3)
Table 4.2. Influence of the sample mass on the IGC measurements. Values are 
mean and (standard deviation).
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The dispersive component of surface energy was not affected by the sample 
mass. The specific interactions of the four vapours were found to be statistically 
different (ANOVA P<0.05), the lowest values being observed with the lowest 
sample mass. The resulting K q/K a ratios were nevertheless very comparable, 
with values varying from 1.68 to 1.75. Overall, the sample mass did not affect 
significantly the determination of the acid-base nature of PEG 4000. The PEG 
data presented below corresponds to the average of the measurements 
undertaken with three different sample masses.
Materials
Specific polar interaction (KJ/mol) Acid-basecharacteristics
Ys
(mJ/m^)
Acetone Chloroform Ethanol Ethylacetate Ka Kd Kd/K a
Lactose fines 8060 1135 12728 10885 0.143 -0.007 -0.05 42.8(53) (26) (65) (53) (0.16)
Lactose/PEG 6081 2992 8834 7614 0.094 0.055 0.59 34.7(1 %) fines (132) (68) (99) (137) (0.7)
Lactose/PEG 6532 3500 9191 8014 0.096 0.101 1.06 38.4(5 %) fines (32) (33) (15) (26) (0.3)
Lactose/PEG 6942 3809 9767 8153 0.097 0.121 1.25 35.4(10 %) fines (68) (173) (175) (241) (0.6)
PEG 4000 9821(259)
7898
(252)
13286
(368)
10353
(209) 0.12 0.206 1.71
33.1
(0.2)
Table 4.3. IGC measurements for the different lactose/PEG systems and 
lactose fines. Values are mean and (standard deviation).
The surface energies of the different systems were first examined in terms of 
their dispersive surface energies (ys^ ) (Figure 4.10). PEG 4000 with a size 
distribution of 45 to 90 pm, exhibited a relatively low dispersive surface energy 
(33.1(0.2 mJ/m^) compared to lactose monohydrate (chapter 3). The crystalline 
lactose was found to have a surface energy of 42.8 (0.2) mJ/m^. This relatively 
high value may be due to the relatively small size of these particles as shown by 
SEM. The surfaces of the co-spray-dried systems were less energetic than 
those of pure lactose. The ys^  of fines consisting of 5 % PEG was found to be 
higher (38.4 (0.3) mJ/m^) compared to that of the systems containing either 1 % 
PEG (34.7 (0.7) mJ/m^) or 10 % PEG (35.4 (0.6) mJ/m^). Overall, the ys"* 
decreased when incorporating PEG, demonstrating that PEG incorporation 
increased the hydrophilicity of the spray-dried systems. Moreover, the ys^  of the 
different co-spray-dried systems were closer to the ys^  of the PEG than the
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lactose, indicating the presence of PEG at the surface of the particles (as 
already seen on SEM). Those particles may be mimicking the PEG 4000 
surface, as their dispersive surface energies were comparable. Low surface 
energy materials exhibit low van der Waals forces and therefore systems 
containing those particles may be seen as good candidates due to the reduction 
of thestrong drug to carrier adhesion forces.
1% PEG 5% PEG 10% PEG PEG 4000
Figure 4.10. Dispersive components of the crystalline lactose, the different 
lactose/PEG systems and PEG 4000. Values are mean (n=3).
In polar terms, there were also significant differences between the different 
systems studied. The Kd/Ka ratios, determined by the cross sectional approach, 
are shown in Figure 4.11. Values of K q/ K a greater than 1 suggest a basic 
nature on a solid surface, whereas values less than 1 imply an acidic nature. 
Accordingly, the crystalline lactose fines had a negligible K q , which was close to 
zero and an acidic surface. This was in agreement with the values obtained for 
the coarse lactose described in Chapter 3. PEG 4000 gave a greater K q value, 
indicative of its predominantly basic surface. This material was found to have 
nearly twice as many basic sites compared to acidic sites with a K q/ K a ratio of 
1.71. In general, most oxygen-containing organic compounds are Lewis bases 
because of their lone pairs of electrons. Based on its general chemical 
structure, PEG can be regarded as an electron pair donor and therefore the IGC 
results were in accordance with the theoretical approach. The K q values of the 
different co-spray-dried systems increased with increasing PEG concentration 
( K q increasing from 0.055 for a 1 % PEG system to 0.121 for a 10 % PEG
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system), whereas the Ka values remained constant. As a result, the Kq/Ka ratios 
increased indicating that the surface basicity was also increasing.
This may also indicate that more PEG crystals were present on the lactose/PEG 
surface and therefore that the amount of asperities due to those PEG crystals 
was higher.
-0.05
Lactose 1% PEG  5% PEG  10% PEG  PEG  4000
Figure 4.11. Acid-base characteristics of the crystalline lactose, different 
lactose/PEG systems and PEG 4000. Values are mean (n=3).
4.5.2. Different factors affecting drug deposition
4.5.2.1. Influence of the lactose/PEG ratio
The role of fine lactose in dry powder excipients has been widely addressed 
(Louey and Stewart, 2002; Louey et a!., 2003; Islam et a!., 2004). Additionally, 
the use of L-leucine as a ternary component has also been reported (Lucas et 
al., 1999). The use of other amino acids, methionine, phenylalanine and valine, 
was also investigated with varying results (Staniforth, 2000). Tee et al. (Tee et 
al., 2000) have used different sugars (mannitol and sorbitol) as coarse and fine 
carriers. They concluded that the chemical nature of the coarse carrier was 
more important in the resulting FPF of 88 than that of the fines. All these 
studies have in common the use of ternary components that had reasonably 
smooth surfaces. 8ince the lactose/PEG particles may display different levels of 
asperities, as suggested by surface energy data, it was anticipated that the
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deposition properties could be correlated with differences in surface energies. 
Two grades of carrier lactose (Aero Flo 65 and Pharmatose 325M) were 
selected and air-jet sieved. The air-jet method is a single-sieve system for dry 
powders. In this technique, the sieve is mounted in a sealed chamber and the 
air is drawn upwards through the sieve from a rotating slotted nozzle to fluidise 
the sample. Undersized particles are carried downward through the sieve to a 
collection canister. Each lactose grade was sieved for 15 minutes using a sieve 
aperture of 45 pm (Endecotts, UK). This was done to remove particles that were 
less than 45 pm in size. In all following tables, the presence of an air-jet sieved 
material will be indicated by a preceding (A) in the formulation name.
Experiments were conducted with the hydrophobic drug model, since 
preliminary studies described in chapter 3 showed that higher respirable 
fractions of BDP were obtained using a lactose carrier with a high proportion of 
lactose fine particles. The role of fine lactose in the dispersion of the hydrophilic 
drug model from lactose mixtures was also studied in the previous chapter. SS 
deposition patterns appeared to be less related to the fine concentration.
Different binary mixtures consisting of air-jet sieved lactose and lactose/PEG 
fines (containing 1, 5 or 10 % (w/w) PEG 4000) were prepared in 5 g batches. 
The powders were mixed for 30 minutes at 42 rpm. To each of these binary 
mixtures, micronised BDP was added so that the final drug concentration was 
equal to 4 % (w/w). The final mixing step was carried out using a Turbula Mixer 
at a speed of 42 rpm for 20 minutes. After conclusive content uniformity 
assessment (varying from 3.6 to 4.6 %), the reservoir of a Clickhaler® was filled 
with the final mix and measurements undertaken using a TSI as described in 
chapter 2.
Aerosol deposition studies were first conducted with blends of BDP and the 
Aero Flo 65 based formulations (Table 4.4). The different EDs and RDs are 
represented in Figure 4.12 by the grey columns, whereas the FPFs are 
represented by the black points. Significant differences in the deposition of the 
micronised drug were observed after removing the fines from the carrier 
surface. In fact, formulation 2 produced a RD of 69 (23) pg, over 5 times less 
than the values obtained for the untreated formulation (RD of 388 (55) pg).
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The ED remained constant: 959 (51) pg vs. 929 (114) pg. Overall, this resulted 
in a dramatic decrease in FPF (7.3 (1.5) %) vs. 40.6 (3.5) %). When assessing 
the effect of incorporating 10 % (w/w) of crystalline lactose/PEG fines containing
1,5, 10 % (w/w) PEG 4000, it appeared that no significant improvement in the 
ED was observed for the 1 and 5 % PEG systems (Formulations 4 and 5) 
compared to the original Aero Flo 65 (Formulation 1). Adding 10 % fines 
containing 10 % PEG (Formulation 5) however had a detrimental effect on the 
ED when compared to the two other co-spray-dried systems. The ED dropped 
from the similar values of 1007 (151) pg when using fines containing 1 % PEG 
and 954 (74) pg for the 5 % PEG, to the lower value of 799 (84) pg for the 10 % 
PEG. On comparison to the air-jet sieved Aero Flo 65, the data indicated that 
there was a significant improvement in both the RD and the FPF of BDP 
whichever lactose to PEG ratio was used. All formulations delivered similar RD, 
indicating that the nature of the fines did not seem to have a significant impact 
on the deposition properties of the formulations. The FPF of the different 
formulations containing lactose/PEG fines ranged from 22.8 (4.3) to 31.6 (5.8) 
%.
Formulation Carrier ED(pg)
RD
(pg)
FPF
(%)
1
2
o
Aero Flo 65
A Aero Flo 65 
A Aero Flo 65 +fines
954
(51)
929
(114)
1007
388
(55)
69
(23)
229
40.6
(3.5) 
7.3
(1.5) 
22.8o
A
Containing 1 % PEG 
A Aero Flo 65 +fines
(151)
954
(58)
227
(4.3)
23.7
c
Containing 5 % PEG 
A Aero Flo 65 +fines
(74)
738
(61)
234
(5.3)
31.6O Containing 10 % PEG (77) (88) (5.8)
Table 4.4. Influence of the nature of the fines on BDP deposition from the Aero 
Flo 65 based carriers. Values are mean and (standard deviation).
157
1600 -
1400 T
'S  1200 1
% 1000 O■a
800 -10
O
400
600
200
Æt
♦ FPF
2 3 4
Formulation
Figure 4.12. In vitro deposition of the different Aero Flo 65 based formulations 
with BDP as drug model. Values are mean (n=3).
The results of adding lactose/PEG systems used as fines to an air-jet sieved 
Pharmatose 325M are presented in Table 4.5 and Figure 4.13. Removing the 
majority of lactose fines also had a detrimental effect on the performance of this 
particular grade of lactose. The air-jet sieved grade (Formulation 2) produced a 
RD of 91 (13) pg and an FPF of 10.6 (1.2) %, compared to 204 (33) pg and
18.4 (2.7) % for the untreated Pharmatose 325M (Formulation 1). Adding 
crystalline lactose/PEG systems had a beneficial effect on the RD not only 
compared to the air-jet sieved grade but also compared to the original lactose. 
Here again, the RD for the different formulations was similar with RD varying 
from 263 (11) pg to 347 (105) pg depending on the lactose to PEG ratio in the 
added fines (Formulations 3 to 5). When the level of PEG 4000 in the fines was 
increased to 10 %, the ED, as observed in the case of the Aero Flo 65 based 
formulations, decreased (860 (84) pg). This may be related to poor packing and 
poor flowability of the formulation containing 10 % fines consisting of 10 % 
PEG. The ED was not affected with the other types of fines that were prepared.
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Formulation Carrier ED
iM a l
RD
iyal
FPF
Pharmatose 325M
A Pharmatose 325M
A Pharmatose 325M + fines 
containing 1 % PEG 
A Pharmatose 325M + fines 
containing 5 % PEG 
A Pharmatose 325M + fines 
containing 10 % PEG
1110 204 18.4
(35) (33) (2.7)
927 91 10.6
(23) (13) (1.2)
1209 347 28.3
(169) (105) (5.1)
1277 307 24.6
(184) (18) (5.3)
860 263 30.9
(84) (11) (3.4)
Table 4.5. Influence of the nature of the fines on BDP deposition from 
Pharmatose 325M based carriers. Values are mean and (standard deviation).
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Figure 4.13. In vitro deposition of the different Pharmatose 325 M based 
formulations with BDP as drug model. Values are mean (n=3).
When comparing the delivery of respirable BDP particles using different 
carriers, the FPF was the most useful parameter to consider, since the amount 
of emitted drug differed. The highest FPFs were obtained in both cases with the 
highest proportion of the polymer in the fines. The greater PEG concentration 
was thought to be associated with a higher amount of small asperities on the 
surface of the lactose/PEG fines. The presence of those asperities is likely to 
result in a reduction in the van der Waals attractive forces, due to an increased 
separation distance between the surface and the associating drug particles. The 
differences in performance observed between the two lactose grades 
decreased when the 10 % PEG fines were introduced in the formulation.
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Without modifications the Aero Flo 65 displayed a FPF and a RD, which were 
about double that of untreated Pharmatose 325M. After adding 10 % crystalline 
fines consisting of 10 % PEG, the modified carriers exhibited comparable 
performances for the three in vitro parameters. This may represent a significant 
advantage for the formulator, in that differences between marketed lactose 
grades from different sources can be removed.
To further examine the effect of adding 10 % fines containing 10 % PEG, 
experiments were conducted with the hydrophilic drug model. The data for the 
deposition of SS is shown in Table 4.6 and Figure 4.14.
Formulations Carrier E.Diyal
R.D
iMSl
FPF
( 0 /
Aero Flo 65
Pharmatose 325 M
A Aero Flo 65 + fines 
containing 10 % PEG 
A Pharmatose 325 M + fines 
containing 10 % PEG
1271 395 31.2
(61) (12) (0.9)
1219 303 24.9
(125) (53) (3.2)
691 292 42.4
(14) (16) (1.7)
1065 487 45.8
(50) (21) (0.9)
Table 4.6. SS aerosol deposition from different lactose carriers. Values are 
mean and (standard deviation).
?1200
-o 800
dE 400 II I
Formulation
Figure 4.14. In vitro deposition of the different lactose modified carriers with 
SS as drug model. Values are mean (n=3).
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The addition of 10 % lactose/PEG (containing 10 % PEG) had a detrimental 
effect on the ED of the hydrophilic drug whichever grade of lactose was chosen. 
This was in accordance with the results obtained with BDP where decreased 
EDs were also found with this particular formulation. Both modified formulations 
gave rise to improved FPFs: 42.4 (1.7 % for the Aero Flo 65 based formulation 
and 45.8 (0.9) % for the Pharmatose based formulation. Modifying the surface 
of the carriers did not result in a standardisation of the performances of the 
hydrophilic drug model due to differences in EDs.
4.5.2.2. Mixing sequence
Preliminary studies have shown the importance of the mixing sequence on the 
deposition of different drugs from dry powder formulations. Zeng et a/. (Zeng et 
a i, 1999) investigated the effect of particle size and the addition sequence of 
the different components on the deposition of SS from a Rotahaler® coupled to 
a TSI. Ternary mixtures composed of coarse lactose (63-90 pm), lactose fines 
of two different volume mean diameters (5 pm or 15.9 pm) and SS were 
prepared using different mixing sequences. They reported an improvement in 
both RD and FPF for the formulations containing fines compared to that for the 
control.
Mixing the coarse lactose with the smaller-sized fines prior to adding the drug 
led to the highest dispersion efficiency. Larger-sized fines also have a positive 
impact on the efficiency of the formulation, even if the mixing sequence 
appeared to be less significant. The least efficient formulations were obtained 
by mixing SS and coarse lactose prior to adding the fines. These results were 
confirmed in another study by the same author (Zeng et a i, 2000b), in which 
the content homogeneity and dispersibility of BDP from different lactose carriers 
were evaluated. The effect of the chosen sequence of powder component 
addition confirmed the previous study: all ternary formulations exhibited a higher 
dispersibility of BDP than the binary mixtures (coarse lactose and drug). It also 
confirmed that pre-blending coarse lactose and fine lactose prior to adding BDP 
led to a higher RD and FPF (21.7 (4.8) pg and 4.9 (0.8) %) compared to the 
values obtained when mixing the drug and the coarse lactose prior to adding 
the fines (13.6 (4.4) pg and 3.1 (1.0) %). The authors attributed such an effect 
to the coverage of high energy binding sites on the coarse particles by the fines,
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leaving the drug particles to adhere to less energetic alternative binding sites. 
This in turn resulted in higher efficiency. However, in another study by Lucas et 
al. (Lucas et al., 1998a), the order of addition of lactose fines did not affect in 
vitro deposition of either SS or albumin, from a Diskhaler®, leading the authors 
to suggest another possible mechanism involving the presence of small drug- 
fine aggregates. This was indicative of a redistribution of the drug from the 
coarse carrier to the ternary component. Louey et al. (Louey and Stewart, 
2002) also concluded that the dispersion of ternary mixtures comprising SS, 
coarse lactose and fine lactose were independent on the order of mixing. 
Acknowledging the existence of these conflicting results, the purpose of this 
section was to assess whether the mixing sequence involving the lactose/PEG 
fines had an impact on the deposition patterns of both BDP and SS. In addition 
to the data already described and used as controls, the impact of mixing the 
drug with the coarse carrier prior to adding the fines had to be assessed. The 
Aero Flo 65 was designated as the control carrier as it was the most efficient in 
delivering the hydrophobic drug. The air-jet sieved Aero Flo 65 was mixed with 
BDP for 30 minutes using a Turbula mixer at 42 rpm before adding the 
lactose/PEG fines and blending for a further 20 minutes. Each time, the overall 
drug and fine concentrations were 4 % (w/w) and 10 % (w/w) respectively.
The results of experiments conducted to study the effect of the mixing sequence 
on drug deposition from the Clickhaler® are summarised in Table 4.7 and shown 
in Figure 4.15. In the following table, the notation “fines” refers to lactose/PEG 
crystalline fines containing 10 % (w/w) PEG 4000.
Formulation__________ Carrier___________ ED (pg) RD (pg) FPF (%)
1 A Aero Flo 65 + BDP
2 A Aero Flo 65 + fines +BDP
3 A Aero Flo 65 + BDP + fines
4 A Aero Flo 65 + SS
5 A Aero Flo 65 + fines +SS
6 A Aero Flo 65 + SS + fines
Table 4.7. Influence of the mixing sequence on the performances of SS and 
BDP. Values are mean and (standard deviation).
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929 69 7.3
(114) (23) (1.5)
799 256 31.6
(84) (72) (5.8)
960 139 14.6
(80) (24) (2.5)
1114 358 31.7
(37) (14) (1.2)
690 292 42.3
(14) (16) (1.7)
1200 406 33.8
(49) (41) (2.9)
■o
u_
Formulation
Figure 4.15. Influence of the mixing sequence on the FPF of SS and BDP 
formulations. Values are mean, n=3..
Regardless of the mixing sequence, ternary ordered mixes (Formulations 2, 3, 5 
and 6) exhibited higher FPFs than the corresponding binary mixes 
(Formulations 1 and 4). As previously described, adding a ternary component 
(here, crystalline lactose/PEG fines) to an air-jet sieved lactose had an impact 
on the RD and FPF for both drugs. This effect may be partly due to the 
coverage of active binding sites on the coarse lactose by the fines, affecting the 
particulate interaction between the drug and the coarse carrier. Only more 
passive sites would remain available for adhesion during the second stage of 
blending. When BDP was mixed with the coarse carrier prior to adding the 
fines, the RD was found to be equal to 139 (24) pg and the FPF to 14.6 (2.5) % 
(Formulation 3). Those values were significantly higher than those obtained with 
the binary mixture consisting of the air-jet sieved grade and the drug 
(Formulation 1). Therefore, if the fines were only acting by occupying the high 
energy binding sites, then their addition to a binary ordered mix would have had 
no effect on the FPF. The improved deposition observed with Formulation 3 
may be due to some redistribution of BDP and fines between active and passive 
adhesion sites on the surface of the coarse carrier occurring during the powder 
mixing. Another possibility is the existence of small aggregates or individual 
particles free within the mix, acting as an alternative carrier as previously 
described by Clarke et al. (Clarke et al., 2001). An example is in Figure 4.16.
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Figure 4.16. Scanning electron micrograph of a ternary mixture consisting of A 
Aero Flo 65, lactose/PEG 10% fines and BDP.
The ED was also influenced by the blending process, the lowest being observed 
for Formulation 2 (799 (84) pg). The dramatic increase in both the RD and FPF 
for BDP for Formulation 2 compared to Formulations 1 and 3 corroborated the 
observations of Zeng et al. (Zeng et al., 2000b), who had previously shown an 
improvement in the dispersion and deaggregation of BDP particles. The 
addition sequence during the formulation had a different impact on SS 
deposition. The performances of SS were similar for the binary mixture 
(Formulation 4) and the ternary mixture where the fines were added last 
(Formulation 6). Adding the fines to a carrier prior to adding SS (Formulation 5) 
led to the highest FPF with a value of 42.3 (1.7) %, compared to 31.7(1.2) % for 
Formulations 4 and 33.8 (2.9) % for Formulation 6. Although the ED for 
Formulation 5 dropped dramatically compared to the control (Formulation 4), it 
was in accordance with the ED of Formulation 2 with the same mixing sequence 
but containing BDP (690 (14) pg vs. 799 (84) pg). The RD of Formulations 5 
and 2 were also comparable (292 (16) pg vs. 256 (72) pg).
In conclusion, the addition of fines and the mixing order do not have the same 
effects with different drug models. As previously described, these results 
indicate that BDP is much more sensitive to the presence of fines than SS.
164
4.5.2.3. Effect of the fine concentration
Lucas et al. (Lucas et al., 1998b) investigated the role of fine particle lactose on 
aerosol performances of albumin based dry powder formulations using the 
Diskhaler® device. They pre-mixed fine particle lactose (Sorbolac 400; VIVID =
5.4 pm) with a coarse lactose (63-90 pm) carrier. The concentration of fines 
used varied from 2.5 % to 10 % (w/w). The active was then blended with this 
binary mixture. The performance modifying effect of fine lactose was 
demonstrated by the improvement in albumin FPF, which increased from 31.7 
(2.4) % for a coarse lactose to 49.8 (5.1) % in the case of carrier lactose pre­
treated with 10 % (w/w) fines. The role of the concentration of the ternary 
component in the dispersion of SS from a Rotahaler® coupled to a TSI was 
examined by Louey et al. (Louey and Stewart, 2002). Batches containing 5 % 
w/w drug and 0-10 % (w/w) fines were prepared. Two types of materials were 
used as fines: micronised lactose (VIVID = 4.0 pm) and micronised glucose 
(VIVID = 4.4 pm). The authors found that increasing ternary concentration 
increased the FPF to a maximum level of around 40 %. In another study, Islam 
et al. (Islam et al., 2004) demonstrated the relationship between the fine lactose 
concentration and the dispersion of salmeterol xinafoate. They found a 
reasonably good linear relationship and significant regression between the FPF 
of the active and the concentration of fine lactose (less than 5 pm) (r^= 0.908 
and r^= 0.972) for Aero Flo 65 and Aero Flo 95 respectively). Other research by 
Al-Hadithi (Al-Hadithi, 2004) showed no beneficial effect of adding crystalline 
lactose fines (5 to 15 % (w/w)) to an air-jet sieved Pharmatose 325M in term of 
SS deposition.
Modifying lactose grades by adding lactose/PEG fines influenced the deposition 
profiles for the two model drugs studied. This section aims to define the level of 
added fines needed for optimum deposition.
Different percentages of fine lactose/PEG 4000 particles were added (0, 2.5, 5,
7.5 and 10 % (w/w)) to the air-jet sieved Aero Flo 65. The effect of ternary 
concentration in excess of 10 % (w/w) was not determined since the ED 
appeared to be affected by 10 % fines due to possible poor flowability of the 
blend. The PEG to lactose ratio in the spray-dried particles was 10 % (w/w).
165
The effect of the fine concentration was studied for both SS and BDP. The 
drugs were added last to reach a 4 % (w/w) concentration. The blending 
process was the same as presented in Section 4.6.1.
The relationship between FPF of the active (BDP or SS) and the concentration 
of lactose/PEG fines is shown in Figure 4.17. Good linear relationships between 
FPF and fine content were found for both drugs (r^= 0.76 for BDP and 0.75 for 
SS). Moreover, the steeper gradient for BDP compared to SS points out again 
that BDP is more likely to be influenced by the surface carrier than SS. When 
considering the hydrophobic drug model, it appeared that the greatest stepped- 
increase in the fine particle fraction was obtained with the addition of 5 % (w/w) 
of lactose/PEG fines. While the ED was maintained (929 (114) pg vs. 999 (32) 
pg), the RD increased from 69 (23) pg to 225 (16) pg. This improvement was 
also demonstrated by an increase in FPF, rising from 7.4 (1.6) % to 22.5 (1.2) 
%. Adding 7.5 % fines did not have an effect on the ED either, with a valur of 
970 (12) pg. However, this formulation resulted in a significant lower RD (150 
(12 pg)), which was linked to a lower FPF (15.5 (1.3) %). Adding 10 % fines, as 
previously described, had a detrimental effect on the ED. Regarding the 
hydrophilic drug model, the addition of fines up to a level of 7.5 % does not 
seem to impact to the same extent on the performance of the carriers. Both the 
RDs and the FPFs were comparables with values ranging from 306 (10) pg to 
58 (14) pg and 31.0 (2.2) % to 34.5 (1.1) % depending on the formulation 
considered. The higher FPF observed with the 10 % fines (42.3 (1.7) %) was 
mainly due to the decrease in the ED (690 (14) pg). These findings were in 
accordance with the work previously carried out in our laboratory. Adding 
lactose/PEG crystalline fines at these specified levels did not improve the 
efficiency of the carrier in delivering SS.
BDP SS
% of fines ED (pg) RD (pg) FPF (%) ED (pg) RD (pg) FPF (%)
0% 929 (114) 69 (23) 7.4 (1.6) 1114(37) 358 (14) 31.7(1.2)
2.5 % 990 (29) 110(31) 10.8 (3.3) 995 (53) 309 (29) 31.0(2.2)
5% 999 (32) 225(16) 22.5 (1.2) 886 (12) 306(10) 34.5(1.1)
7.5 % 970 (12) 150(12) 15.5 (1.3) 990 (18) 339 (19) 34.2 (1.8)
10% 799 (84) 256 (72) 31.6 (5.8) 690 (14) 292 (17) 42.3(1.7)
Table 4.8. Influence of the fine concentration on both BDP and SS deposition. 
Values are mean and (standard deviation).
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% of lactose/PEG 4000 fines added
Figure 4.17. Relationship between FPF of SS and BDP and the concentration 
of lactose/PEG fines. Values are mean (n=3)).
4.5.2.4. Effect of tfie drug concentration
The concentration of micronised drug in the powder formulation is usually low 
with a typical drug to carrier ratio of 1 to 67.5 (Zeng et al., 2000a). All 
experiments that have been described were conducted with a drug 
concentration of 4.0 % (w/w), in accordance with the ratio employed in the 
commercial Asmasal™ formulation. In this section the effect of SS and BDP 
concentrations was evaluated. It is known that the drug to carrier ratio may 
influence the deposition profiles. Lucas (Lucas et al., 1999) studied the 
deposition of SS-coarse lactose carrier formulations with different drug loadings. 
Formulations with 0.96 and 3.2 % (w/w) drug were prepared and tested using a 
Diskhaler® and a modified TSI with a cut-off diameter of 5.3 pm. An increase in 
drug concentration led to a higher drug deposition (FPF of 11.1 % and 16.5 % 
respectively). This was in accordance with the earlier observations of 
Ganderton (Ganderton, 1992; Steckel and Müller, 1997). However, the effect of 
the drug to carrier ratio is not always straightforward. Steckel et al. (Steckel and 
Müller, 1997) investigated the influence of the percentage of BUD (1, 5 and 9 % 
(w/w)) in the interactive mixtures containing a coarse lactose carrier on the 
deposition from the single-unit dose Spinhaler® and the multiple-unit dose 
Easyhaler®. Three different lactose sieve fractions were studied; below 32 pm, 
between 63 and 90 pm, and between 125 and 180 pm.
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For the 63-90 pm fraction, it was found that increasing the drug to carrier ratio 
resulted in a signifiant decrease in FPF, independent of which sieve fraction or 
device was used. For example the FPF dropped from 28.40 (0.74) % using a 1 
% drug loading to 23.69 (0.46) % using a 9 % drug loading. Those values 
dropped from 37.25 (0.41) % to 25.96 (2.19) % using the same conditions and 
the Easyhaler®.
The aim of this section was to aerosolize formulations containing different ratios 
of drug to lactose carrier. Formulations were prepared by mixing the Aero Flo 
65 with a range of active concentrations (1, 2 and 4 % (w/w)) using either BDP 
or SS. This was carried out using a Turbula mixer for 30 minutes at 42 rpm. The 
aerosol deposition data obtained from these formulations are summarised in 
Table 4.9.
BDP SS
Drug ED RD FPF ED RD FPF
loading (M9) (M9) (%) (M9) (M9) (%)
954 388 40.6 1271 395 31.2
4%
(52) (55) (3.5) (61) (12) (0.9)
487 122 25 636 214 33.7
2%
(55) (23) (2.2) (128) (38) (1)
233 59 25.1 357 108 30.5
1 %
(33) (12) (1.7) (32) (12) (4.8)
Table 4.9. Effect of the drug to carrier ratio on the deposition profiies of BDP 
and SS. Values are mean and (standard deviation).
Increasing the percentage of drug in the formulation led to an increase in the 
ED. As expected, positive correlations between the drug loading and the EDs 
for the two drugs were observed. For the hydrophobic drug model, a 1 % (w/w) 
drug loading resulted in an ED of 233 (33) pg. Doubling the drug loading to 2 % 
(w/w) increased the ED to 487 (55) pg, twice that of 1 % drug loading. The RDs 
followed the same trend with an increase from 59 (12) pg to 122 (23) pg. This 
resulted in similar FPF of BDP for these two drug loadings: 25.1 (1.7) % vs.
25.0 (2.2) % for 1 and 2 % drug loading respectively. Further doubling the 
concentration to 4 % was seen to raise the ED to 954 (52) pg and the RD to 388 
(55) pg, leading to a 40.6 (3.5) % FPF. This more effective dispersion of the
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powder at high coverage of drug has been already described by Ganderton 
(Ganderton, 1992). He stated that at high drug loading, more drug particles may 
be adhering with less strong binding affinities to the surface of the lactose 
carrier, leading to higher FPF.
For the hydrophilic drug model, the ED and the RD increased in parallel with 
increasing drug loading. As a result of this, similar FPFs were obtained for the 
different formulations. The FPF for the 1 % blend was 30.5 (4.8) %, 33.7 (1) % 
for the 2 % blend and 31.2 (0.9) % for the 4 % blend. In conclusion, in vitro 
deposition appeared to be independent of the SS concentration.
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4.6. General conclusions
The aim of the work described in this chapter was to study some of the factors 
influencing the performance of dry powder formulations for inhalation using two 
drug models, SS and BDP. A new type of crystalline fines consisting of 
lactose/PEG co-spray-dried system was evaluated as a ternary component for 
DPI technology. The major findings are summarised below associated with the 
original objectives of the work carried out.
Investigating the suitabilitv of different lactose/PEG 4000 svstems as fines for 
DPI formulations:
Lactose/PEG 4000 particles were produced by spray drying, the concentration 
of PEG varying from 1 to 10 % (w/w). The different polymer to lactose ratios 
were not seen to affect either the general morphology or the particle size 
distribution of the particles. Physico-chemical characterisation of these systems 
by dynamic vapour sorption and inverse gas chromatography highlighted the 
major differences in the particles produced. Visual examination by SEM and 
surface energy data generated by IGC confirmed the presence of crystalline 
PEG at the surface of the particles. The presence of those crystals at the 
surface of the particles may play in important role in decreasing the van der 
Waals attraction forces responsible for the adhesion of particles.
Examination of the influence of the lactose to PEG ratio in the sorav-dried 
product on the performance of a coarse carrier:
Two different coarse lactose grades were used in this study (i.e. Pharmatose 
325M and Aero Flo 65). The influence of adding fines containing different 
amounts of PEG to a coarse carrier was dependent on the carrier type. The 
addition of fines did not improve the performances of the original Aero Flo 65, 
which was found to perform well on its own. Moreover, the RDs for the 
formulations based on this carrier were independent of the nature of the fines 
added. However, higher RDs and FPFs were obtained in ternary mixtures for 
the Pharmatose 325M carrier.
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Overall, blending 10 % fines containing 10 % PEG 4000 to air-jet sieved lactose 
grades prior to adding the BDP seemed to standardise the in vitro 
performances. To assess the robustness of this specific formulation, SS was 
also tested. Although the FPFs were improved, the EDs varied from one grade 
to the other, hence limiting the practical use of this approach.
Examination of the effect of the blending sequence on the deposition patterns:
The mechanism by which the addition of fine modifies the drug deposition in 
these dry powder formulations was not fully understood. Observations from the 
mixing sequence study were not fully consistent with the theory of the active 
sites saturation. A competitive adhesion was more likely to have occurred, with 
the drug being distributed between the large carrier particles and the fine 
lactose/PEG particles to produce an equilibrium mixture as stated by Louey et 
al. (Louey and Stewart, 2002). Moreover, the high drug loading (4 %) and the 
high concentration of fines added are likely to involve aggregation and 
multilayer formation, leading to more complex adhesion processes.
Examination of the influence of varying the concentration of fines and drug on 
the aerosol performance of different coarse lactose carriers:
When the added fines were increased from 0 % to 10 % in the air-jet sieved 
Aero Flo 65, the FPF increased from 7.4 % to 31.6 % for the hydrophobic drug 
model. The optimal level of added fines was found to be 5 % (w/w), at which 
there was a balance between the effect of the flow properties of the powder (i.e. 
affecting the release of the dose from the inhaler) and the optimum BDP 
deposition. The introduction of fines to the coarse lactose did not result in any 
improvement in the ability of the carrier to liberate SS from its surface.
The drug to carrier ratio also appeared to influence the FPF of the hydrophobic 
drug model with an increase in the detachment from the carrier particles at high 
drug loading. This study highlighted once again the differences between the 
drugs, with the hydrophilic drug model deposition not being affected by the drug 
loading.
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Chapter
5
Partially amorphous 
lactose/PEG fines used as 
surface modifiers for DPI
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5.1. Summary
In chapters 3 and 4 the importance of fine particles on the aerosol performance 
of the carrier had been confirmed. The effect of adding different types of 
crystalline fines had also been extensively studied in the literature. The 
controlled addition of crystalline lactose/PEG fines into the mixes had varying 
results on the deposition pattern of the two drug models. A consequence of 
adding a large amount of fines was the apparent reduction in the powder flow, 
which had significant implications on the obtained RDs. This chapter evaluates 
the use of partially amorphous lactose/PEG fines to be recrystallised onto two 
coarse lactose surfaces. Based on the early surface energy measurements 
presented in chapter 4, it appeared that adding lactose/PEG fines resulted in an 
apparent “PEG like” surface. This current chapter also aims to compare the 
performances of these new systems with the performance of a PEG 4000 
carrier. In the second part of this chapter, the overall applications of surface 
energy data in predicting DPI performances were investigated.
5.2. Introduction
In a recent work, Al-Hadithi (Al-Hadithi, 2004) introduced amorphous lactose 
fines onto a crystalline carrier surface. The amorphous fines were allowed to 
crystallise onto the coarse surface by controlled crystallisation at 53 % RH using 
a “specially built” conditioning chamber. The crystallisation time varied from 0.5 
to 5 hours. The modified carriers were then blended with one of the two model 
drugs (SS or BDP). In vitro assessment was performed using a Clickhaler® 
coupled to a TSI. Significant improvement in the SS deposition was observed 
when the crystallisation time was 2 hours. Following these 2 hours of 
crystallisation, the RD of SS was found to be equal to 499 (169) pg, with an ED 
of 1250 (320) pg. However, this improvement was not maintained for systems 
that underwent crystallisation for upwards of 2 hours. Furthermore, the 
deposition from the hydrophobic model employed (BDP) did not follow this trend 
and the efficiency of those treated surfaces appeared to be inferior compared to 
their SS analogs.
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5.3. Aims and objectives
The principle aims of the work described in this chapter were to modify the 
physical characteristics of two coarse lactose surfaces and to correlate the 
surface free energy of the different systems to the deposition of both hydrophilic 
and hydrophobic drug models.
The objectives were to:
• Fuse partially amorphous lactose/PEG fines onto the surface of air-jet 
sieved coarse lactose and to assess their influence on the performance 
(section A);
• Determine different surface energy parameters by IGC in order to 
examine how the surface energy of the carriers was affected by physical 
changes (section A);
Compare the deposition profiles of these modified carriers with a PEG 
carrier (section A);
Determine the correlations between IGC data and deposition patterns 
(section B).
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SECTION A: Investigation of modified lactose carriers and PEG 4000 [45-90]
|jm as a control probe carrier
5.4. Materials and methods
5.4.1. Production of the fines
Alpha-lactose monohydrate and PEG 4000 were added to purified water to give 
a 10 % (w/v) solution. PEG was added so that the polymer concentration was 
equal to 10 % by weight of lactose. The raw materials used were identical to the 
ones used to generate crystalline lactose/PEG 4000 co-spray-dried systems 
(investigated in chapter 3). The BOchi 191 was used to spray dry the solution at 
constant process conditions, following the parameters described in chapter 2, 
Section 2.2.1. The physico-chemical properties of the spray-dried material were 
analysed using SEM, X-ray diffraction and dynamic vapour sorption. The 
conditions and instruments used in this study were as reported in chapter 2.
5.4.2. Surface treatment of lactose crystals
Two different grades of a-lactose monohydrate (Pharmatose 325M and Aero 
Flo 65) were air-jet sieved over a 45 pm mesh sieve, as previously described in 
chapter 4. As soon as the spray drying process was over, the fines were 
collected and blended with the air-jet sieved coarse carrier for 30 minutes at 42 
rpm using a Turbula mixer. The fines were left to recrystal lise for 24 hours at 
room temperature. BDP or SS were then added at a concentration of 4.0 % 
(w/w) and mixed for 30 more minutes at 42 rpm. Content uniformity assessment 
and in vitro deposition studies were conducted as previously described.
5.4.3. Investigation of PEG 4000 as a control probe carrier
It was necessary to evaluate the use of PEG 4000 directly as drug carrier. This 
was a way to assess the importance of the chemical nature of a surface. PEG 
4000 flakes were ground manually and sieved to obtain a particle size fraction 
of 45 to 90 pm. This size fraction was then blended with each micronised drug
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(4 % (w/w)). The Aerolizer® was used instead of the Clickhaler® as a device 
since the reservoir device was inefficient in delivering this formulation (see 
section 5.5.4)
5.5. Results and discussion
5.5.1. Characterisation of the partially amorphous lactose/PEG fines
A scanning electron micrograph (Figure 5.1) of the spray-dried product showed 
particles with an apparently smoother surface than that observed for crystalline 
lactose/PEG fines (Figure 4.1). The particle shape is governed by the relatively 
low presence of asperities, which are due to the presence of surface crystalline 
PEG.
Figure 5.1. Electron micrograph of partially amorphous lactose/PEG system.
X-ray diffraction along with DVS was used to characterise the co-spray-dried 
product. A sample of the spray-dried product was analysed as soon as the run 
was finished. Corrigan et al. (Corrigan et al., 2002) stressed the importance of 
the timing of the first analysis due to the rapid crystallisation of these systems.
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The XRPD diffractogram (Figure 5.2) displayed a partially amorphous 
lactose/PEG system with some peaks indicative of some crystallisation having 
already taken place. Figure 5.3 showed the same sample after 24 hours, which 
is consistent with a recrystallised sample.
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Figure 5.2. X- ray diffraction data of lactose/PEG 4000 (10 %) showing the 
partially amorphous compound.
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Figure 5.3. X-ray diffraction data of lactose/PEG 4000 (10 %) after 24 hours 
showing crystallisation of the partially amorphous compound.
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The water vapour sorption properties of partially amorphous lactose/PEG were 
analysed using a DVS-1 (Figure 5.4). A three-step experiment was set up. After 
the initial drying phase (0 % RH for 360 minutes), the powder was exposed to 
80 % RH. A swift mass uptake of water was observed due to vapour sorption at 
this elevated RH. The maximum water absorption was found to be equal to 6.6 
%. This uptake was followed by a nearly instant mass loss whilst the sample 
remained at 80 % RH. This mass loss was due to the crystallisation of the 
amorphous sample, which is a consequence of the sorbed water. The sorbed 
water induced plasticization of the amorphous phase, lowering the glass 
transition temperature below the experimental temperature (25°C). The newly 
acquired mobility of the molecules enabled the rapid crystallisation and the 
displacement of the water. The expulsion of the plasticizing water was not 
complete and even after the final drying step, some of the water (approximately
1.4 %) is retained as a partial monohydrate.
200 400 600 800 1000 1200 1400
Time/mins
Figure 5.4. Water sorption for partially amorphous lactose/PEG 4000.
5.5.2. Characterisation of the modified carriers
Figure 5.5 shows a micrograph of a modified lactose surface with small 
spherical lactose/PEG fines associated with the coarse carrier.
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mFigure 5.5. Scanning electron micrograpti of the” fused system”.
Surface energy measurements by IGC were obtained as described in chapter 2. 
Two different batches of surface modified lactose carriers were analysed and 
the different parameters measured are summarised in Tables 5.1 and 5.2.
Run 1 Run 2 Run 3 Run 4 Run 5 Run 6 Average
(mJ/m )
35.7 37.5 36.4 34.7 35.6 35.1 35.8(1.0)
Acetone
(J/mol)
5456 5642 5637 5550 5787 5982 5676(186)
Chloroform
(J/mol)
2514 2722 2522 2635 2713 2729 2639(100)
Ethanol
(J/mol)
8094 8298 8067 8181 8256 8203 8183(90)
Ethyl acetate 
(J/mol)
7115 7507 7268 7304 7446 7499 7357(155)
Table 5.1. Surface energy parameters of the modified Aero Flo 65 obtained with 
2 different columns and three repeats for each column.
The modified Aero Flo 65 (Table 5.1) exhibited on average a relatively low 
dispersive surface energy, with a Ys^  of 35.8 (1.0) mJ/m^ compared to that of the 
original grade (42.9 (0.3) mJ/m^). This may anticipate a lower binding tendency 
of the drug and increased aerosolisation efficiency. The Ka and Kd were 
determined using the cross-section method, because the linear fit with the 
boiling point method was seen to be poor (r  ^below 0.4). The calculated Kd/Ka 
ratio was found to be equal to 0.44 (0.02) with a Ka value of 0.0922 (0.001) and 
a Kd value of 0.0411 (0.002). These acid-base properties were very similar to
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the ones of the Pharmatose 325M based formulation (Table 5.2), which had a 
calculated K q/K a ratio of 0.47 (0.02). The corresponding K a  value of the latter 
formulation was equal to 0.0921 (0.002) and the Kd value was 0.0435 (0.003). 
The Ys^  was also similar with an average value of 34.4 (1.2) mJ/m^
Run 1 Run 2 Run 3 Run 4 Run 5 Run 6 Average
(mJ/m )
36.7 34.1 34.0 34.5 33.1 34.2 34.4(1.2)
Acetone
(J/mol)
5859 5789 5753 5671 5592 5795 5743(96)
2718
(120)
Chloroform
(J/mol)
2915 2700 2742 2701 2540 2713
Ethanol
(J/mol)
8615 8237 8217 8006 7783 7977 8139(287)
Ethyl acetate 
(J/mol) 7710 7266 7422 7342 7072 7320
7355
(209)
Table 5.2. Surface energy parametersof the modified Pharmatose 325M 
surface obtained with 2 different columns and three repeats for each column.
Having examined the surface energy parameters of the different formulations in 
chapters 3, 4 and 5, it appeared important to plot some of the results that were 
described fully in these previous chapters. Figure 5.6 presents the dispersive 
component determinations and Figure 5.7 summarises the individual probe 
interactions with each powder surface.
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37.6
366
35.8
34.4
□ Aero Flo 65 (1)
I Pharmatose 325M (2)
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□ A Aero Flo 65 + fused fines (5)
□ A Pharmatose 325M + fused fines (6)
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Figure 5.6. Effect of powder modification on the resulting dispersive energy. 
Values are mean and based on at least three measurements.
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Compared to the dispersive surface energies of the different grade of lactose 
alone (Formulations 1 and 2), those of mixtures containing lactose/PEG fines 
(Formulations 3 to 6) were generally lower with a ys^  comparable to that of 
lactose/PEG fines alone. Interestingly, the variations observed between the two 
a-lactose monohydrate samples diminished after the surface treatment. 
Moreover, the differences in specific interactions were also affected by the 
addition of lactose/PEG fines. Examination of the specific free energy of 
adsorption (dG) for each probe also showed a “standardisation” of the surface 
properties, especially for the fused systems. Previous work detailed in chapter 4 
showed that modified carriers, consisting of air-jet sieved grades of lactose 
mixed with 10 % lactose/PEG fines, exhibited comparable aerosol 
performances for the hydrophobic drug model. The idea that surfaces with 
similar energies would result in similar deposition patterns was further tested 
with the fused system.
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(2)
□  A Aero Flo 65 + fines 
(3)
B A Pharmatose 325M  
+ fines (4)
□  A Aero Flo 65 + fused 
fines (5)
□  A Pharmatose 325M  
+ fused fines (6)
Figure 5.7. Effect of powder modification on the specific interactions of polar 
probes. Values are mean and based on at least three measurements.
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5.5.3. Deposition studies
The deposition data of SS and BDP in the TSI via the Clikhaler®is summarised 
in Table 5.3.
SS BDP
ED RD FPF ED RD FPF
(M9) (M9) (%) (M9) (M9) (%)
A Aero Flo 65 + 1024 358 34.9 955 119 12.8
lactose/PEG fused fines (37) (21) (0.9) (172) (7) (2.8)
A Pharmatose 325M + 1065 349 32.8 945 191 20.2
lactose/PEG fused fines (53) (21) (0.5) (96) (51) (4.3)
Table 5.3. SS and BDP aerosol deposition from modified lactose carriers. 
Values are mean and (standard deviation).
The data in Table 5.3 showed that there were signicant differences in the 
deposition of SS and BDP. Comparing the performance of the two carriers, the 
EDs of SS (1024 (37) pg and 1065 (53) pg) were comparable for both carriers. 
The RDs of the drug were also similar, with values varying from 358 (21) pg to 
349 (21) pg. As a result, the modified carriers gave rise to statistically (p=0.05) 
similar FPFs of SS (34.9 (0.9) % vs. 32.8 (0.5) %). In contrast, for BDP, the 
modified carriers gave poor RDs, ranging from 119 (7) pg for an Aero Flo 65 
based carrier to 191 (51) pg for the Pharmatose 325 M based carrier. Overall, 
the resulting FPF of BDP from the two carriers was low, with values ranging 
from 12.8 (2.8) % to 20.2 (4.3) %.
As a conclusion, fusing lactose/PEG fines on the surface of air-jet sieved 
lactose had a mixed effect on the aerosol performances of the resulting carrier, 
depending on the drug model evaluated. Adding crystalline fines dispersed and 
deaggregated the hydrophobic drug better than using a fused system. This 
confirms the importance of free fines in weakening the drug agglomerates.
5.5.4. Deposition studies using PEG 4000 as a model carrier
The individual crystalline PEG 4000 particles (Figure 5.8) adopted the usual 
tomahawk shape. As previously mentioned, this size fraction (45-90 pm) was 
then blended with each micronised drug.
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The blend coefficient of variation was higher than 5 % due to the difficulty to 
disperse the drug particles efficiently (C.V. of 7.4 for SS and 9.3 for BDP). 
Despite these poor blend homogeneities, evaluation for drug deposition was still 
carried out.
A c c  V  S p o t  M . jq n  
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Figure 5.8. Scanning electron micrograph of PEG 4000 [45-90] pm.
Difficulties in aerosol generation were also encountered with PEG 4000 (45-90 
pm) using the Clickhaler® The total inhaler weight loss was lower than that of 
the lactose carrier, with the amount of powder leaving the device varying from
15.4 mg to 16.2 mg for runs comprising ten actuations. This may be due to sub- 
optimal flow properties or density. A unit dose device, the Aerolizer® was 
therefore used as an alternative device. This study also provided a good 
opportunity to investigate the influence of the device on the deposition.
The loss of patent protection for many of the key drugs in asthma therapy (i.e. 
SS, terbutaline sulphate, BDP and BUD) has resulted in an increased 
prescribtion of generic products. As a result of this, the number of newly 
developed DPI devices also increased (Smith and Parry-billings, 2003). For 
example, SS could be administered in 2002 in the European Union using 8 
different devices (Clickhaler®, Easyhaler®, Pulvinal® and Turbuhaler® as 
multiple-dose reservoirs; Cyclohaler® and Rotahaler® as single-dose capsules; 
Diskhaler® as a small multiple-dose replaceable cartridge; and 
Diskus/Accuhaler® as a multiple unit-dose strip). Drug-carrier formulations can
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produce significantly different performances depending on the device that is 
used (Srichana etal., 1998).
The Aerolizer® and Clickhaler® differ in the aerosol production and also in the 
device resistance to air flow. The flow (F) through an inhaler device follows the 
equation:
F  = [Equation 5.1 ]
Where VÂP is the pressure gradient developed across the device and R the 
device resistance.
Both devices are of medium resistance, approximately 0.1 cm of H2O at a rate 
of 0.5l_/min for the Clickhaler® and 0.06 cm of H2O at a rate of IL/min for the 
Aerolizer®. A TSI operating at 60 Umin for 5 seconds was employed to detect 
the FPF from the firing of a single dose from the Aerolizer®.
Three capsules with the same fill weight (30 mg) were tested for each 
formulation. Aerosol deposition studies were performed with the two drug 
models at a concentration of 4 % (w/w). The results are summarised in Table
5.4
ED RD FPF
(pg) (pg) (%)
SS deposition 
BDP deposition
1407
(171)
993
(65)
556
(96)
337
(32)
39.6
(4.9)
33.9
(1.2)
Table 5.4. Evaluation of PEG 4000 as a carrier for DPI formulation. Vaiues are 
mean and (standard deviation).
As previously mentioned, three 30 mg capsules with 4 % (w/w) drug blends 
were tested. Based on a uniform blend, the total amount of drug in the impactor 
and the device should not exceed 1200 pg. However, SS data showed a higher 
amount of drug recovered (1407 (171) pg). Nevertheless, the calculated FPF 
was still indicative of the ability of the carrier to disperse both drugs efficiently. 
In both cases, the percentage of respirable particles was high, with a FPF 
ranging from 33.9 (1.2) % for BDP to 39.6 (4.9) % for SS. It was surprising to 
find that PEG was performing so well with the two drug models. One possible
184
explanation may be found in the surface energy properties of this material: its 
of 33.1 (0.2) mJ/m^ suggests lower van der Waals interactions compared to 
other materials such as lactose. The aerosol generation mechanism of the 
inhaler being different, it was also important to carry out a comparative study 
between the Clickhaler® and the Aerolizer®.
5.5.5. Comparative study between the Clickhaler® and the Aerolizer®
5.5.5.1. BDP deposition obtained using the Aerolizer®
All formulations previously tested with the reservoir device were reaerosolised 
using the capsule-based device following the method described in chapter 2. 
Results are presented in the following tables and figures.
Formulation________ Carrier________ ED (pg) RD (pg) FPF
1 Lactohale LH 100
2 Pharmatose 325M
3 A Pharmatose 325M
4 Aero Flo 65
5 A Aero Flo 65
6
7 A Aero Flo 65 + fines
8
A Pharmatose 325M+ 
fines
9
A Pharmatose 325M + 
fused fines 
A Aero Flo 65 + fused 
fines
814 220 27.1
(68) (14) (2.9)
831 178 21.6
(78) (14) (2.8)
773 178 23.1
(47) (23) (3.6)
916 292 31.9
(92) (46) (2.7)
870 175 19.9
(65) (52) (4.5)
1093 428 39.1
(261) (107) (0.6)
883 242 27.5
(16) (39) (4.7)
869 137 15.7
(52) (36) (0.4)
941 186 19.8
(38) (9) (1.1)
Table 5.5. Aerosolisation of BDP from different lactose carriersusing the 
Aerolizer® Vaiues are mean and (standard deviation).
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Figure 5.9. BDP deposition obtained from nine DPI formulations using two 
different inhaler types. Values are mean (n=3).
The importance of developing a BDP formulation in combination with the design 
of the device is illustrated by the data presented in Figure 5.9. The differences 
in deagglomeration efficiency for these two inhalers were highlighted by the 
different FPFs obtained from the same powder formulation, using the same 
inspiratory manoeuvre. The FPFs ranged from 15.7 to 39.1 % with the 
Aerolizer® device and from 7.3 to 40.6 % with the Clickhaler® device. As an 
example, with the Aerolizer® Lactohale LH 100 showed a larger FPF (27.1 (2.9) 
%) compared to the same formulation in the Clickhaler® (15.6 (0.8) % FPF). The 
regular-shaped lactose batches (Formulations 1 to 5) showed a high capsule 
retention, in that the powder emissions were quite low. This observation was in 
accordance with previously published work on the evaluation of five different 
batches of Lactohale using the Aerolizer® or the Easyhaler® (Steckel et al., 
2004b). Different adhesion tendencies of the lactose/BDP blend to the inner 
wall of the capsule may be responsible for the decreased emission. The FPF 
obtained with the different formulations containing lactose/PEG fines 
(Formulations 6 to 9) generally appeared to be less dependent on the device 
chosen. Overall, the FPFs obtained with the Aerolizer® appeared higher than 
with the reservoir device.
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5.5.5.2. SS deposition obtained using the Aerolizer*^
Formulation Carrier ED (pg) RD (pg) FPF (%)
1 Lactohale LH 100
2 Pharmatose 325M
3 A Pharmatose 325M
4 Aero Flo 65
5 A Aero Flo 65
6 A Pharmatose 325M+ fines
7 A Aero Flo 65 + fines
g A Pharmatose 325M +
fused fines
9 A Aero Flo 65 + fused fines
889 306 34.4
(25) (25) C2 5)
897 350 38.9
(126) (53) 03 8)
997 379 38.0
(33) (23) (1.3)
1019 431 42.3
(29) (16) (2.4)
911 279 30.6
(28) (13) 03 6)
1005 390 38.8
(57) (42) (2.3)
1130 452 39.9
(77) (40) (1.9)
1136 322 28.3
(158) (69) (3.4)
1111 309 27.8
(21) (14) 0D.9)
Table 5.6. In vitro SS deposition using the 
(standard deviation).
Aerolizer® Values are mean and
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Figure 5.10. SS deposition obtained from nine DPI formulations using two 
different inhaler types. Values are mean and n=3.
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Here the FPFs ranged from 27.8 to 42.3 % with the Aerolizer device and from 
24.9 to 45.8 % with the Clickhaler® device. Again, as a general trend, the 
capsule-based device showed better results than the reservoir one with respect 
to the SS FPF for the non-modified grades of lactose. This device was also 
more efficient in aerosolising SS (average ED of 1010 (98) pg) than BDP 
(average ED of 887 (92) pg). Those two values corresponded to 84 % and 74 % 
of the targeted dose respectively. Furthermore, the device retentions were 
noticeably lower in the Aerolizer® for the irregularly-shaped lactose 
(Formulations 6 to 9). The Clickhaler® gave marginally higher FPFs for PEG 
modified formulations than the Aerolizer®.
These results confirmed the hypothesis that a given formulation would perform 
differently, in terms of FPF, depending on the device chosen. A possible 
explanation for these differences may be linked to the variations in pressure 
drop across the inhalers. The flow rate being kept constant at 60 L/min and the 
devices having a different resistance to airflow, the pressure drop was likely to 
be different and hence resulted in a different fluidization process. This could 
have been assessed by modifying the flow rate so that the pressure drop across 
the device stayed constant (4 kPa).
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SECTION B: Applications of surface energy data to predicting DPI 
performances
IGC was found to be useful in highlighting small differences in surface energy 
for surfaces of different grades of lactose (chapter 3). Those differences, which 
should affect the performance of the BDP deposition, could not have been 
detected using any other physical technique employed in this thesis. In chapter 
4, measurements of surface energetics proved to be useful in the 
characterisation of the different lactose/PEG co-spray-dried systems. The 
surface modification of the air-jet sieved grades of lactose by fusing partially 
amorphous fines on the surface was also evaluated by this technique. All IGC 
data was compiled here to correlate with the DPI performances of all produced 
formulations.
5.5.6. Relationship between dispersive free energy and deposition
Formulation_____________Carrier______________ Ys (mJ/m )
31.81 A Pharmatose 325M
2 A Pharmatose 325M + fused fines
3 A Aero Flo 65 + fused fines
4 A Aero Flo 65 + fines
5 A Aero Flo 65
6 A Pharmatose 325M + fines
7 Pharmatose 325M
8 Lactohale LH 100
9 Aero Flo 65
(0.4)
34.4 
(1.2)
35.8 
(0.9)
36.6 
(1.0 )
37.4 
(0.5)
37.6 
(1.2 ) 
40.1 
(0.2)
42.5 
(0.8)
42.9
JMI
Table 5.7. Dispersive component of the surface energy of the different iactose 
based carriers. Values are mean and (standard deviation).
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Attempts to correlate the dispersive component of free energy and the FPF of 
SS and BDP determined using the Clickhaler® and the Aerolizer® are presented 
in Figures 5.11 to 5.14. The different are represented by the grey columns, 
whereas the FPFs are represented by the black points.
44
42
40
38
36
—)
S’
Q)
C0)
m 34
ë
o 32
^  30 f i .
4 5 6
Formulation
Î
Î
jS O
1 45
-  40
-  35
-  30
Ll_
25 CLLL
- 20 Q_Q
- 15 QÛ
-  10
5
0
Figure 5.11. Relationship between dispersive energy of the different carriers 
(grey columns) and BDP FPF (black points) using the Clickhaler®. Values are 
mean (n=3).
Formulation
Figure 5.12. Relationship between dispersive energy of the different carriers 
(grey columns)and BDP FPF (black points) using the Aerolizer®. Values are 
mean (n=3).
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No correlations between and BDP FPF could be found using the reservoir 
device (Figure 5.11). In Figure 5.12, the FPFs of Formulations 1 and 5 
(corresponding to the air-jet sieved grades of lactose) did not fit in with the 
increasing trends between ys^  and BDP FPF using the Aerolizer®. Two 
increasing tendencies could be separated: one consisting of the original lactose 
batches (Formulations 7, 8 and 9) and the other consisting of the modified 
systems containing the lactose/PEG fines (Formulations 2, 3, 4 and 6).
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Figure 5.13. Relationship between dispersive energy of the different carriers 
(grey columns) and SS FPF (black points) using the Clickhaler®. Values are 
mean (n=3).
As previously described in chapter 3, an apparent correlation was found 
between the dispersive component of free energy of the commercially available 
lactose batches (Formulation 7, 8 and 9) and the deposition profile of SS using 
the Clickhaler® (Figure 5.13). Similarly, for Formulations 1 to 6 (excluding 
Formulation 5), an increase in ys^  was linked to an increase in SS FPF. 
However, these local trends could not be extrapolated to the entire set of 
formulations. Regarding a possible relationship using the Aerolizer®, no clear 
trend was detected, although most of the formulations with a low yg^  appeared 
to exhibit a lower FPF than those with a higher dispersive component value. 
This may be attributed to the reduced spread of FPFs using this particular 
device.
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Formulation
Figure 5.14. Relationship between dispersive energy of the different carriers 
(grey columns) and SS FPF (black points) using the Aerolizer®. Values are 
mean (n=3).
As a general conclusion, no obvious trends were established for BDP using the 
Clickhaler® and for SS using the Aerolizer® However, both for BDP using the 
Aerolizer® and for SS using the Clickhaler® trends were established each time 
for the same two groups of formulations. There was an increase in FPF with 
increasing for the marketed grades (Formulations 7, 8 and 9) and for the 
formulations containing the lactose/PEG systems (Formulations 2, 3, 4 and 6). 
No correlation including the air-jet sieved grades could be identified. As 
extensively described in chapter 2, ys^  and specific interaction parameters were 
used to quantify the properties of a material surface. The ys^  results were 
therefore not indicative of the true adhesion of the drug to the carrier. Moreover, 
attempts to correlate the dispersive energies of the carriers with FPF data did 
not take in consideration the intrinsic properties of the drugs.
5.5.7. Surface energy interaction theory
Due to difficulties in determining the acid-base contributions with the different 
methods described in chapter 2, a model developed by Cline and Dalby was 
instead evaluated. In their recent study (Cline and Dalby, 2002), the authors 
found a promising and convincing relationship between FPF and a parameter 
called surface energy interaction (SEI), which takes into account both the
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dispersive component of surface energy and the acid-base properties of the 
different materials. Chloroform and tetrahydrofuran were respectively chosen as 
an acidic and a basic probe, in order to determine the Lewis acidity (Ka) and 
basicity (K d). In this current study, tetrahydrofuran was replaced by ethyl 
acetate, which was not corrosive to the seals. The so-called SEI was obtained 
through harmonisation of the units of dispersive energy and the specific polar 
interactions. To do so, the specific interaction of each probe was converted to 
mJ/m^ through Avogadro’s number (molecule/mol) and the cross-sectional area 
of the probe (a. A/molecule). This allowed the SEI to be calculated in the unit 
mJ/m^ throughout.
SEI = 2 V / 1 + / 2  + [Equation 5,2]
Another approach also described by Cline et al. was to calculate SEI in mJ/g. 
The specific surface areas (SSA) of the powder were determined in this study 
by IGC using the method described by Schultz et al. (Schultz et al., 1987).
R T \n V , = 2 N a ^ | r J r /  + R T \ n [Equation 5.3]
Where R is the gas constant; T is the absolute temperature; Vn is the net 
retention volume; Po is the partial pressure of the solute; ;%is the bidimensional 
spreading pressure of the adsorbed film to a reference gas phase state; a is the 
surface area of the probe; S is the specific area of the sample; g is the specific 
weight of the sample; and and / l are the dispersive components of the 
surface tension of the solid and liquid probe respectively.
The calculation of SSA using IGC measurements nevertheless should be 
approached with caution since several problems may arise. The determination 
of the surface area of the different powders is based on the intercept term, 
obtained by linear extrapolation down to the y-axis over the alkane line (decane 
to hexane), as illustrated in Figure 2.16. This intercept is going to be affected by 
any change in the slope of the plot and therefore the calculated surface area 
might not be representative of the true surface area. Moreover, this approach 
assumes linearity of the relationship in the extrapolated region (i.e. Co to C 5) 
which may not be true (Chow et al., 2004).
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Prior to recalculating the different parameters (ys^ , K a  and K d ) in mJ/g, it was 
decided to compare the calculated surface IGC data to the one obtained from 
the BET nitrogen adsorption technique. Results are presented in Table 5.8.
Carrier Material SSA determined by BET (m^ /g)
SSA determined 
by IGC (m^ /g)
6.001 3.84
(0.011) (0.174)
4.656 3.73
(0.212) (0.293)
0.133 0.127
(0.001) (0.011)
0.186 0.498
(0.027) (0.122)
0.194 0.267
(0.008) (0.017)
0.218 0.254
(0.009) (0.011)
0.272 0.208
(0.001) (0.013)
0.290 0.359
(0) (0.017)
0.291 0.226
(0.001) (0.011)
0.333 0.723
(0.012) (0.077)
0.337 0.389
(0.011) (0.045)
SS 
BDP 
Lactohale LH 100 
A Aero Flo 65 
A Pharmatose 325M 
Pharmatose 325M
A Aero Flo 65 + fines
A Pharmatose 325M + 
fines
Aero Flo 65
A Pharmatose 325M + 
fused fines 
A Aero Flo 65 + fused 
fines
Table 5.8. Specific surface area of different materials determined by IGC and 
BET nitrogen adsorption. Vaiues are mean (n-2).
There was a large disagreement between the data sets obtained from the two 
methods. More essentially, there were no apparent parallel trends in the surface 
areas for the different materials. Specific surface area determination by IGC 
showed similar values for both drugs (3.84 (0.174) m^/g and 3.73 (0.293) m%  
for SS and BDP respectively), whereas differences in SSA were obvious when 
using the BET nitrogen adsorption technique (6.001 (0.011) m^/g and 4.656 
(0.212) m^/g for SS and BDP respectively). This discrepancy was also pointed 
out by Chow et al. who concluded in the unsuitability of IGC for specific surface 
area determination. All calculations involving the SSA were therefore based on 
the data obtained from the BET nitrogen adsorption technique and the IGC 
calculations were disregarded.
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Before calculating the SEI, it was decided to assess the relationship between 
the FPF and the SSA of the carriers, since preliminary work based on a limited 
amount of points (detailed in chapter 3) found a trend between BDP deposition 
and the latter parameter. Those results were dissimilar to the findings of 
Kawashima et al. (Kawashima et al., 1998b) who came to the conclusion that 
carriers with a larger surface area separated fewer drug particles (in this case 
pranlukast hydrate) from their surface under shear force in the air stream. 
Flowever, Cline and Dalby (Cline and Dalby, 2002) did conclude in an increased 
FPF with an increased SSA of the carrier. This observation could at first be 
difficult to understand, since a higher surface area may allow more contacts and 
interactions between the drug and carrier surfaces, which would lead to 
decreased DPI performances. The authors concluded in the need for a certain 
minimum interaction level between the drug particle and the carrier, especially 
during the mixing and aerosolisation process. This was stated to be particularly 
important for highly cohesive drugs, which have a general tendency to 
agglomerate. Figures 5.15 to 5.18 plotted the SSA of the different carriers 
against FPF of both drug models using the different devices. The different SSAs 
are represented by the grey columns, whereas the FPFs are represented by the 
black points.
CO 0.15
Carrier
Figure 5.15. FPF of BDF (black points) obtained with the Clickhaler® vs. SSA 
(m^/g) of carrier (grey columns). Values are mean.
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Figure 5.16. FPF of BDP (black points) obtained with the Aeroiizer® vs. SSA 
(m^/g) of carrier (grey columns). Vaiues are mean.
Assessment of the relationship between specific surface area and BDP FPF 
revealed a certain correlation between the two factors. An increase in the SSA 
of the carrier resulted in an apparent increase in BDP FPF confirming the 
original observation established in chapter 3. This was particularly true when 
the Clickhaler® was used as the device (Figure 5.15). However, this SSA 
relationship would have predicted higher FPFs for the “fused” systems. This 
observation was not supported by the deposition data and the useful insight 
given by this parameter should therefore be treated with caution.
0.4 T 
0.35 
0.3 
S  0.25 +
i  0.15 
0.1
0.05 + 
0
4 5 6
Carrier
50 
45 
40 
35
30 ^  
25 ^  
+ 20 & 
15 
+ 10 
5 
0
Figure 5.17. FPF of SS (black points) obtained with the Clickhaler® vs. SSA 
(m^/g) of carrier (grey columns). Values are mean.
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Figure 5.18. FPF of SS (black points) obtained with the Aerolizer® vs. SSA 
(m^/g) of carrier (grey columns). Vaiues are mean.
Overall, links between SSA and the hydrophilic drug model deposition were not 
very clear (Figure 5.18 and 5.19). This parameter did not therefore appear to be 
able to predict reliably the deposition of this drug.
5.5.7.1. Surface energy interaction (mJ/m^)
5.5.7.1.1. SEI between the carrier and BDP
The data presented in Table 5.9 summarises in vitro BDP deposition patterns 
obtained with the different carriers using two different devices and the 
calculated SEI in mJ/m^, in an attempt to assess a possible correlation between 
the two factors.
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A Pharmatose 325M + 
fused fines 
A Pharmatose 325M + 
fines
A Aero Flo 65 + fused 
fines
110.6 31.6 27.3
(0.3) (5.8) (4.7)
111.8 7.3 19.9
(2.9) (1.6) (4.4)
112.5 18.4 21.6
(1.7) (2.7) (2.8)
112.7 10.9 23.1
(8.3) (1.0) (3.6)
117.9 20.2 15.7
(2.1) (4.3) (0.4)
122.8 30.9 39.1
(13) (3.4) (0.6)
123.4 12.8 19.8
(1.4) (2.8) (1.1)
148.6 15.6 27.1
(1.1) (0.8) (2.9)
157.2 40.6 31.9
(0.8) (3.5) (2.6)
Formulation Carrier A^oNzeV
1 A Aero Flo 65 + fines
2 A Aero Flo 65
3 Pharmatose 325M
4 A Pharmatose
5
6
7
8 Lactohale LH 100
9 Aero Flo 65
Table 5.9. SEI (mJ/m^) between BDP and the different carriers and FPF 
obtained by using the Clickhaler® and the Aerolizer®, Values are mean and 
(standard deviation).
The SEIs between the hydrophobic drug model and the different carriers varied 
from 110.6 (0.3) mJ/m^ to 157.2 (0.8) mJ/m^. The highest value was found to 
correspond to the interaction between the Aero Flo 65 and BDP (Formulation 
9). Interestingly, this carrier was found to produce the highest FPF with the 
reservoir device. This supports the idea that the stronger the adhesion, the 
higher the FPF produced. The information contained in the above table is 
represented as grey columns for SEI (mJ/m^) and black points for the drug FPF 
in Figures 5.19 and 5.20. Based on those plots, no clear increasing trend 
between SEI and FPF was observed, irrespective of the device employed. The 
SEI theory in mJ/m^ did not appear efficient in predicting the hydrophobic drug 
model deposition. Other factors such as electrostatic forces, particle shape and 
relative humidity of the environment would be expected to play an important role 
in the observed in vitro deposition pattern.
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Form ulation
Figure 5.19. SEI (mJ/m^) of BDP with different lactose based carriers (grey 
columns) as a function of BDP FPF (black points) using the Clickhaler®, Values 
are mean (n=3)
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Figure 5.20. SEI (mJ/m^) of BDP with different lactose based carriers (grey 
columns) as a function of BDP FPF (black points) using the Aerolizer®.
5.5.7.1.2. SEI between the carrier and 88
Analogous to BDP, the existence of a possible relationship between 8EI 
(mJ/m^) and FPF investigated for with the hydrophilic drug model. The data 
presented in Table 5.10 is represented in the corresponding Figures 5.21 and 
5.22.
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Formulation Carrier SEI(mJ/m^)
FPF % 
Clickhaler®
FPF % 
Aerolizer®
1 A Aero Flo 65 + fines 110.2(0.3)
111.4
42.4
(1.7)
31.7
39.9
(1.9)
29.12 A Aero Flo 65 (2.9) (1.2) (0.6)
3 Pharmatose 325M 112.1(1.7)
24.9
(3.2)
38.9
(0.7)
4 A Pharmatose 325M 113.4(9.0)
27.2
(2.8)
38.0
(1.3)
c A Pharmatose 325M + 118.8 34.9 28.30 fused fines (2.1) (0.9) (3.4)
c A Pharmatose 325M + 123.7 45.8 38.7D fines (14.0) (0.9) (2.3)
7 A Aero Flo 65 + fused 124.6 32.8 27.8f fines (1.4) (0.6) (0.9)
8 Lactohale LH 100 151.3(1.2)
28.1
(0.2)
34.4
(2.4)
9 Aero Flo 65 160.7(0.8)
31.2
(0.9)
42.3
(2.4)
Table 5.10. SEI (mJ/m^) between S3 and the different carriers and FPF 
obtained by using the Ciickhaier® and the Aeroiizer®. Values are mean and 
(standard deviation).
The SEI values for S3 were similar to those obtained for BDP. This can be 
explained by the similar surface energy properties exhibited by the two model 
drugs when the calculations were done in mJ/m^ (Table 5.11). Although the SEI 
parameters for the different interactions were very similar between SS and 
BDP, the depositions remain profoundly different. As an example, while the SEI 
between an air-jet sieved Aero Flo 65 mixed with lactose/PEG fines and BDP 
(Formulation 1 in Table 5.9) was identical to the SEI between the same carrier 
and SS (Formulation 1 in Table 5.10) with values of 110.2 (0.3) mJ/m^ and 
110.6 (0.3) mJ/m^, the corresponding FPFs were markedly less for BDP than SS 
whichever device was employed. This model did therefore not give a direct 
explanation for the differences seen between the two drug models.
Material Kd Ka Kd
________ (mJ/m ) (mJ/m ) (mJ/m ) (mJ/g) (mJ/g) (mJ/g)
SS 
BDP
Table 5.11. IGC parameters for micronised S3 and BDP. Values are mean 
and (standard deviation).
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50.0 51.8 3.8 300 314 23.8
(3.9) (0.1) (0.1) (24) (3.4) (1.3)
53.1 ** 42.6 3.1 246.8 198 14.5
.... (3) (0.3) (0.1) (15) (1.5) (0.3)
** The results obtained from IGC of BDP were in accordance with the data 
obtained by Columbano (Columbano, 2000) who also studied this 
corticosteroid.
Furthermore, the data plotted in Figures 5.21 and 5.22 also indicated a lack of 
positive trend between the surface energy and the deposition. Therefore, this 
SEI concept required further evaluation, since differences between the drug 
models were more obvious in using mJ/g as a unit, because of differences in 
88 As.
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Figure 5.21. SEI (mJ/m^) of S3 with different lactose based carriers (grey 
columns) as a function of SS FPF (black points) using the Clickhaler®, Values 
are mean (n=3)
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Figure 5.22. SEI (mJ/m^) of BDP with different lactose based carriers (grey 
columns) as a function of BDP FPF (black points) using the Aerolizer®, Values 
are mean (n=3)
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5.5.7.2. Surface energy interaction (mJ/g)
5.5.7.2.1. SEI between the carrier and BDP
The different carriers listed in Table 5.12 are represented by formulation 
numbers, which correspond to those in Figures 5.23 and 5.24. Those figures 
display the relationships between SEI in mJ/g and FPF of BDP determined 
using two different devices. An increase in SEI (mJ/g) was accompanied by an 
overall increase in BDP FPF for both devices. However, for the last two carriers 
(i.e Formulations 8 and 9 corresponding to the fused systems) this trend was 
not confirmed with high SEIs and low FPFs. The high SEI of the fused system 
may be attributed to their greater SSA. Interestingly, those systems also 
appeared to minimise the relationship between the FPF and the SSA as shown 
in Figure 5.15. As a general trend, it appeared that a certain minimum energy 
interaction between the carrier and the BDP particle was needed to pull the 
drug apart during the blending and the aerosolisation process.
Formulation Carrier SEI FPF % FPF %(mJ/g) Clickhaler® Aerolizer*
105.2 7.3 19.9
(2.8) (1.6) (4.4)
109.5 10.9 23.1
(7.9) (1.0) (3.6)
114.6 18.4 21.6
(1.7) (2.7) (2.8)
117.8 15.6 27.1
(0.9) (0.8) (2.9)
125.8 31.6 27.3
(0.3) (5.8) (4.7)
149.3 30.9 39.1
(6.7) (3.4) (0.6)
184.4 40.6 31.9
(0.9) (3.5) (2.6)
186.7 20.2 15.7
(3.4) (4.3) (0.4)
189.2 12.8 19.8
(2.0) (2.8) (1.1)
1 A Aero Flo 65
2 A Pharmatose
3 Pharmatose 325M
4 Lactohale LH 100
5 A Aero Flo 65 + fines
6
7 Aero Flo 65
8
A Pharmatose 325M + 
fines
9
A Pharmatose 325M + 
fused fines 
A Aero Flo 65 + fused 
fines
Table 5.12. SEI (mJ/g) between BDP and the different carriers and FPF 
obtained by using the Clickhaler® and the Aerolizer®. Vaiues are mean and 
(standard deviation).
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Figure 5.23. SEI (mJ/g) of BDP with different lactose based carriers (grey 
columns) as a function of BDP FPF (black points) using the Clickhaler^, Values 
are mean (n=3)
190
45
170 40
35
150
- 30
130
25
110 20
1590
10
70 -
50
F orm ulation
Figure 5.24. SEI (mJ/g) of BDP with different lactose based carriers (grey 
columns) as a function of BDP FPF (black points) using the Aerolizer^, Values 
are mean (n=3)
5.5.7.2.2. SEI between the carrier and SS
No direct relationship between SEI in mJ/g and FPF of SS could be identified 
(Figures 5.25 and 5.26). The theory developed by Cline and Dalby (Cline and 
Dalby, 2002), indicating that the greater the SEI between the drug and the 
carrier, the greater the drug FPF evolved, did not apply to this data set. For 
example, as seen in Table 5.13, Formulation 5 exhibited a SEI of 140.7 (0.3)
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mJ/g with SS, whereas this value increased to 212 (1) mJ/g for Formulation 8. 
The model would have had predicted a higher FPF for the latter formulation. 
Unfortunately the earlier deposition study did not support this prediction, with 
FPF dropping from 42.4 % to 31.2 % using the Clickhaler® as the chosen 
device.
Formulation Carrier SEI FPF % FPF %(mJ/g) Clickhaler® Aerolizer*
117.7 31.7 29.1
(2.9) (1.2) (0.6)
123.7 27.2 38.0
(9.8) (2.8) (1.3)
128.2 34.9 38.9
(2 0) (0.9) (0.7)
139.3 28.1 34.4
(1.0) (0.2) (2.4)
140.7 42.4 39.9
(0.3) (1.7) (1.9)
169.5 45.8 38.7
(8.0) (0.9) (2.3)
209.9 34.9 28.3
(2.9) (0.9) (3.4)
212.0 31.2 42.3
(1.0) (0.9) (2.4)
218.6 32.8 27.8
(2.3) (0.6) (0.9)
A Aero Flo 65 
A Pharmatose 
Pharmatose 325M 
Lactohale LH 100
A Aero Flo 65 + fines
A Pharmatose 325M + 
fines
A Pharmatose 325M + 
fused fines
Aero Flo 65
A Aero Flo 65 + fused 
fines
Table 5.13. SEI (mJ/g) between S3 and the different carriers and FPF obtained 
by using the Clickhaler® and the Aerolizer®, Values are mean and (standard 
deviation).
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Figure 5.25. SEI (mJ/g) of SS with different lactose based carriers (grey 
columns) as a function of SS FPF (black points) using the Clickhaler®. Values 
are mean (n=3)
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Figure 5.26. SEI (mJ/g) of S3 with different lactose based carriers (grey 
columns) as a function of S3 FPF (black points) using the Aerolizer®, Values are 
mean (n=3)
5.5.8. Spreading coefficient approach
Differences in drug deposition could not directly be related to the SEI either in 
mJ/m^ or in mJ/g. A last attempt to correlate surface energy data to the TSI 
deposition pattern of the two drug models was done with the calculation of 
spreading coefficients. Ahfat et al. (Ahfat et al., 1997) in an attempt to predict 
the mixing performance of binary and ternary systems, modelled the solid-solid 
interaction by calculating the spreading coefficients (1) of two solid phases. In 
this current study, the spreading coefficients of the drugs over the carriers (Igc 
or Àbc) were calculated by taking the difference between the work of adhesion 
between the two components and the work of cohesion of the drug. A positive 
result would show a tendency for the drug to spread over the carrier. The 
spreading coefficient of the carrier over the drug (les or Icb) could be similarly 
determined and would give an indication of the tendency of the carrier to spread 
over the drug. The spreading coefficients (in mJ/m^) of the active particles over 
the different lactose-based carriers and that of the different carriers over the 
drugs are listed in Table 5.14.
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A Aero Flo 65+ fine 
A Aero Flo 65 
Pharmatose 325M 
A Pharmatose 325M 
A Pharmatose 325M + fused fines 
A Pharmatose 325M + fines 
A Aero Flo 65 + fused fines 
Lactohale LH 100 
Aero Flo 65
(mJ/m^)
X<;s
(mJ/m^)
Xtc
(mJ/m^)
Xcb
(mJ/m^)
-48.4 35.2 -43.8 35.6
(2.1) (0.8) (4.6) (0.7)
-47.2 34.3 -42.6 34.7
(4.2) (5.7) (5.5) (5.7)
-46.5 34.7 -41.9 35.1
(3.0) C3.6) (4.9) (3.4)
-45.2 33.1 -41.7 32.4
(13.4) (19.9) (13.0) (19.4)
-39.8 -30.5 -36.5 -31.4
(3.3) (7.0) (5.0) (7.0)
-34.9 18.3 -31.6 17.4
(25.8) (25.7) (24.4) (22.5)
-34.0 -24.1 -31.0 -25.3
(2.6) (5.3) (4.7) (6.9)
-7.3 4.3 -5.8 1.6
(2.6) (2.8) (4.9) (2.7)
2.1 -5.9 2.8 -9.4
(2.2) 02.2) (4.8) (2.2)
Table 5.14. Spreading coefficients (mJ/m^) of SS over lactose-based carriers 
(Àsc), BDP over carriers (Àbc), carriers over SS (Acs) and carriers over BDP (Acb). 
Values are mean and (standard deviation).
Since the work of cohesion was very similar for both drugs (154.4 (3.7) mJ/m^ 
for BDP and 158.6 (1.4) mJ/m^for 88), the corresponding calculated spreading 
coefficients were of identical extent. This was unexpected since it was thought 
that BDP would be more cohesive than 88 (based on 8EM pictures). Moreover, 
in a recent work by Begat et al. (Begat et a/., 2004), the cohesive-adhesive 
balances in DPI formulations have been quantified by atomic force microscopy 
(AFM). The measurements suggested that the BUD-BUD interactions were 
3.84-fold greater that the BUD-lactose interactions, while lactose-lactose 
interactions were 2.36-fold greater that the BUD-lactose interactions. This 
suggested very strong BUD cohesive bonds that would result in the formulation 
exhibiting poor blend homogeneity and poor deposition. Regarding 88, the data 
indicated that the interactions between 88 and lactose were 16.88 times and 
1.22 times greater than the cohesive 88 and lactose interactions. The IGC 
technique, utilized to measure the characteristics of the interparticulate forces, 
did not enable direct correlation with the in vitro observations.
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The drugs were not easily spread over any carrier except the Aero Flo 65. In 
this case, the positive values indicated a favourable spreading. Interestingly, the 
deposition data for BDP showed a good deposition with this carrier, indicating 
that increased spreading led to a more efficient dispersion. However, the 
scanning electron micrograph (Figure 5.27) of a binary system consisting of 
BDP and Aero Flo 65 showed a different picture, with BDP particles appearing 
as drug agglomerates and binding with the carrier surface on a limited amount 
of contact points. Therefore, the spreading coefficient data did not seem to 
support the SEM observation. The spreading coefficients of the carriers over the 
drugs are also listed in Table 5.14. Except for the Aero Flo 65 and the fused 
systems, the spreading coefficients were positive, indicative of good spreading 
tendencies. This was expected to occur, since the work of cohesion for these 
systems was much less than that for the highly energetic micronised particles. 
The spreading of the fused systems was found to be less favourable than the 
spreading of other carriers over either drug.
^c r.V  Spot M.iqn Dr I WÜ I--------------------- 1 10 pm
10 0 kV  3 0 1646x S I 10 6 Sp Bl)l> |?8/110?)  le t 1068
Figure 5.27. Scanning electron micrograph of Aero Flo 65 mixed with BDP.
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Figures 5.28 and 5.29 show the plots of the in vitro deposition patterns of the 
two drugs obtained with the two inhalers (Clickhaler® and Aerolizer®) versus the 
spreading coefficients of the active models over the different carriers.
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Figure 5.28. FPF of SS using the clickhaler (A) or the Aerolizer (B) as a 
function of the spreading coefficients of SS over carriers (mJ/m^), Values are 
mean (n=3)
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Figure 5.29. FPF of BDP using the clickhaler (A) or the Aerolizer (B) as a 
function of the spreading coefficients of BDP over carriers (mJ/m^). Values are 
mean (n=3)
The major differences observed in the deposition pattern of the different drugs 
could not be directly explained by the spreading coefficients of the drugs over 
the different lactose-based carriers calculated in mJ/m^.
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Figures 5.30 and 5.31 show the FPFs obtained using the two inhalers versus 
the spreading coefficients of the carriers over the drugs. No overall direct 
correlation was found between both drugs and the corresponding spreading 
coefficients calculated in mJ/m^, whichever device was used to perform the in 
vitro testing.
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Figure 5.30. FPF of SS using the clickhaler (A) or the Aerolizer (B) as a 
function of the spreading coefficients of carriers over SS (mJ/m^). Values are 
mean (n=3)
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Figure 5.31. FPF of BDP using the clickhaler (A) or the Aerolizer (B) as a 
function of the spreading coefficients of BDP over carriers (mJ/m^). Values are 
mean (n=3)
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To further assess the usefulness of this approach to predict DPI performances, 
these coefficients were calculated in mJ/g by using the surface area of the 
materials. This offered a greater differentiation between the drugs, since the 
recalculated work of cohesion now varied from 718 (17.0) mJ/g for BDP to 949 
(11.1) mJ/g for SS. Those values (Table 5.15) were unexpected since BDP 
appeared to be more cohesive than SS, leading to higher agglomeration 
tendency (confirmed by SEMs). As the deposition in stage 2 of the twin 
impinger depends, to a certain extent, on the ability of the drug to deaggregate 
when liberated into the air stream from the device, BDP deposition is usually 
lower than SS deposition.
Spreading coefficients of both drugs over the different carriers were all negative, 
indicating a difficult dispersion. The spreading coefficients of BDP were less 
negative than SS. This may suggest a higher adherence to the surface for the 
hydrophobic model compared to the hydrophilic active. However, this 
observation offers little explanation for the differences seen between the carrier 
efficiencies in liberating the hydrophobic drug.
'Àsc
(mJ/g)
Acs
(mJ/g)
Abe
(mJ/g)
Acb
(mJ/g)
-831.3 103.4 -612.8 90.9
A Aero Flo 65 (14.4) (7.3) (21.6) (7.1)
- 825.3 113.0 - 608.5 98.8
A Pharmatose 325M (20.8) (25.0) (20.8) (15.1)
- 820.8 111.3 - 603.4 97.7
Pharmatose 325M (12.3) (4.8) (19.7) (4.3)
- 809.7 119.8 - 600.2 98.3
Lactohale LH 100 (11.7) (2.5) (19.5) (2.3)
- 808.3 120.3 - 592.2 105.4
A Aero Flo 65 + fines (2.8) (0.6) (18.6) (0.6)
- 779.5 146.5 - 568.7 126.2
A Pharmatose 325M + fines (29.0) (15.3) (27.1) (13)
- 737.0 162.3 - 533.6 133.9
A Pharmatose 325M + fused fines (13.8) (2.8) (19.6) (1.8)
-739.1 161.4 -531.3 137.0
Aero Flo 65 (12.3) (5.3) (21.8) (5.4)
- 730.1 168.8 - 528.8 139.1
A Aero Flo 65 + fused fines (13.1) (4.7) (21.4) (3.4)
Table 5.15. Spreading coefficients (mJ/g) of S3 over lactose-based carriers 
(Âsc), BDP over carriers (Àbc), carriers over S3 (Acs) and carriers over BDP (Acb)- 
Values are mean and (standard deviation).
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Assesment of possible relationship between the different factors are presented 
in Figures 5.32 to 5.35. Firstly, as done for the calculations in mJ/m^, the 
aerosol performances were plotted against the spreading coefficients of the 
drugs over the carriers (in mJ/g) (Figures 5.32 and 5.33).
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Figure 5.32. FPF of SS using the clickhaler (A) or the Aerolizer (B) as a 
function of the spreading coefficients of SS over carriers (mJ/g)_ Values are 
mean (n=3)
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Figure 5.33. FPF of BDP using the clickhaler (A) or the Aerolizer (B) as a 
function of the spreading coefficients of BDP over carriers (mJ/g), Values are 
mean (n=3)
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Figure 5.35. FPF of BDP using the clickhaler (A) or the Aerolizer (B) as a 
function of the spreading coefficients of BDP over carriers (mJ/g). Values are 
mean (n=3)
As an example, the Aero Flo 65 and a carrier composed of fused lactose/PEG 
fines on an Aero Flo 65 surface should, based on the calculated spreading 
coefficients, deliver BDP with the same efficiency. Here again, this was not 
supported by the aerosol deposition studies.
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5.6. Conclusions
A partially amorphous lactose/PEG 4000 product was successfully generated 
by spray drying followed by spontaneous recrystallisation onto air-jet sieved 
lactose surfaces. The aims of this chapter were three-fold and the major 
findings are summarised below associated with the original objectives of the 
work carried out.
Investigation of the fusion of partiallv amorphous fines onto the surface of air-iet 
sieved coarse lactose and assessment of the impact on the DPI performance:
Partially amorphous lactose/PEG 4000 particles (containing 10 % PEG) were 
mixed with air-jet sieved grades of lactose and left to recrystallise for 24 hours. 
The final concentration of fines was equal to 10 % (w/w). The resulting 
crystalline products were analysed by IGC and it was found that the surface 
energy properties of the modified carriers were equivalent with regards to both 
the dispersive component of the free energy and the acid-base properties. 
These physical changes were seen to modify the surface interaction with the 
two asthma drugs and their subsequent deposition. It was shown that this new 
fused system was efficient in delivering SS respirable drug particles but was 
less appropriate for BDP (Table 5.3).
Examination of PEG 4000 [45-901 um as a coarse carrier for DPI formulations:
PEG 4000 was found to be a useful model for investigation, although this 
polymer has not been approved for delivery to the lungs. It was found to be a 
good carrier for both SS and BDP when blended with 4 % drug using the 
Aerolizer® as a model device. To assess whether this deposition was not solely 
due to the type of device chosen, a comparative study between the reservoir 
device and the capsule based one was performed. The preponderant role 
played by the device was illustrated by differences in performances using the 
same formulation using the Aerolizer® or the Clickhaler® (Figures 5.9 and 5.10). 
Once again it is important to stress the importance of developing a formulation 
in combination with the design of the device.
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Examination of the IGC application in predicting DPI performances:
In addition to early findings observed on a limited amount of points (n=3) and 
detailed in chapter 3, a recent work (Cline and Dalby, 2002) suggested a strong 
relationship between surface energy data and in vitro performance. The 
separate components of surface energy were converted from mJ/m^ to mJ/g by 
taking in consideration the specific surface area of the material. The 
determination of SSA by IGC did not appear to be accurate, confirming the 
findings of Chow et al. (Chow et al., 2004). Using the BET nitrogen adsorption 
technique, the SEIs in mJ/g were calculated and correlations with the 
hydrophobic drug deposition were promising. However, little insight for the SS 
deposition was possible with the calculation of this parameter, confirming the 
“fragility” of this theory to generally explain the deposition data of different drugs 
from different carriers.
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Chapter
6
Surface modification of the 
drug substance
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6.1. Summary
Dry powder formulations generally consist of mixtures of micronised drugs with 
larger carrier particles. To meet the particle size requirements for the respiratory 
drug delivery, the active ingredient is subjected to a micronisation process, 
usually carried out by air-jet milling. From the data presented in the previous 
chapters, it is clear that the deposition patterns are drug related. It seemed 
therefore appropriate to consider methods to make different drug particles with 
same aerosol efficiencies. In this study, spray drying was investigated as a 
potential method for the production of crystalline drug particles. SS was co­
spray-dried with various proportions of PEG (300 or 4000) and lactose from a 
solution using the Büchi 191. Characterisation of their solid-state properties 
revealed the amorphous nature of the produced particles. Adding different 
proportions of lactose monohydrate to the solution to be spray dried did not 
affect the physical properties of the resulting particles. When mixed with a 
lactose-based carrier and tested in vitro, the deposition properties were poor 
compared to a formulation based on a crystalline SS. Further experiments were 
undertaken to co-spray dry drug substances (SS and BDP) and PEG 4000 from 
suspensions using both the Büchi 191 and the Niro SD MICRO™. Here again, 
depositions were lower than those observed with original drug models.
6.2. Introduction
The potential of spray drying to produce lactose/PEG fines for dry powder 
inhalers has been described in Chapters 4 and 5. Using an adequate process, 
spray drying may result in the direct preparation of crystalline products. The aim 
of the work described in the present chapter was to investigate this process with 
the active compounds in order to modify the physico-chemical characteristics of 
the drugs. Differences have been described about the aerosol performances of 
lactose-based formulations that were attributed to both the carrier and drug. The 
properties of the active have a significant impact on its deposition profile. Based 
on this previous work, BDP appeared to be far more sensitive to its environment 
than SS. This is probably due to the cohesive nature of the hydrophobic drug in 
a “hydrophilic environment, i.e. lactose”.
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The objectives of this chapter were two-fold: (1) to generate crystalline 
drug/PEG systems, with the required specifications for lung delivery, and (2) to 
evaluate these modified actives in terms of aerosolisation behaviour.
The surface modification of hydrophobic cohesive drug particles has been 
investigated by Kawashima et al. (Kawashima et al., 1998a) who modified 
pranlukast hydrate (PH) surface properties with the incorporation of hydrophilic 
colloidal silica. Three different methods of silica incorporation were conducted: 
(1) mechanically sheared mixing, (2) freeze drying and (3) spray drying of 
aqueous dispersions of the drug and colloidal silica. The in vitro properties of 
the surface modified PH particles were evaluated using a Spinhaler® connected 
to a TSI. The spray drying method was found to improve the inhalation 
behaviour of the drug at high concentrations of silica (10 % (w/w)), with an FPF 
of 43.7 (3) % compared to 13.4 (1.7) % for the original PH formulation. The 
modification of the hydrophobic surface to a more hydrophilic one with silica 
particles was confirmed by a contact angle study. The contact angle of modified 
PH particles decreased in a linear fashion with increasing amount of the 
incorporated hydrophilic excipient, indicating that both components were mixed 
randomly on the surface. Figure 6.1 summarises this new particle design 
method.
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Figure 6.1. Schematic representation of the effect of PH modifications on the 
aerosol properties, reproduced from Kawashima et ai. (Kawashima et ai., 
1998a)
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Corrigan et al. also investigated the co-spray drying of drugs and different 
excipients (Corrigan et a!., 2003; Corrigan et a!., 2004). The authors spray-dried 
the thiazide diuretic drug bendrofiumethiazide (BFMT), in the presence of PEG 
4000 (10, 20 and 30 % (w/w) of polymer) to determine if amorphous BFMT/PEG 
systems with improved dissolution properties (compared to BFMT alone) could 
be formed. The co-spray-dried formulations were all amorphous, as determined 
by powder diffraction. However, the presence of the PEG polymer appeared to 
destabilise the amorphous BFMT at higher weight ratios causing faster 
recrystaliisation.
in another study, the same authors spray-dried SS and lactose and/or PEG. Co­
spray drying SS with two different PEGs (PEG 4000 and 20000) resulted in 
systems of varying crystal Unity, whereas SS/lactose systems were all 
amorphous. The systems containing 20 or 40 % PEG 4000 did show some 
peaks indicative of crystallinity but to a lower extent compared to physical 
mixes. The SS/PEG 4000 (20 % PEG) appeared to consist of fused aggregates 
of spheres (25-30 pm in diameter), whereas the SS/PEG 4000 (40 % PEG) 
consisted of agglomerates of approximately 70 pm in diameter. Regarding the 
SS/PEG 20000, only the systems with 40 % of polymer proved to be partially 
crystalline. All other systems were entirely amorphous.
Based on this work, it appeared justified to further examine the influence of the 
PEG on the physicochemical properties of the resulting co-spray-dried systems, 
with the final goal being the formation of stable crystalline drug-PEG particle to 
probe the interaction with a lactose-PEG carrier.
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6.3. Aims and objectives
As previously stated, the aims of this chapter were to investigate spray drying 
as a method for the production of modified drug particles for DPI formulation. 
Different SS/PEG systems were investigated as probes for a modified 
lactose/PEG carrier. The amount of polymer reaching the lungs is of concern 
and no direct clinical applications of these systems were considered at this 
stage of the research.
The objectives were:
• To spray dry the two drug models in the presence of PEG 4000, as 
solutions or suspensions using a Büchi 191 or a Niro SD MICRO™;
• To characterise the physico-chemical properties of the resulting products 
and to use them as probes for modified lactose-based carriers.
6.4. Material and methods
6.4.1. Production of modified drug models
• Spray drying from a solution
Microparticles of SS/PEG 4000 consisting of 1 ,5  and 10 % PEG 4000 by 
weight of total solid, were prepared by spray drying from solution in water using 
the Büchi 191. A 10% (w/v) solution was spray-dried under the experimental 
conditions (method Mi) described by Columbano e ta l (Columbano eta!., 2003) 
and presented in Table 6.1.
Parameters Settings (Mi)
Outlet temperature (®C) 145-150
Inlet temperature (®C) 75-80
Aspirator (%) 80
Pump (%) 15
Atomiser airflow rate (Normliter/h) 800
Table 6.1. Parameters used to spray dry SS/PEG at different ratios.
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The physico-chemical properties of the resulting products were characterised by 
SEM, X-ray diffraction, DVS and IGC as described in Chapter 2 under each 
section heading for each instrument.
Spray drying conditions were further varied with the Büchi 191 (Table 6.2). In all 
experiments involving different methods (M2 , M3 or M4 ), the feed solution 
employed was a 10 % (w/v) solution. Different PEG molecular weights were 
tested (300 and 4000 g moM). Regarding the SS/PEG 300 formulations, three 
polymer concentrations (5, 10, 20 % (w/w)) were prepared following the spray 
drying parameters corresponding to the methods Ms and M4 .
Parameters M2 M3 M4
Outlet temperature (®C) 125 180 100
Inlet temperature (®C) 77 89 65
Aspirator (%) 12 20 15
Pump (%) 60 50 100
Atomiser airflow rate (Normliter/h) 600 600 550
Table 6.2. Different spray drying parameters employed to generate SS/PEG 
particles.
Additionnaly, 8 8  was co-spray-dried with various proportions of lactose and 
PEGs. Two different sets of experiments were undertaken. In the first one, a 
solution comprising 1 % PEG 4000, 9 % lactose monohydrate and 90 % 8 8  
was spray dried following Mi and M 3 .
The effect of the addition of the sugar on the resulting particle characteristics 
was further studied using a low molecular weight PEG polymer (300 g moM) 
following M3 or Mi. The composition of the solution that was used was 9 % PEG 
300, 1 % lactose monohydrate and 90 % 8 8 . In all experiments involving 
lactose monohydrate, the amount of solids was 1 0  % w/v.
• 8 pray drying from a suspension
8 pray drying the hydrophilic drug as a suspension was achieved on the Niro 8D 
MICRO™ following the parameters previously described in Chapter 2, 8ection 
2.2.1.2.10. Twenty percent PEG 4000 (by weight of total solids) was dissolved 
in ethanol (200 ml total volume) (HPLC grade). 88 was suspended in the 
medium and sedimentation prevented by agitation using a magnetic stirrer. The 
material was spray-dried as a 1% (w/v) suspension.
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Regarding BDP suspension, the active particles were dispersed into an 
aqueous PEG 4000 solution following the same conditions described for the 
preparation of the SS solution. The resulting preparation was spray-dried using 
the Büchi 191 following the operating conditions described in Table 6.3.
Parameters Settings
Outlet temperature (®C) 145-150
Inlet temperature (°C) 85-90
Aspirator % 60
Pump % 15
Atomiser airflow rate (Normliter/h) 800
Table 6.3. Spray drying parameters employed to spray-dry BDP/PEG from an 
aqueous solution using the Büchi 191.
6.4.2. Evaluation of the aerosol properties
The modified drug particles were tested in vitro using the Clickhaler® coupled to 
a TSI as described in Chapter 2. The formulation tested consisted of the 
SS/PEG particles and a modified lactose carrier filled into the reservoir of the 
device. The lactose based carrier consisted of the airjet sieved Aero Flo 65 
mixed with 10 % crystalline lactose/PEG fines (containing 10 % (w/w) PEG 
4000) as described in Chapter 4. The final drug concentration was equal to 4 % 
(w/w) and the blending carried out using a Turbula mixer for 30 minutes at 42 
rpm.
6.5. Results and discussion
6.5.1. Spray drying from a solution
Described in the following subsection are the the physico-chemical properties of 
the different co-spray dried formulations using the Buchi 191 and SS as a drug 
substance.
6.5.1.1. Characterisation of the particles
The scanning electron micrographs of spray-dried SS/PEG 4000 (prepared by 
Mi) at different ratios are shown in Figure 6.2. All solutions investigated were 
successfully spray dried, resulting in a transformation in the physical
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appearance. Increasing the PEG proportion from 1 % (Figure 6.2 A) to 5 % 
(Figure 6.2 B) or even 10 % (Figure 6.2 C) did not seem to affect the 
morphology of the particles. All particles appeared to be spherical with a pitted 
surface and a diameter generally less than 5 pm, making them potentially good 
candidates for pulmonary delivery. This is consistent with prior work, where SS 
has been shown to produce microfine spherical particles in the respirable size 
range when spray dried on its own. (Chawla et al., 1994).
Figure 6.2. Influence of the PEG 4000 concentration (1 % w/w = Figure A, 5 
% w/w = Figure B, 10% w/w = Figure C) on the resulting particle morphologies.
The water sorption data (obtained by DVS) of the different co-spray-dried 
formulations and feed material (crystalline SS) are shown in Figures 6.3 and 6.4 
respectively. As previously described, the different relative humidities are 
illustrated by the blue line, whereas the mass changes of the sample are 
represented by the red line. As a non hygroscopic nor hydrate forming drug
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(Ward and Schultz, 1995), it was expected that SS would not absorb water to a 
large extent. Brodka-Pfeiffer et al. (Brodka-Pfeiffer et al., 2003) could not 
measure the water uptake of crystalline SS by this method. However, 
Columbano et al. (Columbano et al., 2002) reported a significant uptake of 
water when crystalline SS was exposed to 75 % RH. The small particle size 
(linked to an important surface area) was suggested as the reason for surface 
water adsorption.
To confirm these earlier observations by Columbano et al., the DVS 
experiments were repeated. Rapid water uptake (up to 0.23 % (w/w)) was 
observed when the sample was exposed to 80 % RH. The water was then 
desorbed very quickly when the RH was reduced to 0 % (Figure 6.3).
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Figure 6.3. Water sorption analysis of crystalline SS.
From the water sorption data of the SS/PEG 4000 systems (Figure 6.4), it was 
clear that all systems were amorphous. Particles containing 5 or 10 % (w/w) 
PEG equilibrated to similar maximum water contents of approximately 11.3 % 
(w/w) when exposed to 80 % RH. The maximum water uptake for the sample 
containing 1 % (w/w) PEG (orange line) was slightly higher with around 12 % 
mass increase. The release of water from the SS/PEG particles at 80 % RH 
was characterised by two different desorption rates: the release of water was 
faster in the first part than in the second part of the desorption curve. Moreover, 
the system containing 1 % PEG was more efficient in releasing the water
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compared to systems containing more PEG. The time for the onset of weight 
loss of the different SS/PEG systems was very similar at all ratios that were 
investigated.
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Figure 6.4. DVS mass plot of SS/PEG 4000 systems as a function of time and 
%RH.
When SS was spray-dried alone, a different DVS profile was observed (Figure
6.5, (Columbano et ai., 2002)). After exposure to 75 % RH, a rapid weight 
increase up to 13 % (w/w) was followed by a slow desorption process even 
when the RH was adjusted from 75 to 0 %. This indicated that the rate-limiting 
step was the diffusion of water through the solid and not the concentration 
difference between the particle surface and the vapour. After 65 hours at 75 % 
RH, the water content of the spray-dried SS was still 6 % (w/w). Some water 
could have been trapped between drug crystals explaining the water retention.
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Figure 6.5. Water vapour sorption of spray-dried SS at 25°C (Columbano et 
a!., 2 0 0 2 ).
Following from gravimétries studies, the surface energetics of the different spray 
dried formulations were evaluated (Table 6.4). The different co-spray-dried 
products were examined in terms of their dispersive surface energies (yg^ ) 
(Figure 6:6) and their acid-base properties (Figure 6.7), calculated using the 
cross-sectional method as described in Chapter 2.
Materials
Specific polar interaction (kJ/mol) Acid-basecharacteristics
Ts 2 
(mJ/m )
Acetone Chloroform Ethanol Ethylacetate Ka Kd Kd/Ka
88 7980(155)
1052
(58)
11506
(117)
10396
(112) 0.137 -0.011 -0.08
50
(3.9)
88/PEG 5140 1743 7960 6943 0.089 0.019 0.22 35.71 % (136) (40) (117) (117) (0.7)
88/PEG 5381 2054 7934 7109 0.089 0.038 0.43 34.75% (42) (64) (71) (48) (1.6)
88/PEG 5434 2121 7990 6788 0.085 0.050 0.60 32.810% (68) (173) (176) (241) (0.4)
PEG 9821 7898 13286 10353 0.120 0.206 1.71 33.14000 (259) (252) (368) (209) (0.2)
Table 6.4. Surface energy data of spray-dried SS/PEG systems from 
solutions and PEG 4000. Values are mean (standard deviation).
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Figure 6.6. Dispersive components of the crystalline SS, the different SS/PEG 
systems spray dried from a solution and PEG4000. Values are mean (n=3)
The surfaces of the spray-dried systems in the presence of PEG were less 
energetic than those of purely crystalline SS. Decreasing ys^  whith increasing 
the PEG proportion was consistent with the data presented in Chapter 4, where 
the 7 s^  of lactose/PEG fines ranged from 34.7 (0.7) mJ/m^ for a system 
containing 1% PEG to 38.4 (0.3) mJ/m^for a system containing 5 % PEG. Here 
again, the ys^  of the different co-spray-dried systems were closer to the ys^  of the 
PEG than the other component, indicating the presence of PEG at the surface 
of the particles (already seen in Chapter 4).
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Figure 6.7. Acid-base characteristics of the crystalline lactose, different 
lactose/PEG systems spray dried from a solution and PEG 4000.
The addition of PEG at different concentrations in the spray-dried SS solution 
also had a substantial effect on the K d/K a values. The increase in the K q/K a ratio 
was mainly due to an increase in Kq values as Ka stayed almost constant for the 
formulations tested. This effect was linked to an increase in the amount of PEG 
present in the feed solution. Increasing the PEG concentration, may lead to 
more PEG molecules migrating to the surface of the particle causing a “PEG 
like effect”. Those results were in accordance with earlier findings (Chapter 4) 
based on lactose/PEG co-spray-dried systems.
6 .5.1.2. Deposition studies
The aerosol performances of the PEG modified formulations (Table 6.5) were 
determined using the TSI coupled to a Clickhaler®. The deposition data 
obtained for the unmodified 8 8  (Formulation 1), used as a reference, was as 
reported in Chapter 4 (Formulation 3 in Table 4.6)
Formulation active used ED (pg) RD (pg) FPF (%)
1 8 8 691 (14) 292 (16) 42.4(1.7)
2 8 8 /PEG 1 % 723 (29) 146(16) 2 0 . 2  (2 .2 )
3 8 8 /PEG 5 % 1119(47) 214(12) 19.1 (0.6)
4 8 8 /PEG 10 % 1076 (54) 152 (23) 14.1 (1.7)
Table 6.5. Deposition of modified SS/PEG particles produced by spray drying 
from solutions. Values are mean (standard deviation).
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On analysing the RDs for these formulations, it was found that the aerosol 
properties of these systems were quite disappointing compared to the 
crystalline SS. As shown in Figure 6 .8 , the FPFs were indeed different in our 
study, with FPFs ranging from 42.4 (1.7) % for the formulation containing the 
micronised SS (Formulation 1) to 14.1 (1.7) % for the formulation containing the 
SS/PEG spray-dried active with 10 % PEG (Formulation 4). As a conclusion, 
data show a significant decrease in FPF for the PEG modified SS formulations, 
possibly due to their amorphous natures. Chawla et al. (Chawla et al., 1994). 
reported similar in vitro behaviour for spray-dried and micronised SS from the 
Spinhaler® (FPF of 7.63 (3.02) % and 10.36 (6.76) % for the spray-dried and 
micronised materials respectively). A second explanation may be found in the 
presence of PEG which may cause those unstable particles to adhere to each 
other, increasing the MMAD values and therefore being too large for an efficient 
pulmonary application.
u_
% of PEG 4000 incorporated in the SS particles
Figure 6 .8 . Influence of the % of PEG 4000 contained in the SS particles on 
the obtained FPFs. Values are mean (n=3)
Different options were considered to generate crystalline material following the 
spray drying of solutions. The first parameters that were varied were the spray 
drying conditions. Three new set-ups (Table 6.2) were investigated. A solution 
consisting of 10 % SS/PEG 4000 was employed in each case. Here again, 
varying the settings did not markedly affect the particle morphology or apparent
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size. The systems under investigation consisted of smooth spherical particles 
with indentations (Figure 6.9).
Figure 6.9. SS/PEG 4000 systems containing 10 % PEG co-spray-dried 
following M2 {A), M3 (B) or M4 (C).
The amorphous nature of the spray-dried samples was confirmed and an 
example is shown in Figure 6.10. From the results it can be seen that the spray 
drying conditions did not cause retention of the crystalline material.
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Figure 6.10. X-ray diffraction scan of spray-dried SS/PEG 4000 10 % following
M2.
The second parameter to be investigated was the PEG molecular weight. Liquid 
PEG 300 was used instead of PEG 4000 and different runs performed following 
M3 or M4 spray drying conditions. Three different solutions consisting of 5, 10 or 
20 % PEG 300 were studied using each of the two methods. Varying the PEG 
grade did not affect either the particle morphology or the amorphous nature of 
the co-spray-dried systems. Examples of SEMs and X-ray patterns are shown 
in Figures 6.11 and 6.12 respectively.
Figure 6.11. Influence of the PEG 300 concentration (5 % (A) or 10 %(B)) on 
the resulting particle morphologies following M4.
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Figure 6.12. X-ray diffraction scan of spray-dried SS/PEG 300 20 % following
M4.
Amorphous material was also obtained when lactose monohydrate was added 
(Figure 6.13). Prior work had suggested that crystalline material could be 
obtained when lactose alone with PEG was spray dried. However, with these 
formulations only amorphous material was obtained.
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Figure 6.13. X-ray diffraction for SS/PEG/lactose co- spray-dried product.
The particle morphology was not influenced by the addition of lactose as ternary 
material (Figure 6.14).
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sFigure 6.14. Electron micrographs of lactose/PEG/SS systems; following M3  
(A), Mi (B).
Moreover, the recrystallisation process appears to be slowed by the presence of 
the PEG. Figure 6.15 shows the XRPD of a SS/PEG300/lactose system after 24 
and 96 hours at room temperature. Partial crystallisation occurred, but the 
kinetic profile was slow with no total recrystallisation observed after 4 days. This 
effect was unexpected and is not fully understood since data presented in 
Chapter 4 showed that the presence of the polymer was responsible for the 
rapid crystallisation of the lactose/PEG system. The interactions between the 
sugar and the polymer would therefore be expected to differ from those existing 
between SS and the polymer. Further investigations are needed in order to 
have a better understanding on the specific interaction between the two 
excipients that could cause fast recrystallisation.
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Figure 6.15. X-ray diffraction for SS/PEG/lactose after 24 h (A) and 96 h (B) 
stored at ambient conditions.
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6.5.2. Spray drying from a suspension
6.5.2.1. Salbutamol sulphate
6.5.2.1.1. Characterisation of the particles
The main advantage of spray drying from a suspension is for the active to 
maintain its crystalline nature. Spray drying of the active in the presence of the 
polymer would result in a PEG coating onto the particle surface. Difficulties in 
ensuring homogenous particle size distributions and coating efficiencies are the 
principal disadvantages of this approach.
Characterisation of the resulting particles was essential to ensure that the spray 
drying process did not affect the physical properties of the drug. Assessment by 
SEM, X-ray diffraction, DVS and IGC were done for this purpose and the results 
are presented below. As seen in Figure 6.16, the modified SS/PEG particles 
kept the original shape and apparent size of the starting material indicating that 
the production of such systems was possible and non-destructive.
Figure 6.16. Electron micrograph of (A) 10% suspension, (B) 20% suspension, 
(C) original.
237
Confirmation of the crystallinity of the drug was further obtained by X-ray 
diffraction. The presence of the specific peaks of crystalline SS using different 
proportions of PEG 4000 was seen and an example shown in Figure 6.17.
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Figure 6.17. XRPD of spray-dried SS/PEG (10% PEG)
DVS analysis was used to further characterise hygroscopicity and the results 
shown in Figures 6.18 and 6.19. The conditions employed were as described in 
Chapter 2.
The extent of water uptake when exposed at 80 % RH, depended on the 
amount of PEG added to the suspension. For a 10 % (w/w) PEG (Figure 6.18) 
the mass gain corresponded to approximately 0.35 % whereas this value 
increased to nearly 0.9 % for a 20 % PEG. This is consistent with the fact that 
the polymer is hydroscopic and therefore more water is taken up at higher 
ratios. No lag phases were observed and the desorption profiles were very 
similar indicating that the PEG was present at the surface of the formed 
particules.
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Figure 6.18. Water sorption for SS/PEG 4000 (10 %).
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Figure 6.19. Water sorption for SS/PEG 4000 (20 %).
The surface energy of the co-spray dried SS (Table 6.6) shows a relatively low 
dispersive component and relatively high Kd/Ka ratios compared to the 
micronised sample. This indicates that the co-spray dried drugs present 
predominantly basic polar surfaces. The addition of PEG 4000 at different 
concentrations did not result in major changes (ys^  varying from 36.7 (0.3) to 
37.3 (0.3) and K q/K a  varying from 0.52 to 0.42).
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This might be explained by considering that the droplet will go through rapid 
changes in concentration during the process, and therefore the final PEG 4000 
concentration in the different systems might not be exactly 10 or 20 % (w/w).
Materials
Specific polar interaction (KJ/moi) Acid-basecharacteristics
7s 2 
(mJ/m )
Acetone Chloroform Ethanol Ethylacetate K a  K d K q/K a
88 7980 1052 11506 10396(155) (58) (117) (112)
10% 6050 3120 8330 7743
PEG (33) (45) (34) (30)
20% 6070 2696 8447 7724
PEG (87) (51) (87) (106)
PEG 9821 7898 13286 10353
4000 (259) (252) (368) (209)
0.137 -0.011 -0.08
0.096 0.050 0.52
0.097 0.041 0.42
0.120 0.206 1.71
50
(3.9)
36.7
(0.3)
37.3
(0.3)
33.1
i0 2 1
Table 6 .6 . Surface energy data of the references and the spray-dried 
SS/PEG systems (10 or 20 % w/w of polymer) from suspensions. Values are 
mean (standard deviations).
The IGC data indicates that spray drying 88, from a suspension, in the 
presence of PEG (Figures 6.20 and 6.21) did result in significant changes in the 
surface energetics. Interestingly, when compared to the surface energetics of 
88/PEG particles obtained after spray drying from a solution (Table 6.4), the 
values are comparable with a decrease in ys  ^and an increase in K a/K q values. 
The of 88/PEG co-spray dried (containing 10 % PEG) was 32.8 (0.4) when 
starting from a solution and 36.7 (0.3) when starting from a suspension. The 
lower value of the ys^  observed might be explained by the amorphous nature of 
the produced particle.
Moreover, the Ka/K q values ranged from 0.52 to 0.60, indicating that in the case 
of a solution, the PEG is migrating to the surface of the particle.
It might be interesting to evaluate in more details those different systems in 
order to understand why an 88/PEG material, being amorphous and obtained 
after spray drying from a solution, exhibits dispersive and acid-base 
characteristics similar to that for crystalline 88/PEG obtained from a 
suspension.
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Figure 6.20. Dispersive components of the crystalline SS, the different SS/PEG 
systems spray dried from a suspension and PEG4000. Values are mean (n=3)
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Figure 6.21. Acid-base characteristics of the crystalline SS, different SS/PEG 
systems spray dried from a suspension and PEG 4000.
6.5.2.1.2. Deposition study
Using the TSI and the Clickhaler there was little difference beween the EDs of 
the micronised and the SS spray dried from suspension (Table 6.7). Moreover, 
similar RDs lead to comparable FPFs (ranging from 34.9 (0.9) % for the 
micronised drug to 28.1 (1.2) % for the SS/PEG 20%) as seen in Table 6.7 
below.
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1024 358 34.9
(37) (21) (0.9)
1051 320 30.6
(148) (30) (2.9)
983 276 28.1
(67) (45) (1.2)
This study shows that modifying the surface of SS did not markedly affect the in 
vitro performance compared to a micronised active.
Formulation Active used ED (pg) RD (pg) FPF (%)
1 SS
2 SS/PEG 10%
3 SS/PEG 20 %
Table 6.7. Deposition of modified SS/PEG particles produced by spray drying 
from suspensions. Values are mean (standard deviations)
6.5.2.2. Beclomethasone dipropionate
6.5.2.2.1. Charaterisation of the particles
Spray drying BDP/PEG suspensions produced a powder consisting of apparent 
agglomerated particles (Figure 6.22). A possible reason for this microscopic 
observation might be the absorption of moisture by these spherical particles. 
Nevertheless, no apparent degradation of the active was observable based on 
X-ray diffraction patterns (Figure 6.23). Gravimetric studies and surface energy 
measurements were undertaken to further characterise the modified BDP 
particles.
Figure 6.22. Electron micrographs of (A) crystalline BDP,and (B) spray-dried 
BDP/PEG suspension.
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Figure 6.23. X-ray diffraction patterns of BDP before (A) and after (B) spray 
drying on the Büchi 191.
The water vapour sorption data of the crystalline BDP used throughout this 
dissertation is presented in Figure 6.24. The material was dried and subjected 
to the same RH as previously described. The sorption of water, illustrated by 
the increase in sample mass, reached a maximum before slightly dropping at 80 
% RH. The increase in weight at the equilibrium corresponded to approximately 
0.5 %. The rate of desorption when the sample was dried again was very fast 
with no final mass gain.
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Figure 6.24. DVS mass piot of crystalline BDP as a function of time and % RH.
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The sorption isotherms for the co-spray dried systems showed different profiles 
(Figures 6.25 and 6.26). The water uptake for those systems was higher when 
compared to crystalline BDP (Figure 6.24) due to the presence of the PEG at 
the surface of the particle. For the particles containing 10 % of polymer (Figure 
6.25), the mass gain recorded was around 0.9 %, approximately twice as much 
as for crystalline BDP. This value went up to around 1.6 % when the PEG 
concentration was increased to 20 % (w/w). In both cases, comparable to what 
was observed for the control, a slight drop in the weight was detected when the 
samples were undertaking the humidification stages. No final mass gains were 
detected.
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Figure 6.25. DVS mass plot of spray-dried BDP/PEG 10% from a suspension.
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Figure 6.26. DVS mass piot of spray-dried BDP/PEG 20% from a suspension.
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The surface energetics of the different particles produced were also studied and 
the data presented in Table 6.8. Comparable to the data obtained for SS/PEG 
co-spray dried systems, the ys^  were lower due to the incorporation of PEG 
(Figure 6.27). Here again, the ys^  of the different co-spray-dried systems were 
closer to the yg^  of the PEG than to that of BDP. In terms of polar properties, the 
presence of the PEG, presumably at the surface of the particles, had an effect 
(Figure 6.28). The surfaces became more basic mainly due to an increase of 
the Kd values. The effect of the PEG on the surface energy properties was 
comparable whether the starting material was lactose (Chapter 4), SS or BDP.
Materials
Specific polar interaction (kJ/mol) Acid-basecharacteristics
Ys  ^
(mJ/m )
Acetone Chloroform Ethanol Ethylacetate K a K q K d/K a
BDP 6610(48)
826
(14)
9194
(34)
8476
(66) 0.114 -0.011 -0.091
53.1
013)
10% 6817 3129 7881 8737 0.096 0.098 1.01 39.7PEG (217) (90) (83) (180) 016)
20%
PEG
10779
(83)
8931
(21)
11624
(19)
11843
(7)
0.096 0.05 2.66 29.5(0.1)
PEG 9821 7898 13286 10353 0.12 0.206 1.71 33.14000 (259) (252) (368) (209) (0.2)
Table 6 .8 . Surface energy data of the crystalline references and the spray- 
dried BDP/PEG systems (10 or 20 % (w/w of polymer) from suspensions and 
PEG 4000. Values are mean (standard deviations).
10 % PEG 20 % PEG P E G  4000
Figure 6.27. Dispersive components of the crystalline BDP, the different 
BDP/PEG systems spray dried from a suspension and PEG4000. Values are 
mean (n=3)
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Figure 6.28. Acid-base characteristics of the crystalline BDP, different 
BDP/PEG systems spray dried from a suspension and PEG 4000.
The following figures (Figures 6.29 and 6.30) summarise the effect of the PEG 
on both the dispersive component and the acid base properties on the resulting 
co-spray dried systems. The crystalline drugs and PEG 4000 are also shown 
as controls.
□ BDP 
■ SS
crystalline
reference
10% PEG 20 % PEG PEG 4000
Figure 6.29. Influence of the PEG concentration (in the suspension) on the 
dispersive component of the resulting SS or BDP co spray dried particles. 
Values are mean (n=3)
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Figure 6.30. Influence of the PEG concentration (in the suspension) on the acid 
base properties of the resulting SS or BDP co spray dried particles.
Co-spray drying a suspension of either SS or BDP in the presence of PEG had 
an important effect on the dispersive component of the resulting particles. 
Adding 10 % (w/w) of polymer in the starting suspension resulted in particles 
exhibiting similar Ys^  values for the two modified actives. From this data, it could 
be assumed that the “PEG treatment” of the surfaces resulted in similar 
dispersive interactions. However, when the polymer concentration was 
increased to 20 % (w/w), differences between the two systems were observed. 
Adding more PEG had little or no effect on the ys^  value of the SS/PEG product, 
whereas for BDP/PEG, a further decrease was observed (Figure 6.29).
Important differences were also seen for the acid-base properties of the 
modified drugs (Figure 6.30). Adding 10 % PEG to the starting suspension 
resulted in an increase in the K a /K q values. The effect was more prononced for 
BDP. Adding 20 % PEG marginally affected the acid-base properties of the 
SS/PEG system, whereas a sharp increase in the ratio of basic to acidic sites 
was observed for the BDP/PEG particles.
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As a conclusion, in term of surface energetics, BDP seemed to be more 
affected by its surface modification than SS. This is in agreement with the work 
described elsewhere in this thesis showing the intrinsic differences between the 
two actives chosen as models.
6.5.2.2.2. Deposition study
The effect of modifying the surface properties of the BDP particles while 
keeping the general morphology (size and shape) and crystallinity was further 
investigated by undertaking deposition studies as previously described 
throughout this work.Table 6.9 shows the dispersion and deaggregation profiles 
of the modified particles. Unlike the hydrophilic model, these modifications 
influence the deposition data. The amounts of drug reaching the lower stage of 
the impinger were disappointing, with FPF values of 7.3 (2.6) % for the system 
containing 10 % of polymer and 3.7 (0.4) % for the system containing the 
highest proportion of PEG (Formulation 3). These values were mainly due to 
difficulties in deaggregation the particles since the drug emission was not 
particularly affected by the treatment. These results were unexpected since the 
surface properties described earlier would have suggested less cohesion 
between the micronised particles. A possible explanation could be the 
hydroscopic nature of these entities, which could lead to the generation of other 
types of forces such as capillary ones, which could increase the drug-drug 
interactions and therefore decrease the FPF values.
Formulation Active used ED (pg) RD (pg) FPF (%)
1 BDP
2 BDP/PEG 10%
3 BDP/PEG 20 %
Table 6.9. Deposition of modified BDP/PEG particles produced by spray drying 
from solutions. Values are mean (standard deviation).
955 119 12.8
(172) (07) (2.8)
914 66 7.3
(27) (22) (2.6)
800 30 3.7
(34) (01) (0.4)
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6.6. Conclusions
Chapters 4 and 5 focussed on the concept of modifying the carrier surface to 
examine approaches to “standardise” carriers to achieve carrier independent 
aerosol performances of both SS and BDP. This chapter aimed to modify the 
active to examine the potential to standardise the drug particulate properties of 
different actives. Particles were prepared by spray drying using different 
processing parameters. The major conclusions of this chapter are summarised 
below.
Investigation of the production of active/PEG svstems bv sprav drying solutions 
or suspensions:
Spray drying a solution consisting of 38 and PEG 4000 following the same 
processing parameters as used to produce crystalline lactose/PEG particles 
resulted in amorphous material. Varying the polymer to drug weight ratio, PEG 
molecular weight (PEG 300 instead of PEG 4000) or even the parameters of the 
spray dryer, was not followed by recrystallisation. Adding a ternary excipient 
such as lactose monohydrate did not affect the nature of the produced particles 
either. The particle morphologies were found to be independent of the different 
parameters investigated. They consisted of homogeneous spherical particles 
with clean surfaces having indentations. Next, the drug substances were spray 
dried from suspensions. The resulting particles were crystalline with no obvious 
alterations to their chemical properties (confirmed by XRPD). Their micron size 
made them good candidates for inhalation.
Characterisation of the ohvsico-chemical properties of the newlv modified drug 
models:
The amorphous nature of the SS/PEG particles obtained by spray drying of the 
solutions was confirmed by both XRPD and DVS. The surface energetics of 
those systems tended to be similar to the values obtained from crystalline S3, 
with a decrease in the dispersive component and an increase in the Kd/Ka 
values. Amorphous materials are described as more energetic than crystalline 
ones and thererefore it was expected that these 33/PEG systems would display
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higher Ys^  values. The crystalline nature of the SS/PEG spray dried from a 
suspension was also confirmed using gravimetric studies and X-ray diffraction. 
IGC data for the crystalline particles containing 10% PEG (Table 6.6) showed 
comparable results to those observed for the amorphous particles containing 
the same proportion of polymer (Table 6.4). This was particulary true for the 
acid-base contributions with values varying from 0.60 to 0.52 respectively. 
Regarding BDP/PEG systems, differences in the surface energetics were also 
important with a decrease in the dispersive van der Waals forces. Here again, 
the drug particles appear “coated” with a PEG film, responsible for this PEG like 
surface energy pattern.
Assessment of their deposition patterns:
The surface modifications of the actives were further investigated by in vitro 
measurements. The modified drugs were mixed with a modified carrier 
consisting or air-jet sieved Aero Flo 65 with 10 % lactose/PEG fines fused on its 
surface. This modified carrier was as described in Chapter 5 and the 
methodology employed as described in Chapter 2. Although it was possible to 
produce spray dried SS/PEG of suitable size for inhalation, the aerosol results 
obtained with the Clickhaler® proved to be disappointing with an inefficient 
aerosolisation for the amorphous SS/PEG systems and comparable FPFs of the 
crystalline SS/PEG particles to those obtained with the reference micronised 
SS. A possible explanation for such results is that the amorphous SS/PEG 
particles were present as strong self-agglomerates. The results agree with the 
work of Chawla et al. (1994) who found that a greater fraction of a micronised 
drug was delivered to the lower stage of a TSI compared to a spray dried form. 
They attributed such results to the effect of adhesion and cohesion forces. The 
hydrophobic drug deposition was even more affected by the surface treatment 
with an FPF value as low as 3.7 % for the particles containing 20 % of polymer. 
BDP/PEG particles may adhere more strongly to the modified coarse lactose 
than the crystalline reference. As a general conclusion, the aerosol results 
proved that having a “PEG like drug surface” mixed with a “PEG like coarse 
lactose” did not result in a equivalent performances for the two model drugs. 
Moreover, the micronised BDP performed better than the crystalline BDP/PEG.
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Chapter
7
General discussion and future
work
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7.1. General Discussion
Inhalation technology has been widely acknowledged in the past decades for 
both local and potential systemic applications. Different types of devices namely 
pressurised metered dose inhalers, nebulisers and dry powder inhalers are 
used routinely for the pulmonary delivery of drugs for various respiratory 
indications. The issues faced by the transition from CFG to HFA propellants 
contributed to a renewed interest in DPI technologies over the past two 
decades. Standard DPI formulations generally consist of a micronised drug 
blended with a coarse a-lactose monohydrate carrier. The drug detachment 
from the carrier particle and its subsequent aerosolisation properties will depend 
on the formulation, the inhaler design and patient factors.
The main objective of this work was to gain a better understanding of 
aerosolisation behaviour of active particles from a binary powder mixture with 
different carrier systems. A number of different approaches were used in an 
attempt to understand the drug-carrier interactions. In this thesis, crystalline a- 
lactose monohydrate was used as the key carrier for both SS and BDP drug 
models. Here, three different commercially available grades of this disaccharide 
were used to prepare formulations which were subsequently filled and tested in 
the Clickhaler® DPI (chapter 3). This work brings to the fore the influence of the 
physico-chemical properties of the lactose tested on the BDP deposition profile, 
especially the presence of fine lactose particles (Figure 3.5 A). The aerosol 
performances of SS were less dependent on the choice of carrier (Table 3.4). 
Inverse gas chromatography was particularly important in differentiating 
between the various crystalline a-lactose monohydrate, especially in terms of 
specific interactions with polar probes (Figure 3.9). The method of Ka and Kd 
determination influenced the interpretation of the acid-base properties to in vitro 
deposition patterns correlations. As an example, using the boiling point 
approach a positive trend was established with SS deposition. The surface 
energy is one of the main factors influencing the adhesion of a particle onto a 
surface. For SS an increase in Ka values resulted in an increase in FPFs 
(Figure 3.16). The relationship was less pronounced for BDP, which tends to 
form particle aggregates and therefore does not adhere to the same extent to 
the coarse carrier surface as SS. Regarding the hydrophobic drug model, a
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positive trend was found between the TSI deposition and the amount of fine 
lactose present in the different samples (Figure 3.5 A).
The role played by the fines and the surface energy of the carriers was further 
investigated by the introduction of crystalline lactose/PEG 4000 fines (produced 
by spray drying) to air-jet sieved grades of lactose (chapter 4). Different 
formulation parameters such as type (Tables 4.4 to 4.6) and proportion of 
added fines (Table 4.8), mixing sequence (Table 4.7) and drug concentration 
(Table 4.9) were investigated and all proved to affect the in vitro performance 
for both drug models.
The fines spray-dried following the parameters reported by Chidavaenzi et al. 
(Chidavaenzi et ai., 2001) were all crystalline, regardless of the lactose to PEG 
ratio. The particle size of the different systems, determined by the Mastersizer X 
(Table 4.1), confirmed the potential use of these fines for DPI formulations. The 
changes in surface energy of the particles were investigated using IGC. This 
helped to give an understanding of how the polymer interacted with the lactose. 
Moreover, the changes in both the dispersive surface energy and the acid-base 
properties reflected a change in the hydrophobicity of the particles. The 
presence of asperities on the particle surface was revealed by SEM. These 
asperities, corresponding to PEG crystals, seemed to play an important role in 
the dispersion profiles of BDP, as previously stated by Gilani et al. (Gilani et al., 
2004). The current work demonstrated that the addition of 10 % (w/w) 
crystalline lactose/PEG fines (containing 10 % PEG 4000) to air-jet sieved 
grades of lactose led to similar BDP deposition (Tables 4.4 and 4.5). In other 
words, differences between marketed lactose grades from different sources can 
be minimised. For SS, these modified carriers did not appear to be as effective 
(Table 4.6). However, adding 10 % fines had a detrimental effect on the ED, 
presumably due to bad flow properties for this particular formulation. The study 
(Table 4.8) of the impact of the fine concentration showed good linear 
relationships between FPF and fine content for both drugs. Furthermore, the 
steeper gradient for BDP compared to SS confirmed the hypothesis that BDP 
was more likely to be influenced than SS. In this section of the dissertation the 
necessity to balance the amount of ternary material (so that the improvement in 
FPF is not followed by a decrease in ED) was stressed.
The role of the added fines was further highlighted in the mixing sequence study 
(Figure 4.15). Regardless of the mixing sequence, ternary ordered mixes
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exhibited higher FPFs than the corresponding binary mixes (without the addition 
of fines).
The mechanism of action of such fines is not yet clearly understood and 
different hypotheses are proposed: (1) coverage of active binding sites on the 
coarse lactose by the fines, affecting the particulate interaction between the 
drug and the carrier, (2) redistribution of BDP and fines between active and 
passive adhesion sites during the powder mixing, and (3) existence of small 
aggregates composed of lactose/PEG particles, acting as an alternative carrier. 
Finally, the drug to carrier ratio (Table 4.9) also appeared to influence the FPF 
of the hydrophobic drug model, with an increase in the detachment from the 
carrier particles at high drug loading. The increased FPF observed at higher 
drug concentration could be attributed to the relatively low percentage of drug 
being adhered to high-energy binding sites. This study confirmed once again 
the differences between the drugs, with the hydrophilic drug model deposition 
not being affected by the drug loading.
To assess further the impact of the presence of free fines in the blend and also 
the importance of modifying a lactose surface, partially amorphous lactose/PEG 
fines were produced in chapter 5, following the parameters set by Corrigan et 
al. (Corrigan et al., 2002). Those partially amorphous fines, whose nature was 
confirmed by XRPD and DVS experiments, were fused onto the surface of two 
air-jet sieved lactose grades. Based on IGC data (Tables 5.1 and 5.2) 
confirming that the surface energy properties of the modified surfaces were 
identical, it was hypothetised that the deposition patterns for the two drug 
models would be similar. The data presented in Table 5.3 confirmed that the 
modified carriers gave rise to similar deposition parameters (ED, RD and FPF) 
for the hydrophilic drug model. In contrast, BDP deposition in the second stage 
of the TSI was found to be lower than that from a carrier containing crystalline 
lactose/fines. This confirmed the importance of free fines in the possible 
mechanism of weakening the drug agglomerates.
The effect of chemical composition on carrier efficiency was evaluated using 
PEG [45-90] pm as a carrier probe. Despite poor content uniformity due to 
issues observed with the reservoir device, in vitro assessment was performed 
using the capsule-based Aerolizer®. This study also represented an opportunity 
to consider the device implication on the TSI deposition (Tables 5.5 and 5.6).
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All aerosolisations were made at a flow rate of 60 L/min and the drug deposition 
tests (Table 5.4) showed good performances for both drug models. A possible 
explanation was found in the low van der Waals interactions as indicated by a 
low value of 33.1 mJ/m^. The necessity to investigate a DPI formulation in 
combination with a particular device was illustrated by the data obtained from 
the two inhalers (Figures 5.9 and 5.10). Differences in deagglomeration 
efficiency of the hydrophobic drug model were highlighted by the different FPFs 
obtained from the same powder formulation, using the same inspiratory 
manoeuvre. Similarly, a given 88 formulation performed differently, in terms of 
FPF, depending on the device chosen.
The different IGC studies confirmed the applicability of this technique to monitor 
differences in the crystalline lactose grades and in the spray-dried lactose/PEG 
particles, and to assess the surface modification after fusion of partially 
amorphous fines. A method developed by Cline and Dalby (2002) was applied 
to our data set for direct prediction of T8I deposition data. The strong 
relationship obtained by these researchers between the surface energy 
interactions (8Els) and the aerosol properties of the different formulations could 
not always be confirmed with the carriers presented in this dissertation. The 
only positive trends were observable for BDP deposition when the 8EI 
parameter was calculated in mJ/g (Figures 5.23 and 5.24). Little insight in the 
88 deposition was possible with the calculation of this parameter, confirming 
the lack of generality of this theory to reliably explain the deposition data of 
different drugs from different carriers.
In a shift away from the research focus of modifying the surface properties of 
the carriers, the surface of the drug models was modified by spray drying 
(chapter 6). Initial attempts to spray dry 88 in the presence of PEG (300 or 
4000) from a feed solution resulted in the production of amorphous products 
which did not lead to significant deposition in the stage 2 of the impinger. The 
agglomeration tendency of those particles was put forward to explain these 
disappointing deposition patterns. 8 pray drying suspensions, using the Niro 8D 
Micro TM in the case of 88/PEG suspensions or the Büchi 191 for the 
BDP/PEG systems, led to crystalline products. No improvement of the aerosol 
properties of those modified actives when mixed with modified carriers were
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obtained. The surface modifications of both actives and carriers have 
undoubtedly potential in optimising aerosol properties of the blends and the use 
of new polymers should be addressed.
In conclusion, this dissertation has shown that improvements through carrier 
surface modifications were drug specific and appeared to be dependent on 
many factors such as the device employed, the physico-chemical properties of 
the coarse particles and the surface energetics. Evaluation of drug surface 
modification by spray drying seems to be encouraging, even if time constraints 
did not allow for totally efficient investigation of the spray drying conditions.
7.2. Suggested future work
• Water sorption analysis coupled with near-infrared spectroscopy could 
be used to probe the lactose/PEG crystallisation process. Further studies 
are also required to evaluate the effect of the PEG molecular weight and 
concentration on the physicochemical properties and stabilities of the 
spray-dried lactose/PEG systems;
The work relating to SS/PEG systems could be expanded with the aim to 
understand the differences in crystallisation behaviour observed with the 
lactose/PEG systems;
This dissertation introduced the concept of a universal carrier which 
would lead to performance equivalency between different lactose 
sources. Additional modifications of the active surface by spray drying 
could be investigated in order to minimise the drug to drug variability. 
This may involve the use of solutions or suspensions and a new range of 
polymers. IGC studies could be extended to monitor the surface 
modification of the drugs;
In this work, surface energy parameters were used to predict DPI 
performance. The different materials tested were found to have similar 
surface energetics and it would be interesting to examine new materials 
exhibiting higher differences in surface energetics.
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